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Abstract 
 
Background:  
After hypoxia-ischaemia and successful resuscitation, cerebral energy 
metabolism transiently recovers to the normal level (latent phase); after a 
variable period of time this phase is followed by secondary energy failure (SEF) 
in those subjects with an adverse outcome. A better understanding of the 
regional evolution of SEF may enhance the application of future neuroprotective 
strategies.  
 
Aims: 
The aim of this thesis was to determine associations between the insult severity, 
regional SEF evolution, and subsequent histo-pathological brain injury using 
magnetic resonance biomarkers. 
 
Methods: 
An established piglet model of neonatal encephalopathy was used. 
1. Twenty-nine piglets were studied either normothermic or hypothermic (35°C 
or 33°C during 2-26 hours after hypoxia-ischaemia). 31-phosphorus 
magnetic resonance spectroscopy (31P MRS) was serially acquired; the brain 
was assessed with histology after 48 hours.  
2. Global 31P MRS, and maps of apparent diffusion coefficient (ADC) and 
transverse relaxation time (T2) were serially obtained in 3 control and 18 
asphyxiated piglets. Histo-pathological brain injury and MR biomarkers were 
compared at time periods of 16-48 hours after hypoxia-ischaemia.  
 
Results: 
1. Severe acute insult, short latent phase, severe SEF, and profound 
histo-pathological brain injury were associated between each other.  
2. Transient recovery in phosphocreatine (PCr) higher than its baseline level 
was indicative of absent subsequent evolution of SEF, whereas sub-baseline 
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PCr recovery was suggestive of severe SEF. 
3. Global 31P MRS biomarkers and regional ADC obtained just prior to 
termination and up to 18-24 hours before termination predicted 
histo-pathological brain injury; the predictive value was optimal for global 
PCr/inorganic phosphate (Pi), followed by global PCr/exchangeable 
high-energy phosphate pool (EPP), Pi/EPP and regional ADC. PCr/Pi, 
PCr/EPP, Pi/EPP and ADC obtained after 6 hours of hypoxia-ischaemia 
predicted later neuronal death. Analysis with time-series data after 
resuscitation showed modest predictive values of 31P MRS and ADC for the 
end point brain injury as early as 3 to 6 hours after hypoxia-ischaemia.  
 
Conclusions:  
Although 31P MRS was more accurate, regional ADC predicted subsequent brain 
injury up to 18 hours in advance of termination. Regional ADC can be used as a 
sensitive early marker for subsequent tissue injury when 31P MRS is not 
available. 
 
  
 5 
Acknowledgments 
 
First and foremost, I would like to express my deepest gratitude to Prof Nikki 
Robertson for her mentorship with continuous encouragement and enthusiastic 
support to the entire research project. I would have never reached any of the 
peaks without her expertise, insight and strong belief in science and the 
research team. I would like to thank Prof John Wyatt for inspiring me and for 
investing on my projects during my first years in the UK, which was 
indispensable for the revival of our multidisciplinary research team. My further 
gratitude goes to Profs Donald Peebles, Gennadij Raivich, Ray Noble and 
Francesco Scaravilli for their supports as expert scientists, who helped improve 
my ability in refining experimental design and analytical approach.  
 
I would like to thank Drs Ernest Cady, Alan Bainbridge, Enrico De Vita, David 
Carmichael, John Thornton, Andrew Priest and Sahan Thalayasingam for their 
tremendous support as medical physicists in developing and standardising 
magnetic resonance biomarkers; especially, my career at UCL owes Drs Ernest 
Cady and Alan Bainbridge, who shared all good days and bad days together. I 
am grateful to Drs Shanthi Shanmugalingam, Jeanie Cheong, Takenori Kato, 
Giles Kendall and Andrew Kapetanakis for their support in experiments, and to 
Dr Linda Herbert for her excellent technique in immune-histochemical staining. 
I would also like to express my gratitude to Dr Angela Poulter for her assistance 
in the inter-Atlantic collaborations after I moved back to Japan. I would also like 
to thank Profs Toyojiro Matsuishi, Yasuki Maeno and Sachio Takashima, who 
helped facilitate the research environment in Japan.  
 
Lastly, I would like to thank my family. I am grateful to Dr George Iwata and Mrs 
Michiko Iwata, who brought me up with love and humour, and helped me nurse 
justice, curiosity and imagination within myself; and to Dr Yoshito Kadowaki, my 
father in law, who warmly supported the completion of my project in the UK 
despite his incurable illness. Above all, I would like to thank my wife Dr Sachiko 
 6 
Iwata, who shared interests and excitements in every little finding both at work 
and home, subsequently turning my ordinal life into an endless fete of 
neuroscience; although Sachiko and I might not always be good parents for our 
children Shinano, Soshi and Yushin, because of our extreme life style as 
intensivists and investigators, I still feel proud that, since your births, we have 
shared all defeats and triumphs in our long exploratory journey.  
  
 7 
Abbreviations 
 
ADC, apparent diffusion coefficient 
ATP, adenosine triphosphate 
aEEG, amplitude-integrated electroencephalogram 
DWI, diffusion weighted imaging 
EPP, exchangeable high-energy phosphate pool  
FA, fractional anisotropy 
FiO2, inspired oxygen fraction  
GFAP, glial fibrillary acidic protein 
H & E, haematoxylin and eosin 
LFB/Nissl, Luxol-fast blue-cresyl violet 
MRS, magnetic resonance spectroscopy 
NAA, N-acetyl aspartate 
NTP, nucleotide triphosphates  
PCr, phosphocreatine  
Pi, inorganic phosphate  
31P, 31-phosphorus  
RoI, region of interest 
T1, longitudinal relaxation time 
T2, transverse relaxation time 
TUNEL, terminal deoxynucleotide transferase nick end labelling 
 
 
 
  
 8 
Contents 
 
Declaration  …………………………………………………………….. 2 
Abstract    ……………………………………………………………. 3 
Acknowledgements  ……………………………………………………………. 5 
Abbreviations   ……………………………………………………………. 7 
Contents    …………………………………………………………… 8 
Index of Figures  …………………………………………………………… 15 
Index of Tables   …………………………………………………………… 18 
 
 
Chapter 1: Introduction…………………………………………………………. .19 
1.1 Epidemiology of perinatal hypoxia-ischaemia and neurological  
 Impairments  …………………………………………………………… 19 
1.2 Clinical features and diagnosis of neonatal encephalopathy…………….. 21 
 1.2.1 Algorithm of diagnosis of neonatal encephalopathy……………… 21 
 1.2.2 Evidence of systemic hypoxia-ischaemia………………………….. 22 
 1.2.3 Clinical findings of encephalopathy………………………………… 23 
 1.2.4 Diagnostic tools: electroencephalogram…………………………... 26 
 1.2.5 Diagnostic tools: conventional MRI…………………………………. 29 
1.3 Mechanisms of cerebral injury in the newborn infant……………………… 30 
 1.3.1 Primary energy failure and acute phase injury cascade………….. 30 
 1.3.2 Latent phase and secondary energy failure………………………… 31 
1.4 Piglet model of neonatal encephalopathy…………………………………... 33 
1.5 Quantitative magnetic resonance biomarkers of cerebral injury…………. 34 
 1.5.1 31P MRS  …………………………………………………………… 34 
 1.5.2 1H MRS  …………………………………………………………… 37 
 1.5.3 Diffusion weighted imaging…………………………………………… 38 
 1.5.4 Maps of longitudinal and transverse relaxation times……………... 42 
 1.5.5 Monitoring of secondary energy failure and therapeutic time  
   window  …………………………………………………………… 43 
 9 
 1.5. 6  Regional variation of energy metabolism following  
   hypoxia-ischaemia…………………………………………………… 44 
1.6 Treatment of neonatal encephalopathy…………………………………….. 47 
 1.6. 1 Therapeutic hypothermia: mechanism…………………………….. 47 
 1.6. 2 Therapeutic hypothermia: current clinical evidence……………… 48 
 1.6. 3 Key factors potentially associated with further improvement of the 
    treatment……………………………………………………………….49 
 
Chapter 2: Aim and Hypothesis………………………………………………... 51 
 Aim    …………………………………………………………… 51 
 Hypotheses   …………………………………………………………… 51 
 Specific hypotheses…………………………………………………………… 51 
 
Chapter 3: General Materials and Methods………………………………….. 52 
3.1 Preparation of the piglet model of asphyxial encephalopathy……………. 52 
 3.1. 1 Surgical procedures………………………………………………… 52 
 3.1. 2 Magnetic resonance biomarkers…………………………………….54 
 3.1. 3 31P MRS …………………………………………………………… 54 
 3.1. 4 Maps of ADC and FA………………………………………………... 55 
 3.1. 5 T2 maps …………………………………………………………… 56 
 3.1. 6 Transient cerebral hypoxia-ischaemia, resuscitation and  
   quantification of acute energy depletion……………………………56 
 3.1. 7  Temperature control and hypothermia…………………………….. 58 
 3.1. 8  Monitoring and treatment of seizure………………………………. 58 
 3.1. 9  Quantification of latent phase and secondary energy failure…… 58 
 3.1.10   Histopathology………………………………………………………. 59 
3.2 Associations between insult severity and therapeutic time window  
 duration   ……..……………………………………………………. 62 
 3.2. 1 Subjects and study groups…………………………………………. 62 
 3.2. 2  Acquisition of magnetic resonance data………………………….. 62 
 3.2. 3  Histopathology……………………………………………………….. 63 
 3.2. 4  Statistical analysis…………………………………………………… 64 
 10 
3.3 Energy metabolism during the latent phase and early evolutional 
  period of secondary energy failure…………………………………………. 65 
 3.3.1  Subjects and procedures…………………………………………….. 65 
 3.3.2  Hypoxic-ischaemic insult……………………………………………… 65 
 3.3.3  Acquisition of magnetic resonance biomarkers……………………. 65 
 3.3.4  Time course……………………………………………………………. 66 
 3.3.5  Statistical analysis…………………………………………………….. 66 
   3.3.5.1 Sham-operated control animals……………………………. 66 
   3.3.5.2 Animals in the study group…………………………………. 66 
   3.3.5.3 Serial metabolite ratios and rates of metabolic change..... 66 
   3.3.5.4 Secondary energy failure severity groups………………… 67 
   3.3.5.5 Baseline metabolism, insult severity and PCr recovery…. 67 
   3.3.5.6 Statistical probability correction…………………………….. 68 
3.4 Temporal and spatial evolution of secondary energy failure and  
 cerebral injury  …………………………………………………………… 69 
 3.4.1 Subjects and procedures……………………………………………... 69 
 3.4.2 Magnetic resonance data processing……………………………….. 69 
 3.4.3 Histo-pathological assessment………………………………………. 70 
 3.4.4 Statistical analysis……………………………………………………… 71 
   3.4.4. 1 Sham-operated control animals……………………………. 71  
   3.4.4.2 Animals in the study group…………………………………. 71 
   3.4.4.3 Statistical probability correction……………………………. 72  
 
Chapter 4: Results……………………………………………………………….. 73 
4.1 Associations between insult severity and therapeutic time window 
 duration   …………………………………………………………… 73 
 4.1.1  Summary …………………………………………………………… 75 
 4.1.2 Experimental courses and general findings…………………………. 75 
 4.1.3 Severity of hypoxia-ischaemia, duration of latent phase and 
subsequent injury indices in each temperature group………………75 
 4.1.4 Association between the insult severity and the latent phase  
   duration  …………………………………………………………… 76 
 11 
 4.1.5 Association between the insult severity and the severity of 
    secondary energy failure……………………………………………… 77 
 4.1.6 Association between the insult severity and neuronal death……… 78 
 4.1.7 Association between the latent phase duration and the severity of 
    secondary energy failure……………………………………………… 78 
 4.1.8 Association between the latent phase duration and neuronal  
   death ………………………………………………………………... 79 
 4.1.9 Association between the severity of secondary energy failure and 
    neuronal death…………………………………………………………. 80 
4.2 Energy metabolism during the latent phase and early evolutional period 
  or secondary energy failure………………………………………………….. 81 
 4.2.1 Summary …………………………………………………………... 81 
 4.2.2 Temporal changes in energy metabolites after 
    hypoxia-ischaemia…………………………………………………….. 81 
   4.2.2.1 Sham-operated animals………………………………….... 81 
   4.2.2.2 Acute insult, recovery and secondary energy failure…… 82 
 4.2.3 Energy metabolism at 2-8 hours after hypoxia-ischaemia and the 
severity of secondary energy failure…………………………………. 84 
 4.2.4 Baseline metabolism, insult severity, and PCr at 2-8 hours after 
hypoxia-ischaemia……………………………………………………... 86 
4.3 Temporal and spatial evolution of secondary energy failure and cerebral 
 injury    …………………………………………………………… 88 
 4.3.1 Summary ………………………………………………………....... 88 
 4.3.2 Sham-operated control subjects……………………………………… 88 
 4.3.3 Temporal changes in magnetic resonance biomarkers up to 24 
    hours after resuscitation………………………………………………. 88 
   4.3.3.1 31P MRS biomarkers……………………………………….. 88 
   4.3.3.2 Maps of ADC………………………………………………... 90 
   4.3.3.3 T2 maps…………………………………………………….. 94 
   4.3.3.4 Histopathological brain injury……………………………… 96 
 4.3.4 Serial magnetic resonance biomarkers obtained 1 to 24 hours 
    after resuscitation and histo-pathological brain injury……………… 99 
 12 
   4.3.4.1 Insult severity, experimental duration, magnetic 
      resonance biomarkers, and histo-pathological brain 
      injury................................................................................ 99 
   4.3.4.2 31P MRS biomarkers and brain injury…………………… 100 
   4.3.4.3 Maps of ADC and brain injury……………………………. 103 
   4.3.4.4 T2 maps and brain injury…………………………………. 104 
 4.3.5  Serial magnetic resonance biomarkers obtained shortly before to  
   24 hours before termination and histo-pathological brain injury….. 105 
   4.3.5.1 31P MRS biomarkers and brain injury…………………… 105 
   4.3.5.2 Maps of ADC and brain injury……………………………. 108 
   4.3.5.3 T2 maps and brain injury…………………………………. 109 
 
Chapter 5: Discussion………………………………………………………… 110 
5.1 Associations between insult severity and therapeutic time window  
 duration …………………………………………………………. 110 
 5.1.1  Summary  ………………………………………………………..... 110 
 5.1.2  Key findings from the study…………………………………………… 110 
 5.1.3  Acute energy depletion and evolution of secondary energy failure 110 
 5.1.4  Level of acute energy depletion and the effect of hypothermic 
neuroprotection………………………………………………………… 111 
 5.1.5  Evolution of secondary energy failure and neuroprotective  
   treatments …………………………………………………………. 112 
 5.1.6  Clinical implications……………………………………………………. 113 
 5.1.7  Strengths and limitations of the study……………………………….. 113 
 5.1.8  Conclusions …………………………………………………………..114 
5.2 Energy metabolism during the latent phase and early evolutional period 
 or secondary energy failure…………………………………………………. 115 
 5.2.1 Summary  ………………………………………………………….. 115 
 5.2.2 Key findings from the study…………………………………………… 115 
 5.2.3 Changes in high energy phosphates during transient 
hypoxia-ischaemia, latent phase and secondary energy failure….. 115 
 
 13 
 5.2.4 Cerebral stress response after the commencement of  
  resuscitation and PCr recovery overshoot………………………….. 116 
 5.2.5 Clinical implications……………………………………………………. 118 
 5.2.6 Limitations and advantages of the study……………………………. 118 
 5.2.7 Future studies …………………………………………………………..118 
 5.2.8 Conclusions …………………………………………………………..119 
5.3 Temporal and spatial evolution of secondary energy failure and  
 cerebral injury  …………………………………………………………..120 
 5.3.1  Summary …………………………………………………………..120 
 5.3.2  Key findings from the study………………………………………….. 120 
 5.3.3  Diagnostic value of global and regional magnetic resonance 
biomarkers for histo-pathological brain injury……………………… 120 
 5.3.4  Spatial changes of ADC and transverse relaxation time during 
    the evolutional process of secondary energy failure……………… 122 
 5.3.5  T2 maps during acute phase after perinatal hypoxia-ischaemia… 123 
 5.3.6  Clinical implications……………………………………………………123 
 5.3.7  Limitations of the study………………………………………………. 124 
 5.3.8  Future studies…………………………………………………………. 125 
 5.3.9  Conclusions …………………………………………………………..125 
 
Chapter 6: Overall conclusion and implication of the findings from  
    this thesis ………………………………………………………..... 126 
6.1 Conclusions  …………………………………………………………..126 
6.2 Latent phase, secondary energy failure and tissue homeostasis……… 127 
6.3 Magnetic resonance biomarkers and histo-pathological findings……… 128 
6.4 Monitoring of secondary energy failure…………………………………… 129 
6.5 Secondary energy failure and cerebral protection………………………. 130 
6.6 Strength and limitation………………………………………………………. 131 
6.7 Future studies  …………………………………………………………..132 
6.8 Implication of the findings from this thesis………………………………… 133 
 
 
 14 
Bibliography   …………………………………………………………. 134 
 
Supplementary Material and Appendix……………………………………… 144 
List of Abstracts and Presented at Meetings from this analysed data……… 145  
List of Publications related to this work………………………………………… 149 
List of Publications derived from this work…………………………………….. 151 
Appendix    …………………………………………………………. 152 
  
 15 
Index of Figures     
 
Fig. 1.1-1:  Neonatal encephalopathy and related outcomes………………… 20 
Fig. 1.2-1:  Classification of aEEG traces after perinatal hypoxia-ischaemia 
  by Hellstrom-Westas and colleagues……………………………… 28 
Fig. 1.2-2:  Mild MRI lesions in the deep grey matter and internal capsule  
  …………………………………………………………… 29  
Fig. 1.3-1:  Primary energy depletion and acute phase injury cascade……... 30 
Fig. 1.3-2:  Evolution of energy failure after the latent phase in a severely 
asphyxiated newborn infant……………………………………....... 31 
Fig. 1.3-3:  Evolution of secondary brain injury………………………………… 32 
Fig. 1.4-1:  Evolution of secondary energy failure in the piglet model of 
  neonatal asphyxial encephalopathy……………………………….. 33 
Fig. 1.5-1:  High resolution 31P MRS spectra from the brain of the piglet 
  model …………………………………………………………… 34 
Fig. 1.5-2:  Temporal changes in PCr/Pi and NTP/EPP in the piglet model  
 of asphyxial encephalopathy……………………………………...... 35 
Fig. 1.5-3:  Cerebral tissue covered by the surface coil in the acquisition of 
  31P MRS spectra from the piglet brain…………………………….. 36 
Fig. 1.5-4:  1H MRS spectra, lactate/NAA and outcome of asphyxiated 
  infants …………………………………………………………... 38 
Fig. 1.5-5:  Conventional MRI and DWI after perinatal hypoxia-ischaemia 
  …………………………………………………………… 40 
Fig. 1.5-6:  Correlation between PCr/Pi and ADC……………………………... 41  
Fig. 1.5-7:  Transverse relaxation time in the thalamus and basal ganglia 
  …………………………………………………………... 42 
Fig. 1.5-8:  Evolution of secondary energy failure in a rodent model of 
  transient hypoxia-ischaemia………………………………………… 44 
Fig. 1.5-9:  Diagram of normal basal ganglia motor control circuit and areas 
damaged by near-total asphyxia………………………………....... 45 
 
 16 
Fig. 1.5-10: Pattern of brain injury after perinatal hypoxia-ischaemia and 
neurodevelopmental outcome at 30 months of age……………… 46 
Fig. 1.6-1:  Systemic hypothermia and therapeutic time window in the piglet 
model of asphyxial encephalopathy……………………………….. 47 
Fig. 1.6-2:  Cooling level and region-specific brain protection………………. 50 
Fig. 3.1-1:  Piglet model after surgical procedures……………………………. 52 
Fig. 3.1-2:  Piglet positioned within the plastic cylinder pod………………….. 53 
Fig. 3.1-3:  Representative 31P spectra from the piglet brain before 
hypoxia-ischaemia…………………………………………………… 54 
Fig. 3.1-4:  Regions of interest on a schema and maps of ADC and FA……. 56 
Fig. 3.1-5:  Schematic diagram summarising the quantification of the acute 
insult severity…………………………………………………………. 57 
Fig. 3.1-6:  Region of interest for histo-pathological assessment in the 
  cortical grey matter…………………………………………………... 60 
Fig. 3.2-1:  NTP/EPP changes of representative piglets over 48 hours…….. 63 
Fig. 3.2-2:  Schematic diagram depicting the histo-pathological regions of 
interest in a coronal slice of the piglet brain………………………. 64 
Fig. 3.4-1:  Brain regions of interest for histo-pathological assessment…….. 69 
Fig. 4.1-1:  Cerebral high-energy phosphates before, during and after 
hypoxia-ischaemia…………………………………………………… 74 
Fig. 4.1-2:  Correlation between the latent phase duration and the insult 
  severity ……………………………………………….................. 77 
Fig. 4.1-3:  Association between the severity of acute insult and secondary 
energy failure…………………………………………………………. 77 
Fig. 4.1-4:  Correlation between the insult severity and neuronal death in  
 the cortical grey matter……………………………………………… 78 
Fig. 4.1-5:  Correlation between the latent phase duration and the severity  
 of secondary energy failure…………………………………………. 78 
Fig. 4.1-6:  Dependences of neuronal death on the latent phase duration 
  …………………………………………………………… 79 
Fig. 4.1-7:  Dependence of neuronal death on the severity of secondary 
  energy failure…………………………………………………………. 80 
 17 
Fig. 4.2-1:  Trajectories of NTP, PCr and Pi over time relative to EPP……… 83 
Fig. 4.2-2:  Metabolite ratios 2-8 hours after hypoxia-ischaemia relative to 
individual baselines…………………………………………………. 85 
Fig. 4.2-3:  Representative 31P MRS spectra from three outcome groups…. 85 
Fig. 4.2-4:  PCr/EPP 2-8 hours after hypoxia-ischaemia…………………….. 86 
Fig. 4.2-5:  Baseline and early 31P MRS biomarkers and PCr recovery……. 87 
Fig. 4.2-6:  Baseline metabolism and recovery PCr/EPP…………………….. 87 
Fig. 4.3-1:  Temporal changes in global 31P MRS biomarkers………………. 89 
Fig. 4.3-2:  Two distinct patterns of ADC changes with time following 
  hypoxia-ischaemia……………………………………..……………. 90 
Fig. 4.3-3:  Temporal changes of ADC in representative regions……………. 92 
Fig. 4.3-4:  Temporal changes of T2 maps…………………………………….. 94 
Fig. 4.3-5:  Temporal changes of T2 relaxation time in representative 
  regions …………………………………………………………… 95 
Fig. 4.3-6:  Representative histo-pathological findings-1..……………………. 97 
Fig. 4.3-7:  Representative histo-pathological findings-2..…………………..... 98 
Fig. 4.3-8:  Associations between 31P MRS biomarkers obtained 1-24  
  hours after resuscitation and histo-pathological brain injury……101 
Fig. 4.3-9:  Associations between maps of ADC obtained 1-24 hours after 
  resuscitation and histo-pathological brain injury……….……….. 103 
Fig. 4.3-10:  Associations between T2 maps obtained 1-24 hours after  
 resuscitation and histo-pathological brain injury………………… 104 
Fig. 4.3-11:  Associations between 31P MRS biomarkers obtained 1-24  
 hours before termination and histo-pathological brain injury…... 106 
Fig. 4.3-12:  Associations between maps of ADC obtained 1-24 hours 
  before termination and histo-pathological brain injury………….. 108 
Fig. 4.3-13:  Associations between T2 maps obtained 1-24 hours before  
 termination and histo-pathological brain injury…….……………. 109  
 18 
Index of Tables    
 
Table 1.2-1:  Outline of diagnostic algorithm for neonatal encephalopathy 
  used in clinical trials of therapeutic hypothermia……………… 21 
Table 1.2-2:  Predictive value of arterial cord blood gas for cerebral palsy... 23 
Table 1.2-3: Encephalopathy grading system by Sarnat and Sarnat……….25 
Table 1.2-4:  Encephalopathy scoring system by Thompson and  
  colleagues…………………………………………………………. 26 
Table 1.6-1:  Therapeutic hypothermia and outcomes at 18 months of age  
  …………………………………………………………… 48  
Table 3.1-1:  Definition of pathological scoring for neuronal damages…….. 61 
Table 3.4-1:  Injury scales for histo-pathological assessment in the white 
 Matter …………………………………………………………… 70 
Table 4.1-1:  Magnetic resonance and histo-pathological injury indices in 
  each temperature group…………………………………………..76 
Table 4.2-1:  Temporal changes in 31P MRS biomarkers in sham operated 
animals …………………………………………………………… 81 
Table 4.2-2:  Rates of change in metabolite ratios during and following 
hypoxia-ischaemia………………………………………………... 82 
Table 4.2-3:  Metabolite ratios before, during, and after hypoxia-ischaemia  
   …………………………………………………………… 84 
  
 19 
Chapter 1: Introduction 
 
1.1 Epidemiology of perinatal hypoxia-ischaemia and 
neurological impairments 
 
Perinatal hypoxia–ischaemia and subsequent neonatal encephalopathy remain major 
causes of neonatal death and permanent neurological impairments worldwide, which 
are responsible for ~23% of annual neonatal deaths (1). Even in the developed world, 
some form of resuscitation is required for ~10% of all newborn infants before 
spontaneous breathing and circulation are established (2). Although the majority of 
these infants are stabilised without further need for intensive medical care, moderate to 
severe neonatal encephalopathy develops, in approximately 1-3 per 1000 live births (3), 
resulting in up to 60% of mortality and at least 25% of survivors with long term 
neurodevelopmental sequelae (Fig. 1.1-1) (4). Perinatal hypoxia-ischaemia also affects 
the long term outcome of infants who were resuscitated at birth but were asymptomatic 
for encephalopathy and had no further neonatal care; these infants are at increased 
risks of having low intelligence quotients at school age compared to their peers who did 
not require resuscitative procedures (5). The incidence of probable intrapartum-related 
respiratory depression, neonatal encephalopathy and subsequent death is much higher 
in developing countries and low resource settings (6). 
 
Until recently there was no efficient treatment for the devastating consequences of 
perinatal asphyxia and neonatal encephalopathy. However, recent experimental and 
clinical evidence has led to the establishment of therapeutic hypothermia, which has 
now been recognised as the first clinically effective neuroprotective treatment for infants 
with neonatal encephalopathy (7-9). Currently, however therapeutic hypothermia is 
offered only to a limited number of infants with neonatal encephalopathy worldwide as 
clinical trials have only shown its safety and efficacy in the developed world setting 
under intensive care conditions (10). In addition some infants reach tertiary care centres 
too late - there is a relatively short therapeutic time window of hypothermia of up to ~6 
hours (11). Furthermore, the number of infants who respond to the treatment is still 
limited, with the number of patients needed to treat to improve outcome remaining 
around 9 for the reduction of death or severe neurodevelopmental impairments at 18 
months of age (12). Many gaps remain in our knowledge of the best treatment for 
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individual babies with neonatal encephalopathy. Despite a consistent presentation, 
neonatal encephalopathy may have diverse aetiologies. The infant’s maturity, 
inflammatory, nutrition, development of seizures, hormonal status and combination of 
these factors may influence the response to an acute hypoxic-ischaemic insult. Further 
work is needed to determine the optimal application of hypothermia for different infants.  
Establishment of early diagnostic biomarkers, such as magnetic resonance imaging 
(MRI) and magnetic resonance spectroscopy (MRS), may facilitate tailored 
neuroprotective treatments. 
 
Figure 1.1-1: Neonatal encephalopathy and related outcomes 
 
In a cohort study which enrolled 57,259 births, 150 cases of neonatal encephalopathy (NE) were 
identified, with the incidence of 2·62 per 1000 births (95% CI: 2·20–3·04). Sixteen infants with NE 
subsequently had definite or probable cerebral palsy, a rate of one in 3572 births. From “The 
relationships between neonatal encephalopathy and cerebral palsy: a cohort study.” by Evans K, 
Rigby AS, Hamilton P, Titchiner N, Hall DM. J Obstet Gynaecol. 2001 Mar;21(2):114-20. 
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1.2 Clinical features and diagnosis of neonatal encephalopathy 
 
1.2.1 Algorithm of diagnosis of neonatal encephalopathy 
Impaired cerebral functions characterised by clinical findings, such as abnormal motion, 
muscle tone, reflexes, and seizures are key features that constitute the diagnosis of 
neonatal encephalopathy (2). However, early recognition of neurological manifestations 
indicative of neonatal encephalopathy requires special expertise, because early clinical 
signs, especially of mild to moderate neonatal encephalopathy, are subjective, affected 
by sleep sates, and difficult to be distinguished from normal conditions. In addition, the 
primary screening of neonatal encephalopathy is generally performed by midwives and 
physicians with limited expertise in neonatal neurology, resulting in the requirement for 
reliable, objective markers for the global stress. Hence, recent large scale clinical trials 
which enrolled infants with neonatal encephalopathy employed a two- or three-step 
diagnostic algorithm (Table 1.2-1) (7-9).  
 
Table 1.2-1: Outline of diagnostic algorithm for neonatal encephalopathy 
used in clinical trials of therapeutic hypothermia 
 
Three major randomised controlled trials of selective head cooling (CoolCap Trial) and whole body 
cooling (NICHD Trial and TOBY Trial) used similar entry criteria to identify infants with moderate to 
severe neonatal encephalopathy. Terms and abbreviations: aEEG, amplitude-integrated 
electroencepharogram. Apgar score, a 10-point scale assigned to assesses the early transition of 
newborn infants. BD, base deficit. Sarnat score, a 3-level clinical grading system to assess the 
severity and development of neonatal encephalopathy from mild (I) to severe (III). 
 
The first stage of diagnosis involves objective clinical evidence of global 
hypoxia-ischaemia, as represented by abnormal cord blood gas analysis and Apgar 
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scores, which also assure that hypoxic-ischaemic stress occurred shortly before or 
around the timing of delivery. To confirm the influence of global hypoxia-ischaemia to 
the cerebral function, the next step of the diagnosis assesses the presence and lack of 
primitive reflexes and pathological neurological findings (13). Electrophysiological 
findings may further confirm the impaired cortical activity in a more objective method. 
Because neonatal encephalopathy is an evolving syndrome commencing at 
resuscitation, physiological and neurological assessments need to be repeated to 
monitor the process and to allow interventions appropriate to the severity of 
encephalopathy and the systemic condition. 
 
1.2.2 Evidence of systemic hypoxia-ischaemia 
Because the systemic condition of asphyxiated infants alters dynamically with time 
before and after the commencement of resuscitative interventions, physiological 
information obtained at or shortly after birth may suggest inconsistent views on the 
severity of global asphyxia between each other. Hence it is important to obtain 
comprehensive information about the patient including clinical findings using alternative 
diagnostic scales and detailed clinical histories. To improve the accuracy and reliability 
of the initial screening scale, diagnostic tools at this stage should be simple, objective 
and reproducible, while obtained scores or information are still associated with the 
natural outcome of the infant. 
Of several biomarkers of intrapartum hypoxia-ischaemia, evidence of severe acidosis 
on the cord blood sample is most frequently used as a handy and objective surrogate 
for the foetal condition (Table 1.2-2) (14). The presence of lactic acidosis with increased 
base deficits is indicative of prolonged anaerobic metabolism. Foetal acidosis defined 
by umbilical cord blood pH of <7.00 and a base deficit of ≥12 mmol/L is known to be 
associated with an increased risk of cerebral palsy (15). A preliminary meta-analysis 
based on nine clinical studies suggested the association between foetal acidosis, 
neonatal death and cerebral palsy (16). Previous observational studies, however, 
provided inconsistent views in the detailed association between cord blood pH and 
outcomes, in part because of various thresholds of abnormal blood gas and end points 
for the outcome of the infant (17, 18). A recent meta-analysis based on the data from 
more than fifty studies confirmed that low arterial cord pH was a strong and consistent 
predictor of the outcome for asphyxiated infants even after adjustments for the study 
design, sample size, cut off level and the clinical endpoint (19), justifying the use of cord 
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blood gas analysis to screen infants at increased risks of mortality and permanent 
neurological impairments.  
 
Table 1.2-2: Predictive value of arterial cord blood gas for cerebral palsy 
A meta-analysis confirmed that low arterial cord pH was associated with the incidence of cerebral 
palsy. From “Strength of association between umbilical cord pH and perinatal and long term 
outcomes: systematic review and meta-analysis.” by Malin GL, Morris RK, Khan KS. BMJ. 2010 May 
13;340:c1471. 
 
The Apgar score is another universal scale assigned for almost all newborn infants born 
in developed countries. The score can be assigned using readily available clinical 
observations without requiring for burdensome data collection (20). Although the Apgar 
score is assigned subjectively for components other than the heart rate, the inter-rater 
agreement of the scores is generally high. The Apgar score can be assessed by nurses, 
midwives and trainee doctors without requiring for special skills and intensive training 
sessions. Negative relationships have been confirmed between the 1 and 5 minutes 
Apgar scores and neonatal mortality in large cohorts of newborn infants (21, 22). While 
the predictive value of the 5 minute Apgar score has been accepted as a simple, reliable 
predictor of neonatal mortality for singleton premature and term newborn infants (15), 
the Apgar score at 10 minutes is likely to provide even more useful prognostic 
information following perinatal hypoxia-ischaemia (20).  
 
1.2.3 Clinical findings of encephalopathy 
The type and severity of neonatal encephalopathy need to be determined by 
comprehensive neurological assessments, which help predict likely neurological 
outcomes and appropriate therapeutic options. Since the clinical features of neonatal 
encephalopathy evolve over a period of days, neurological examinations have to be 
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performed repeatedly. Of scales used for the classification of neonatal encephalopathy, 
the grading developed by Sarnat and Sarnat is most universally used in the neonatal 
intensive care (Table 1.2-3) (13); this grading system assigns one of three categories of 
grade I (mild), II (moderate) and III (severe) encephalopathy to the affected infant based 
on subjective clinical observations. The maximum benefit of this system is yielded when 
it is used serially to record the temporal alteration of neurological findings. Infants who 
were never diagnosed as severe encephalopathy and who were not assigned into 
moderate encephalopathy for more than four days were suggested to have normal 
medium-term outcomes, whereas persistent moderate encephalopathy for longer than 
seven days was suggestive of mortality or neurological impairments. However, in the 
clinical practice, this grading system is frequently used to assess the severity of and to 
estimate the outcome of encephalopathy shortly after birth, occasionally before making 
clinical decisions whether invasive treatments are required to improve the 
neurodevelopmental outcome of affected infants. While this grading system provides 
reliable estimation of the outcome for grade I and grade III encephalopathy, which are 
associated with favourable and poor outcomes respectively, the outcome associated 
with the grade II encephalopathy is various, ranging between intact survival to death or 
severe neurodevelopmental impairments. In addition, the assignment of this grading 
system is time consuming, and the final decision as to whether an infant falls into the 
moderate or severe category is at times difficult, requiring substantial expertise in 
neonatal neurology (23). 
Several other groups also proposed scoring systems for neonatal encephalopathy to 
improve the quality and utility of early diagnosis and outcome prediction (23-26). Of 
these, a scoring system developed by Thompson and colleagues has an outstanding 
advantage in its simplified numeric assignment system (Table 1.2-4). 
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Table 1.2-3: Encephalopathy grading system by Sarnat and Sarnat 
 
An encephalopathy grading system proposed by Sarnat and Sarnat in 1976. A 3-scale 
encephalopathy grade is assigned for the affected infant using a checklist, which comprises 
physiological and neurological signs. Although this grading is currently used to evaluate the 
severity of neonatal encephalopathy, the original concept was to monitor the temporal development 
of encephalopathy from grade I to II and III. From “Neonatal encephalopathy following fetal distress. 
A clinical and electroencephalographic study.” by Sarnat HB, Sarnat MS. Arch Neurol. 1976 
Oct;33(10):696-705. 
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Table 1.2-4: Encephalopathy scoring system by Thompson and colleagues 
A simple scoring system for neonatal encephalopathy developed by Thompson and colleagues. 
One may simply check the item which most precisely reflects the patient’s state, and add the scores 
to quantify the severity of encephalopathy. From “The value of a scoring system for hypoxic 
ischaemic encephalopathy in predicting neurodevelopmental outcome.” by Thompson CM, 
Puterman AS, Linley LL, Hann FM, van der Elst CW, Molteno CD, Malan AF. Acta Paediatr. 1997 
Jul;86(7):757-61. 
 
This system, based on that of Sarnat and Sarnat, employs only nine categories of 
clinical signs, where scores of 0 (normal) to 3 (highly abnormal) are given for each item 
to give total scores between 0 and 22. Total scores of 0 to 9, 10 to 14, and 15 to 22 
correspond to mild, moderate and severe neonatal encephalopathy diagnosed using 
Sarnat’s grading system (23). In addition to its agreement to the previous system, this 
scoring system showed excellent predictive values of neurodevelopmental outcomes for 
asphyxiated newborn infants at 1 year old. For example, the peak score of 15 or higher 
was highly suggestive of abnormal outcomes, with the positive predictive value of 92%, 
negative predictive value of 82%, sensitivity of 71%, and the specificity of 96%.  
 
1.2.4 Diagnostic tools: electroencephalogram 
Studies which used standard electroencephalogram and amplitude-integrated 
electroencephalogram (aEEG) demonstrated that perinatal hypoxia-ischaemia 
attenuates electrocortical activities as a dose dependent manner, reflecting the depth of 
the stress (13, 27). However, electrographic findings are generally normal or of 
minimum suppression for infants with mild encephalopathy. For infants with moderate 
encephalopathy, high frequency domains such as alpha and a part of theta activities 
disappear, and low frequency domains such as delta and a part of theta activities are 
attenuated in their voltage. Such a mildly suppressed electrographic pattern is often 
followed by a burst and suppression pattern, which is highly suppressed and 
occasionally deformed compared to the normal alternating trace of the newborn infant. 
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Electrocortical activities are further attenuated for severe encephalopathy. As well as 
the suppression in voltage, the interval between bursts is significantly prolonged, which 
evolves into a flat trace. The background activity of standard electroencephalogram in 
asphyxiated newborn infants is known to be associated with neurodevelopmental 
outcomes at 2 years old (28). Moderate to severe suppression with or without 
alternating burst suppression pattern is indicative of abnormal neurodevelopmental 
outcomes, whereas normal traces and immature patterns relative to the gestational age 
of the infant are suggestive of normal development. A more recent study which serially 
obtained standard electroencephalogram following perinatal hypoxia-ischaemia 
demonstrated that electroencephalogram obtained after six hours of birth was more 
indicative of the neurodevelopmental outcome compared to twelve, twenty-four and 
forty-eight hours after birth (29). 
Despite the substantial information derived from standard electroencephalogram in 
asphyxiated newborn infants, only a limited number of hospitals can currently provide 
the examination 24 hours a day. In addition, interpretation of electroencephalogram 
traces requires expertise in neonatal neurology. To improve the utility of electrographic 
assessment of the brain function, aEEG has been proposed by clinicians who care for 
high risk newborn infants as a simple and handy alternative for standard 
electroencephalogram (Fig. 1.2-1) (30). This device was developed and initially applied 
for adult patients who underwent cardiac surgeries to monitor the trend of electrocortical 
activity in the 1960s (31). Waveforms of electroencephalogram obtained using two or 
four recording electrodes are filtered and compressed to reconstruct aEEG output. 
Because of its time compressed trend view, one can evaluate a long term recording 
instantly by simple pattern recognition with the minimum instruction and training. 
Despite its simplicity, aEEG obtained within 6 hours of birth from asphyxiated term 
newborn infants has been recognised as a reliable predictor for the outcome of affected 
infants (32, 33). More recent studies suggested that the timing in recovery for the 
amplitude and the sleep wake cycle of the aEEG trace is useful to predict the outcome 
of infants (34).  
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Figure 1.2-1:  Classification of aEEG traces after perinatal      
  hypoxia-ischaemia by Hellstrom-Westas and colleagues 
 
Four types of background patterns recorded from full term asphyxiated new born infants during the 
first six hours of life are shown. (A) Continuous normal voltage with sleep-wake cycles. (B) 
Continuous normal voltage with absent sleep-wake cycles following phenobarbital administration. 
(C) Continuous extremely low voltage pattern with suspected seizure pattern. (D) 
Suppression-burst pattern. (E) Flat tracing, mainly isoelectric. From “Predictive value of early 
continuous amplitude integrated EEG recordings on outcome after severe birth asphyxia in full 
term infants.” by Hellström-Westas L, Rosén I, Svenningsen NW. Arch Dis Child Fetal Neonatal Ed. 
1995 Jan;72(1):F34-8. 
 
Although aEEG obtained within 6 hours of life has been recognised as the best single 
outcome predictor in asphyxiated newborn infants who were cared for under 
normothermia (35), the predictive value is known to be altered or even lost by 
therapeutic interventions such as therapeutic hypothermia (36), suggesting that further 
improvement of the diagnostic algorithm is required potentially by combining with 
additional acute phase biomarkers.  
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1.2.5 Diagnostic tools: Conventional MRI 
Conventional MRI provides detailed information about types and depths of 
hypoxic-ischaemic injury with spatial resolution (Fig. 1.2-2) (37). Following severe 
perinatal hypoxia-ischaemia, abnormal MRI signal intensities in the deep grey matter 
and the posterior limb of the internal capsule are some of the most common findings, 
which predict abnormal neurodevelopmental outcomes in term infants with neonatal 
encephalopathy (38).  
 
Figure 1.2-2: Mild MRI lesions in the deep grey matter and internal capsule 
 
(a) T1-weighted imaging of an asphyxiated newborn infant showing abnormal high signal intensities 
(arrows) within the lentiform nuclei with intact posterior limb of the internal capsule. Follow up 
T1-weighted (b) and T2-weighted (c) imaging at 12 months shows normal appearances. From 
“Magnetic resonance imaging in neonatal encephalopathy.” by Rutherford M, Ward P, Allsop J, 
Malamatentiou C, Counsell S. Early Hum Dev. 2005 Jan;81(1):13-25. 
 
Deep grey matter lesions are often accompanied by injury in the cerebral cortex and 
subcortical white matter around the central sulcus, which become most obvious after 
the first week from injury (37, 38); extensive white matter abnormalities are observed in 
approximately 50% of infants with deep grey matter lesions. Although MRI is useful to 
predict the motor and cognitive outcomes during the early infancy, these abnormal signs 
are not obvious within the first week of life (37, 39), suggesting the requirement to 
incorporate either advanced, quantitative magnetic resonance techniques (e.g. maps of 
transverse relaxation time (T2) and apparent diffusion coefficient (ADC)), or alternative 
biomarkers such as electroencephalogram (40) for early and precise diagnosis of 
neonatal encephalopathy. 
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1.3 Mechanisms of cerebral injury in the newborn infant 
 
1.3.1 Primary energy failure and acute phase injury cascade 
Cerebral injury secondary to hypoxia-ischaemia is an evolving process, which takes 
place over days and weeks. Severe hypoxic–ischaemic events disable mitochondrial 
synthesis of adenosine triphosphate, resulting in the loss of energy-dependent functions 
to maintain cellular homeostasis (41). When severe shortage in energy substrates is 
prolonged, neuronal cells become unable to maintain the cellular membrane potential, 
resulting in neuronal depolarisation and subsequent release of excitatory 
neurotransmitters such as glutamates (Fig. 1.3-1). Persistent excitation of the cerebral 
tissue causes unregulated influx of calcium into the cytoplasmic space, further leading 
to the activation of nitric oxide synthase and the production of reactive oxygen species. 
 
Figure 1.3-1: Primary energy depletion and acute phase injury cascade 
 
Cartoon depicting the acute phase injury cascade following acute hypoxia-ischaemia and 
subsequent primary energy depletion. Prolonged energy depletion results in the accumulation of 
excitatory neurotransmitters, which triggers the influx and deposition of calcium to cytoplasmic 
organellae, generation of oxygen free radicals, mitochondrial dysfunction and prolonged cellular 
death induced by the activation of pro-apoptotic proteins. Such a complex and persistent 
evolutional process of cerebral injury causes acute cellular loss mainly via necrosis and subacute 
to chronic cellular loss via apoptosis and autophagy. 
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1.3.2 Latent phase and secondary energy failure 
Although severe hypoxia-ischaemia exhausts cerebral tissue energy substrates, 
efficient resuscitation may temporary reverse the tissue energy metabolism to normal 
levels (42). Indeed, in asphyxiated newborn infants, phosphorus (31P) magnetic 
resonance spectroscopy (MRS) revealed “at a glance normal” cerebral metabolism 
shortly after delivery (Fig. 1.3-2) (43, 44). This transient period with near-normal energy 
metabolism, or the “latent-phase”, is followed by a secondary phase of impaired 
cerebral energy generation ensued 8 to 24 hours after hypoxia-ischaemia despite 
adequate oxygenation and circulation (42). Secondary energy failure is characterised by 
progressive declines in phosphocreatine (PCr) and nucleotide triphosphates (NTP; 
mainly adenosine triphosphate (ATP)) and increased inorganic phosphate (Pi) (43).  
 
Figure 1.3-2:  Evolution of energy failure after the latent phase in a 
severely asphyxiated newborn infant 
 
Brain tissue energetic metabolites were observed using 31P MRS from a baby born at 37 weeks 
gestation who had sustained severe birth asphyxia. The peaks (1-7) are attributable to 
phosphomonoesters, inorganic phosphate, phosphodiesters, phosphocreatine, and three 
phosphorus nuclei of adenosine triphosphate, respectively. In contrast to the baseline spectrum at 
8 hours, where relative concentrations of phosphocreatine and adenosine triphosphate were still 
maintained at subnormal levels, high energy phosphate peaks fell with time while inorganic 
phosphate increased. The infant died at 60 hours after birth. From “Prognosis of newborn infants 
with hypoxic-ischemic brain injury assessed by phosphorus magnetic resonance spectroscopy.” 
Azzopardi D, Wyatt JS, Cady EB, Delpy DT, Baudin J, Stewart AL, Hope PL, Hamilton PA, Reynolds 
EO. Pediatr Res. 1989 May;25(5):445-51. 
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The severity of secondary energy failure and subsequent neurodevelopmental 
impairments are closely correlated been each other (43, 45, 46). The importance of the 
latent phase is increasingly recognised (47), as this period is likely to constitute a 
"therapeutic window" for neuroprotective treatments such as therapeutic hypothermia 
(7-9, 48, 49). Despite the “normal” high energy phosphate concentrations within the 
brain tissue during the latent phase, evidence of cellular injury at this time has been 
reported, which includes raised lactate dehydrogenase and propidium iodide 
fluorescence (50); abnormal white-matter nerve fibres and increased white-matter 
apoptosis (51); increased β-amyloid precursor protein (52); and calcium accumulation, 
mitochondrial swelling with nuclear chromatin condensation accompanying maximal 
mitochondrial enlargement, and apoptosis and necrosis features (Fig. 1.3-3) (53). It is 
hence important to understand the subtle change in cerebral high-energy phosphates 
during the latent phase in developing early diagnostic biomarkers. However, few studies 
have thus far scrutinised temporal changes in brain energy metabolites in detail.  
 
Figure 1.3-3: Evolution of secondary brain injury 
 
Energy depletion culminating in Bax-dependent mitochondrial permeabilisation represents an 
irreversible commitment to cell death in neonatal brain injury. Adenosine monophosphate-activated 
protein kinase (AMPK) is activated in response to stresses which change either intracellular 
calcium levels or deplete intracellular adenosine triphosphate concentrations. Although AMPK 
works to return energy levels to baseline, prolonged activation results in upregulation of the 
proapoptotic protein, Bim. From “Molecular mechanisms of neonatal brain injury. Thornton C, 
Rousset CI, Kichev A, Miyakuni Y, Vontell R, Baburamani AA, Fleiss B, Gressens P, Hagberg H. 
Neurol Res Int. 2012;2012:506320. 
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1.4 Piglet model of neonatal encephalopathy 
 
Over the past 20 years, our group has used a newborn piglet model of transient 
hypoxia-ischaemia induced by reversible occlusion of the common carotid arteries by 
remotely controlled balloon vascular occluders and simultaneous reduction in the 
inspired oxygen fraction to 0.12 (42). The use of large animal models benefits from 
intensive care settings, which mimics the clinical situation in detail, using mechanical 
ventilation, continuous fluid and drug infusion, and continuous physiological monitoring 
throughout the experiment. Piglets are cared for within the bore of the magnetic 
resonance spectrometer, before, during and after hypoxia-ischaemia, for up to 60 hours 
at a time to serially monitor cerebral energy metabolism. Thus, quantitative measures of 
acute hypoxic-ischaemic insult, latent phase and secondary energy failure are obtained 
non-invasively (Fig. 1.4-1). In addition to the similarity in the experimental setting to the 
clinical practice, there is another outstanding benefit in using this model, because 
piglets have much larger brain compared to rodents, which allows the assessment of 
the regional impact of hypoxia-ischaemia and therapeutic interventions (49). 
 
Figure 1.4-1: Evolution of secondary energy failure in the piglet model of 
neonatal encephalopathy 
 
Temporal changes in cerebral nucleotide triphosphate (mainly adenosine triphosphate) 
concentration relative to exchangeable high-energy phosphate pool is shown before, during and 
after hypoxia-ischaemia. Resuscitation transiently reversed cerebral high energy phosphate to the 
normal level (the latent phase), which is followed by secondary energy failure after 8-24 h of 
resuscitation. 
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1.5  Quantitative magnetic resonance biomarkers of cerebral 
injury 
 
1.5.1 31P MRS 
As described in the previous section, 31P MRS has been utilised as a unique biomarker, 
with which cerebral tissue energy metabolites are directly observed without invasive 
procedures (42-44). Using 31P MRS, temporal changes in high energy phosphates, 
including the transient decline during acute hypoxia-ischaemia, recovery following the 
commencement of resuscitation, latent phase, and the delayed decline due to the 
progress of secondary energy failure, can be monitored continuously (42, 47). 
Metabolites observed using 31P MRS include high energy phosphates such as 
nucleotide triphosphate (NTP), which is mainly adenosine triphosphate (ATP), and 
phosphocreatine (PCr), which serves as a stable high energy phosphate pool, whereas 
inorganic phosphate (Pi), which is virtually the ashes of high energy phosphates, can 
also be monitored simultaneously (Fig. 1.5-1) (54).  
 
Figure 1.5-1: High resolution 31P MRS spectra from the brain of the piglet 
model 
 
Representative spectra from a piglet which developed severe secondary energy failure. (a) before 
hypoxic-ischaemic insult; (b) 1.6 hours after hypoxia-ischaemia; and (c) during secondary energy 
failure 23.4 hours after the commencement of resuscitation. Although no apparent decline is 
observed for PCr and NTP, Pi is slightly increased 1.6 hours after hypoxia-ischaemia (b) versus 
baseline (a). In (c) Pi is further increased, with overt reduction in PCr and NTP, which is 
characteristic of secondary energy failure. From “Phosphorus magnetic resonance spectroscopy 2 
h after perinatal cerebral hypoxia-ischemia prognosticates outcome in the newborn piglet.” by Cady 
EB, Iwata O, Bainbridge A, Wyatt JS, Robertson NJ. J Neurochem. 2008 Nov;107(4):1027-35. 
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Although the MRS signal obtained along different frequencies corresponds to the 
concentration of each metabolite, it is technically difficult to give the absolute 
concentration of these molecules precisely. Hence, currently, ratios of concentrations 
between metabolites have widely been used. PCr/Pi is considered to give sensitive 
stress marker, because PCr serves to maintain the concentration of ATP, thus starting 
declining before the overt change in ATP; in addition, because Pi increases with the 
acceleration of ATP consumption, PCr/Pi is supposed to change dynamically even 
when the shortage in energy substrates is still tolerated by the cerebral tissue (Fig. 
1.5-2) (42). However, PCr/Pi is theoretically influenced by factors including the flux 
within the mitochondrial electron transport chain, re-phosphorylation of adenosine 
diphosphate via creatine kinase, and anaerobic glycolysis under unimpaired substrate 
delivery (11). In our more recent studies, we employed another approach to assess 
energy metabolites; each metabolite is quantified relative to the total mobile 
exchangeable phosphate pool (EPP), which is the sum of Pi, PCr and 3 NTPs (54). This 
method may be inferior in its sensitivity to detect subtle temporal changes in high energy 
phosphates, however, there is an advantage that the temporal change in each 
metabolite can be assessed differently by monitoring Pi/EPP, PCr/EPP and NTP/EPP.  
 
Figure 1.5-2: Temporal changes in PCr/Pi and NTP/EPP in the piglet model 
of asphyxial encephalopathy 
 
Secondary energy failure is identified much earlier in the trend of PCr/Pi compared to NTP/EPP 
because the decline in PCr and the increase in Pi occurs even while ATP levels are maintained 
within the cerebral tissue. From “Temporal and anatomical variations of brain water apparent 
diffusion coefficient in perinatal cerebral hypoxic-ischemic injury: relationships to cerebral energy 
metabolism.” by Thornton JS, Ordidge RJ, Penrice J, Cady EB, Amess PN, Punwani S, Clemence M, 
Wyatt JS. Magn Reson Med. 1998 Jun;39(6):920-7. 
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Early clinical studies which used 31P MRS in infants with severe neonatal 
encephalopathy revealed that the MRS spectrum shortly after birth demonstrates 
‘normal’ cerebral energy metabolism (44). Azzopardi and colleagues demonstrated that, 
after such a latent phase, PCr and NTP decrease and Pi increases despite adequate 
oxygenation and circulation (43). Low levels of high energy phosphates, decreased 
PCr/Pi and increased Pi in the first days of life have been associated with 
neurodevelopmental impairment and increased mortality (43, 45, 46). 
Despite the advantage of31P MRS in allowing direct monitoring of brain tissue energy 
metabolism, the use of 31P MRS is not popular in clinical practice, because of its 
requirement for expertise and special hardware. In addition, the signal of 31P MRS is 
usually obtained from the entire brain without specifying the region of interest, mainly 
because of the weak signal from 31P molecule compared to 1-H (Fig. 1.5-3) (1H). 
 
Figure 1.5-3: Cerebral tissue covered by the surface coil in the acquisition 
of 31P MRS spectra from the piglet brain 
 
Schematic drawing showing the coronal section of the piglet brain, together with the surface coil 
position and the approximate extent of the surface coil sensitive volume. From “Temporal and 
anatomical variations of brain water apparent diffusion coefficient in perinatal cerebral 
hypoxic-ischemic injury: relationships to cerebral energy metabolism.” by Thornton JS, Ordidge RJ, 
Penrice J, Cady EB, Amess PN, Punwani S, Clemence M, Wyatt JS. Magn Reson Med. 1998 
Jun;39(6):920-7. 
 
  
 37 
1.5.2 1H MRS 
Compared to31P MRS, 1H MRS can be performed using most newly built MRI scanners, 
and has various advantages including the short acquisition time, spatial resolution, and 
the potential for absolute quantification of the molecules (55). In addition, because 1H is 
the most common structural element within the human body, a wide range of 
metabolites, such as lactate, N-acetyl aspartate (NAA), choline, creatine, and alanine, 
can be identified at their corresponding unique chemical shifts (Fig. 1.5-4). Although the 
current technique used for the clinical and experimental studies does not allow the 
isolation of peaks for energy metabolites, such as ATP, PCr and Pi, the level of 
anaerobic metabolism within the cerebral tissue can be extrapolated using the lactate 
peak. Following perinatal hypoxia-ischaemia, the concentration of cerebral tissue 
lactate increases according to the depth of acute insult (56, 57). This increase in lactate 
is attributable to impaired oxidative metabolism due to mitochondrial damage, however, 
other mechanisms, such as the alteration of the cellular component, may also be 
involved, because, following severe perinatal hypoxia-ischaemia, the elevation of 
lactate sometimes persists for weeks (58). N-acetyl aspartate is another useful marker 
for intact neurons and axons; a reduction in NAA following perinatal hypoxia-ischaemia 
is associated with reduced neuronal and axonal viability (59-61). A recent meta-analysis 
concluded that lactate/NAA peak-area ratio obtained from the deep grey matter during 
the neonatal period provides the best predictive value of the outcome in infants with 
neonatal encephalopathy with higher sensitivity (82%, 95% CI: 74%–89%) and 
specificity (95%, 95% CI: 88%–99%) compared to conventional MRI, diffusion weighted 
imaging (DWI), and other metabolite ratios of 1H MRS (58).  
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Figure 1.5-4: 1H MRS spectra, lactate/NAA and outcome of asphyxiated 
infants 
 
Left panel: 1H MRS spectra obtained from thalamic region of: (a) a control infant aged 84 hours; (b) 
an infant 19 hours after moderate hypoxia-ischaemia; (c) an infant 17 hours after severe 
hypoxia-ischaemia. Resonance identifications: (1) glutamate/glutamine; (2) myoinositol/glycine; (3) 
choline; (4) creatine; (5) glutamate/glutamine; (6) NAA; (7) lactate. Right panel: Maximum 
lactate/NAA measured at >12 hours (n=28) and neurodevelopmental outcome at 1 year of age (● 
Normal outcome; ▼ impairment with no disability; ■ impairment with disability; ▲dead). From 
“Early brain proton magnetic resonance spectroscopy and neonatal neurology related to 
neurodevelopmental outcome at 1 year in term infants after presumed hypoxic-ischaemic brain 
injury.” by Amess PN, Penrice J, Wylezinska M, Lorek A, Townsend J, Wyatt JS, Amiel-Tison C, 
Cady EB, Stewart A. Dev Med Child Neurol. 1999 Jul;41(7):436-45. 
 
1.5.3 Diffusion weighted imaging 
Diffusion weighted imaging (DWI) is a MRI technique, which is sensitive to acute phase 
brain injury induced by hypoxia-ischaemia (62). DWI reflects changes in water diffusion 
due to redistribution of water between cytoplasmic and extra-cellular spaces, cytotoxic 
oedema and other derangements in cellular homeostasis. After perinatal 
hypoxia-ischaemia, abnormal MRI findings on conventional sequences remain invisible 
within several days of the acute event, when important clinical decisions have to be 
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made to maximise the benefit from neuroprotective interventions (11). In contrast to the 
limited utility of conventional MRI during the acute period, DWI provides more sensitive 
marker in assessing tissue integrity and damage from shortly after hypoxia-ischaemia 
(Fig. 1.5-5). While the assessment of DWI is qualitative, maps of apparent diffusion 
coefficient (ADC) enable objective assessment and comparison of acute phase brain 
injury even when the injury pattern is global and little amount of cerebral tissue is spared 
(63). Following perinatal hypoxia-ischaemia, ADC values are significantly reduced in the 
first week of birth in the white matter and/or deep grey matter. However, ADC values are 
reversed to the normal level after approximately a week. After the second week of life, 
ADC levels of affected regions are either normal or increased (64).  
A study which prospectively assessed DWI from infants with neonatal encephalopathy 
found that infants with poor outcome had lower ADC values at early imaging in the 
Rolandic cortex, hippocampus, deep grey matter and PLIC. However the authors 
suggested that the regional ADC values are of limited predictive value for the outcome, 
while the combined assessment of conventional MRI and the spatial pattern of DWI 
changes were better predictors of neurological outcomes (65). In agreement with this 
finding, a meta-analysis which compared the predictive values of magnetic resonance 
biomarkers during the neonatal period revealed that predictive values of ADC for the 
neurodevelopmental outcome are generally poor, and are inferior to 1H MRS (58). 
Because the timing of MRI scans is inconsistent between subjects, it is difficult to define 
at which phase of the injury evolution (i.e. the latent period, sub-acute phase decline in 
ADC or pseudo-normalisation) the infant was scanned. However, ADC changes 
following transient hypoxia-ischaemia in a piglet model has been demonstrated to have 
tight linear correlations with cerebral high energy phosphate levels, such as PCr and 
ATP (Fig. 1.5-6) (62). This suggests that ADC can be used as the acute phase maps of 
tissue energy metabolism although the difference in background variables between 
clinical and experimental settings, such as the maturational status of the brain, the type, 
timing and depth of hypoxia-ischaemia and the fixed/unfixed timing for studies, need to 
be accounted for. With further experimental validations of ADC with histo-pathological 
assessments at different evolutional stage of neonatal encephalopathy, this technique 
can be used to evaluate the progress of injury and efficacy of treatments, as well as to 
predict the precise outcome of the infant. 
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Figure 1.5-5: Conventional MRI and DWI after perinatal hypoxia-ischaemia 
 
A-F: MRI obtained on the 3rd day of life from an infant with a poor motor outcome. A-C, T1-weighted 
images with absence of normal signal intensity in the internal capsule. D-F, DWI with hyperintense 
signal in the Rolandic cortex, basal ganglia, hippocampus, and cerebral peduncle. G-I: MRI at day 9 
in an infant with a good motor outcome. G, T1-weighted image with an abnormal high signal 
intensity in the globus pallidus and thalamus. H, T2-weighted image with an irregular, abnormal 
high signal intensity in the thalamus and globus pallidus. I, DWI without abnormalities. From 
“Diffusion-weighted and conventional MR imaging in neonatal hypoxic ischemia: two-year 
follow-up study.” by Vermeulen RJ, van Schie PE, Hendrikx L, Barkhof F, van Weissenbruch M, Knol 
DL, Pouwels PJ. Radiology. 2008 Nov;249(2):631-9. 
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Figure 1.5-6: Correlation between PCr/Pi and ADC  
 
Combined scatter plot of ADC against PCr/Piin a piglet model of perinatal asphyxial encephalopathy. 
From “Temporal and anatomical variations of brain water apparent diffusion coefficient in perinatal 
cerebral hypoxic-ischemic injury: relationships to cerebral energy metabolism.” by Thornton JS, 
Ordidge RJ, Penrice J, Cady EB, Amess PN, Punwani S, Clemence M, Wyatt JS. Magn Reson Med. 
1998 Jun;39(6):920-7. 
 
Recently, additional use of fractional anisotropy (FA), which is derived from diffusion 
tensor imaging (DTI), is expected to improve the detection of early microstructural 
changes after hypoxia-ischaemia. FA has been proposed to quantify the overall 
directionality of water diffusion. Cerebral regions with cylindrical microstructure 
(myelinated white matter) have high FA values close to 1 because of anisotropic 
diffusion, whereas regions with highly isotropic diffusion (e.g. cerebro-spinal fluid and 
cystic lesions) have low FA values close to 0 (38). In the cerebral tissue, diffusion is 
greatest parallel to the axonal tract, whereas diffusion is restricted in the perpendicular 
direction. It has been demonstrated that FA values in the white matter decrease 
following moderate to severe perinatal hypoxia-ischaemia, and, unlike ADC, abnormal 
low FA values can be observed persistently after the second week of life, suggesting the 
benefit of combining ADC and FA values (66).  
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1.5.4 Maps of longitudinal and transverse relaxation times 
Clinical diagnosis of cerebral injury using conventional MRI relies on altered tissue 
signal intensities, which are caused by the change in longitudinal (T1) or transverse (T2) 
relaxation times. Although mapping of the longitudinal relaxation time has not widely 
been used in the clinical diagnosis because of its requirement for expertise and 
relatively long acquisition time (67, 68), the opportunity to use T2 maps has 
exponentially increased (Fig. 1.5-7) (69). Most modern MRI scanners can now develop 
T2 maps with the minimum additional scanning time. T2 relaxation time is known to 
increase following perinatal hypoxia-ischaemia (70). 
 
Figure 1.5-7: Transverse relaxation time in the thalamus and basal ganglia 
 
T2-relaxation time of RoIs in the thalamus (left) and basal ganglia (right) by neurodevelopmental 
outcome at age 1 year. a: P <0.05, analysis of variance and Dunnett test versus normal-outcome 
group. Closed circle, normal; open square, moderate; open triangle, severe. From “Comparative 
prognostic utilities of early quantitative magnetic resonance imaging spin-spin relaxometry and 
proton magnetic resonance spectroscopy in neonatal encephalopathy.” By Shanmugalingam S, 
Thornton JS, Iwata O, Bainbridge A, O'Brien FE, Priest AN, Ordidge RJ, Cady EB, Wyatt JS, 
Robertson NJ. Pediatrics. 2006 Oct;118(4):1467-77.  
 
Quantitative maps of relaxation times are expected to improve the diagnostic value on 
MRI by eliminating subjective biases, which were inevitable for the interpretation of 
conventional MRI (69). Compared to ADC, changes in T2 relaxation time are relatively 
less dynamic. However, extrapolated from the temporal change in the signal intensity on 
T2-weighted imaging, temporal changes in T2 relaxation time after perinatal hypoxia 
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ischaemia is unlikely to involve complex biphasic patterns, potentially providing a simple 
interpretation of the finding. Although there currently are only a limited number of 
studies which used T2 maps after perinatal hypoxia-ischaemia, this technique may also 
be used in future in combination with ADC and other imaging biomarkers. 
 
1.5.5 Monitoring of secondary energy failure and therapeutic time window 
Following moderate to severe hypoxia-ischaemia, cerebral metabolism recovers on 
resuscitation but only to develop secondary energy failure hours after the acute event 
(42, 43). Adverse biological reactions responsible for the evolution of secondary energy 
failure include accumulation of excitatory neurotransmitters, intracellular calcium 
accumulation, generation of oxygen free radicals, and mitochondrial dysfunction (71-75). 
A range of magnetic resonance biomarkers obtained using 31P MRS and DWI have 
demonstrated biphasic patterns of metabolic derangement following perinatal 
hypoxia-ischaemia (43, 45, 62). Severity of secondary energy failure represented by low 
cerebral PCr/Pi, NTP/EPP, increased brain lactate and an alkaline intracellular pH in the 
first few days after birth were associated with neurodevelopmental impairment and 
increased mortality (43, 45, 46, 76). Cerebral injury after perinatal hypoxia-ischaemia is 
an evolving process with necrosis and apoptosis, which are predominant mode of 
cellular death during acute phase and thereafter, respectively (73). Neuronal injury at 
the cellular level can be identified with closer inspection even during the latent phase; 
increase in lactate dehydrogenase and propidium iodide fluorescence, abnormal nerve 
fibres and increased apoptotic cells in white matter, increased β-amyloid precursor 
protein, calcium accumulation, mitochondrial swelling with nuclear chromatin 
condensation, and apoptotic and necrotic features, can be observed even during the 
period which corresponds to the latent phase (50-53). Understanding of secondary 
energy failure is especially important because, in experimental models, significant long 
term neuroprotection by therapeutic interventions occurs only when the gap between 
the acute event and the start of treatment remains within ~6 hours; no benefit has been 
observed when treatments are initiated after the evolution of secondary energy failure 
and epileptic activity (11, 77). Further investigations in the animal model targeting the 
mechanism of secondary energy failure, especially detailed energy metabolism during 
the latent period, when normal energy metabolism is maintained despite activated injury 
cascades, is required for the future improvement of acute phase diagnosis and 
treatment. 
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Figure 1.5-8: Evolution of secondary energy failure in a rodent model of 
transient hypoxia-ischaemia 
Concentrations of PCr and total creatine (PCr + creatine) (left panel), and ATP and total adenine 
nucleotides (TAN) (right panel) during and after hypoxia-ischaemia in a newborn rat model of 
transient hypoxia-ischaemia. C, control; H-I, hypoxia–ischemia. Concentrations of during and after 
hypoxia–ischaemia in the immature rat. C, control; H-I, hypoxia–ischemia. From “Secondary energy 
failure after cerebral hypoxia-ischemia in the immature rat.” by Vannucci RC, Towfighi J, Vannucci 
SJ. J Cereb Blood Flow Metab. 2004 Oct;24(10):1090-7. 
 
Quantitative measurements of total mobile phosphate and EPP by MRS, and of total 
adenine nucleotides and total creatine by biochemical methods have demonstrated falls 
at similar times to the declines in NTP/EPP and PCr/Pi (45, 78, 79). Using an 
established rodent model, Vannucci and colleagues demonstrated linear relationships 
between histo-pathological tissue injury and high energy phosphate concentrations at 6 
to 18 hours after hypoxia-ischaemia and with much greater significance at 24 to 48 
hours, and concluded that secondary energy failure was the consequence of evolving 
cellular destruction rather than causal of cellular death in surviving tissue (Fig. 1.5-8) 
(79). Although secondary energy failure observed using 31P MRS is likely to be a 
phenomenon directly associated with a delayed, irreversible metabolic crisis, it is 
unclear whether secondary energy failure directly parallels the temporal evolution of cell 
death itself. 
  
1.5.6 Regional variation of energy metabolism following 
hypoxia-ischaemia 
Although the global evolution of secondary energy failure following perinatal 
hypoxia-ischaemia is already complex in its timing and severity, these factors may be 
spatially different between different cerebral regions and even between cellular 
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components, because the response to hypoxia-ischaemia, resuscitation and treatment 
is likely to be dependent on the background characteristics in metabolism, anatomical 
structure, vascularity and neuronal circuitry (Fig. 1.5-9) (80). 
 
Figure 1.5-9: Diagram of normal basal ganglia motor control circuit and 
areas damaged by near-total asphyxia 
 
Arrows indicate synapses with excitatory glutamate neurotransmitter; blunted lines indicate 
inhibitory synapses. GPi, globus pallidus interna; GPe, globus pallidus externa; STN, subthalamic 
nucleus. If these regions are firing rapidly, the effect on globus pallidus interna and globus pallidus 
externa is expected to be inhibitory because of inhibitory input from putamen, resulting in 
increased heterogeneity in spatial injury pattern. From “Possible mechanisms in infants for 
selective basal ganglia damage from asphyxia, kernicterus, or mitochondrial encephalopathies.” by 
Johnston MV and Hoon AH Jr. J Child Neurol. 2000 Sep;15(9):588-91. 
 
In a primate model of neonatal encephalopathy, different durations and severities of 
ischemia were associated with specific regional distribution of brain injury; partial 
asphyxia resulted in white matter injury whereas total asphyxia led to deep grey matter 
injury (81, 82). In the term newborn infant, cerebral injury following perinatal asphyxia 
has been identified as two major patterns of (i) the watershed predominant pattern 
involving the white matter, extending to cortical grey matter when severe, and (ii) the 
deep grey matter predominant pattern involving the deep grey nuclei and perirolandic 
cortex, extending to the total cortex when severe (Fig. 1.5-10) (83-86). Understanding of 
spatial and temporal evolution of cerebral injury would be important to estimate the 
associated outcome, and also to make important therapeutic decisions which bring the 
greatest opportunity of intact survival to the affected infant. 
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Figure 1.5-10: Pattern of brain injury after perinatal hypoxia-ischaemia and 
neurodevelopmental outcome at 30 months of age 
 
Box plot of the 30-month Mental Development Index (A) and neuromotor score (B) by the pattern of 
injury. MDI was lowest in the infants with the basal ganglia/thalamus predominant pattern, with 
intermediate scores in infants with the watershed pattern (p = 0.0007). Neuromotor impairments 
were most severe in the infant with the basal ganglia/thalamus pattern (p = .0001). From “Patterns of 
brain injury in term neonatal encephalopathy.” by Miller SP, Ramaswamy V, Michelson D, Barkovich 
AJ, Holshouser B, Wycliffe N, Glidden DV, Deming D, Partridge JC, Wu YW, Ashwal S, Ferriero DM. J 
Pediatr. 2005 Apr;146(4):453-60. 
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1.6 Treatment of neonatal encephalopathy 
 
1.6.1 Therapeutic hypothermia: mechanism 
A wide range of experimental evidence has been accumulated supporting the effect of 
mild to moderate cerebral hypothermia (32 to 34°C) applied immediately after transient 
hypoxia-ischaemia to reduce brain injury and to improves behavioural outcome (87, 88). 
Hypothermia applied following perinatal hypoxia-ischaemia suppresses numerous 
chemical reactions on the neurotoxic cascade, which includes the reduction in the 
metabolic rate by 4 to 7% per 1°C temperature reduction, attenuation of inflammatory 
reactions, decrease in the glutamate release, attenuation of the activity of 
N-methyl-D-aspartate receptors, reduction in the production of oxygen free radicals and 
nitric oxide, contribution to the reduction in intracranial pressure, and the prolongation of 
the therapeutic time window for other treatments (Fig. 1.6-1) (89-92).  
 
Figure 1.6-1: Systemic hypothermia and therapeutic time window in the 
piglet model of asphyxial encephalopathy 
 
Duration of latent phase measured by (A) NTP/EPP and (B) PCr/Pi in the normothermic (HI-n), 
hypothermic to 35oC (HI-35) and hypothermia to 33oC (HI-33) groups. Duration of the NTP/EPP latent 
phase was significantly longer in the cooled groups. There was no significant difference in the 
PCr/Pi latent-phase duration between the HI groups. a P<0.01; b P<0.05, compared with HI-n. From 
“Delayed whole-body cooling to 33 or 35 degrees C and the development of impaired energy 
generation consequential to transient cerebral hypoxia-ischemia in the newborn piglet.” by O'Brien 
FE, Iwata O, Thornton JS, De Vita E, Sellwood MW, Iwata S, Sakata YS, Charman S, Ordidge R, Cady 
EB, Wyatt JS, Robertson NJ. Pediatrics. 2006 May;117(5):1549-59. 
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Simultaneously with the beneficial effect of hypothermia for neuroprotection, several 
deleterious effects of hypothermia are known, including the cardiac suppression, 
reduction in cerebral blood flow, and increased blood viscosity (11). Thus the overall 
effect of therapeutic hypothermia is determined by the balance between protective and 
harmful effects, which may vary according to the type and depth of hypoxia-ischaemia. 
In addition to the direct neuroprotective effect of therapeutic hypothermia, both mild and 
moderate systemic hypothermia has been demonstrated to double the duration of the 
latent phase, or therapeutic time window, thus extending the period when additional 
neuroprotective interventions may be beneficial (47).  
 
1.6.2 Therapeutic hypothermia: current clinical evidence 
The results of the first large scale randomised controlled trials of selective head cooling 
and whole body cooling in neonatal encephalopathy was released in 2005, both of 
which showing the improved survival without severe neurodevelopmental impairments 
at 18 months of age (8, 9). Several more medium to large scale studies consistently 
demonstrated the beneficial effect of therapeutic hypothermia (7, 93-95).  
 
Table 1.6-1: Therapeutic hypothermia and outcomes at 18 months of age 
 
From “Neurological outcomes at 18 months of age after moderate hypothermia for perinatal 
hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data.” by Edwards AD, 
Brocklehurst P, Gunn AJ, Halliday H, Juszczak E, Levene M, Strohm B, Thoresen M, Whitelaw A, 
Azzopardi D. BMJ. 2010 Feb 9;340:c363. 
 
A recent meta-analysis based on the accumulated clinical evidence from medium to 
large scale clinical studies confirmed that therapeutic hypothermia of either using 
selective head cooling or whole body cooling ameliorated the outcome measures, such 
as mortality, death or severe neurodevelopmental impairment within overall participants 
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of the studies, and neurodevelopmental impairments in survivors at 18 months of age 
(Table 1.6-1) (12). Subsequently, in October 2010, the International Liaison Committee 
on Resuscitation released its revised recommendation for the newborn resuscitation, 
which strongly recommended the application of therapeutic hypothermia in near term 
and term infants with moderate to severe neonatal encephalopathy within 6 hours of 
birth (96). 
 
1.6.3 Key factors potentially associated with further improvement of the 
treatment 
Although clinical trials of therapeutic hypothermia demonstrated consistent 
neuroprotective effect of cooling, these studies raised important questions about the 
optimal modality, timing and duration of cooling, which maximise the neuroprotective 
effect of the treatment (20, 97). Experimental evidence suggested that inter- and 
intra-subject factors influence the neuroprotective potential of hypothermia; the 
protective effect of therapeutic hypothermia may be less prominent following very 
severe hypoxia-ischaemia (8, 98-100); the optimal temperature for neuroprotection may 
vary between different brain regions (Fig. 1.6-2) (49). If the spatial evolutional pattern of 
cerebral injury can be serially monitored using advanced imaging technique, it would be 
easier to identify a group of infants who respond to specific type of cooling before 
waiting for the assessment of long term outcomes.  
Thus far, no pharmacological treatments have been demonstrated to be clinically 
neuroprotective following perinatal hypoxia-ischaemia in large scale prospective studies 
(101). Nevertheless, a range of neuroprotective drugs are being assessed as add-on 
therapies to cooling (10, 102) expecting additive or synergistic effects. In a rodent model, 
the combination of xenon and hypothermia given 4 hours after hypoxia-ischaemia 
provided synergistic neuroprotection up to 30 days after birth (103). Because cooling 
itself can delay the evolution of secondary energy failure (Fig. 1.6-1) (47), the prolonged 
latent phase may provide sufficient therapeutic time window for additional 
neuroprotective treatments (104, 105). For example, a single dose of topiramate after 
hypoxia-ischaemia in the neonatal rat was not protective itself but extended the 
therapeutic window for brief transient hypothermia of as long as 3 hours (106). A robust 
biomarker, which reflects the severity and pattern of brain injury during the latent phase, 
is desirable to target neuroprotective therapies to patients who are most likely to benefit 
from invasive treatments. 
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Figure 1.6-2: Cooling level and region-specific brain protection  
 
In a piglet model of neonatal asphyxial encephalopathy, whole body cooling to 35oC (HI-35) 
provided modest tissue protection in both the cerebral cortex and deep grey matter, whereas 
cooling to 33oC resulted in improved neuroprotection in the cerebral cortex although protection in 
the deep grey matter was lost. From “Depth of delayed cooling alters neuroprotection pattern after 
hypoxia-ischemia.” by Iwata O, Thornton JS, Sellwood MW, Iwata S, Sakata Y, Noone MA, O'Brien 
FE, Bainbridge A, De Vita E, Raivich G, Peebles D, Scaravilli F, Cady EB, Ordidge R, Wyatt JS, 
Robertson NJ. Ann Neurol. 2005 Jul;58(1):75-87. 
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Chapter 2: Aim and Hypothesis 
 
Aim 
To assess temporal and spatial evolution of cerebral injury in the piglet model of 
asphyxial encephalopathy using serial magnetic resonance biomarkers and 
histo-pathological assessments 
 
Hypotheses  
Regional magnetic resonance biomarkers obtained during the acute phase of perinatal 
asphyxial encephalopathy predict histo-pathological cerebral injury when the brain is 
harvested either shortly after or up to 24 hours after the scan. 
 
Specific hypotheses 
1. A more severe hypoxic-ischaemic insult leads to a shorter latent phase and more 
severe secondary energy failure. 
2. Variation in energy metabolites is associated with the severity of secondary energy 
failure even before the overt evolution of secondary energy failure. 
3. Evolution of secondary energy failure is spatially heterogeneous when observed 
using ADC maps. 
4. Regional ADC values and global 31P MRS markers have different predictive values of 
later tissue damage between each other. 
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Chapter 3: General Materials and Methods 
 
3.1 Preparation of the Piglet model of asphyxial encephalopathy 
Experiments were performed under a UK Home Office Licence in accordance with UK 
guidelines. 
 
3.1.1 Surgical procedures 
An established piglet model of neonatal asphyxial encephalopathy was used with 
modifications in the protocol for each experiment (42, 49). Healthy Large-White piglets 
of either sex born at term were delivered from a licenced farm in the morning of the 
experiment within 24 hours of birth. The piglets were initially sedated with intramuscular 
midazolam (0.2mg/kg). Intensive life support and continuous physiological monitoring 
were provided throughout experiments, including core body temperature (Arbo N44-91, 
Kendall, Powell, TN, U.S.A), heart rate, arterial oxygen saturation (5500 Hudson RCI, 
Temecula, CA, U.S.A.) and the invasive arterial pressure.  
Five-percent isoflurane was given to the piglet as the initial concentration through a 
facial mask during the insertion of the tracheostomy tube. Anaesthesia was maintained 
by the combination of isoflurane (3% during the surgical procedures and <2% for the 
rest of the procedures), nitrous oxide, and a continuous infusion of morphine 
(0.05mg/kg/h). Piglets were mechanically ventilated; ventilator settings were adjusted to 
maintain normal PaO2 and PaCO2 levels at 8 - 13 kPa and 4.5 - 6.5 kPa, respectively, 
allowing for the temperature correction of the arterial blood sample (Fig. 3.1-1). 
 
Figure 3.1-1: Piglet model after surgical procedures 
 
The piglet underwent 
tracheotomy and was 
mechanically ventilated 
under general anaesthesia. 
Balloon vascular occluders 
and umbilical arterial/venous 
catheters were inserted. A 
pulseoxymeter was attached 
to the posterior limb of the 
piglet. 
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An umbilical venous catheter was inserted for the continuous infusion of maintenance 
fluids (10% dextrose, 60ml/kg/day), morphine, and intravenous injections of antibiotics 
(benzylpenicillin 50mg/kg and gentamicin 2.5mg/kg, every 12 hours). An umbilical 
arterial catheter was also inserted to enable continuous monitoring of the heart rate and 
arterial blood pressure, and intermittent blood sampling to measure PaO2, PaCO2, pH, 
electrolytes, glucose, and lactate. Bolus infusions of colloid (Gelofusin, Braun Medical. 
Emmenbrucke, Switzerland) and continuous dopamine infusions (5-15μg/kg/minute) 
were used as required to maintain the mean arterial blood pressure > 40mmHg.  
 
Figure 3.1-2: Piglet positioned within the plastic cylinder pod 
 
An animal is positioned and 
immobilised within a plastic 
pod before insertion into 
the magnet bore. The piglet 
is anaesthetised and 
mechanically ventilated 
through tubes connected to 
the right end of the pod. 
 
 
 
 
Both common carotid arteries were surgically isolated at the level of the fourth cervical 
vertebra and encircled by remotely controlled vascular occluders (OC2A, In Vivo Metric, 
Healdsburg, CA, U.S.A.). All the surgical procedures were undergone using the aseptic 
technique, and the incision was closed by sutures. To enable the continuous monitoring 
of brain metabolism and microstructural changes using the magnetic resonance 
spectrometer, subjects were sheltered within a specially designed plastic pod following 
the surgical procedures (Fig. 3.1-2). Within the pod, piglets were positioned prone with 
the scalp firmly immobilised below the surface coil; the pod was then inserted into the 
bore of the magnet. 
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3.1.2 Magnetic resonance biomarkers 
All or a part of following magnetic resonance biomarkers were serially obtained before, 
during and after transient hypoxia-ischaemia approximately every 3 to 5 hours 
according to the purpose of the study. However, during the insult, only 31P MRS was 
acquired continuously to closely follow the temporal change in energy metabolites. 
 
3.1.3 31P MRS 
A 7 Tesla Biospec spectrometer (Bruker Medizintechnik, Karlsruhe, Germany) was 
used for the acquisition of 31P MRS from the whole brain (31P frequency 121.6 MHz) 
using an elliptical surface coil (6.5 × 5.5 cm) positioned directly on the intact scalp (Fig. 
3.1-3). A single-pulse acquire sequence was used with the repetition time (TR): 10 s, 
quadrature data points: 2048, and the spectral width: 14286 Hz. Spectra were thus 
acquired effectively fully relaxed and, hence, peak-area ratios were directly related to 
metabolite concentration ratios (54). Generally 192 (baseline), 24 (during 
hypoxia-ischaemia and resuscitation), or 384 (thereafter) free induction decays were 
summed during each acquisition, NTP and EPP, where EPP = Pi + PCr + β- + 2γ- NTP. 
 
Figure 3.1-3: Representative 31P spectra from the piglet brain before 
hypoxia-ischaemia 
 
31P MRS spectra acquired from a piglet before hypoxic-ischaemic insult shows peaks of inorganic 
phosphate (Pi), phosphocreatine (PCr) and three peaks of NTP, which is mainly ATP. 
 
MRS data were analysed using AMARES (107) as implemented in the jMRUI software 
(108). Prior knowledge of the multiple structures of NTP peaks was used (fitting 
doublets to α-NTP and γ-NTP and a triplet to β-NTP) but no assumption was made as to 
their relative sizes. NTP is predominately ATP, comprising approximately 70% of the 
NTP signal in the rat pup (109). Thus the observed changes in NTP during this 
experiment predominately reflect changes in ATP. Inorganic phosphate was fitted using 
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4 separate components. The resonant frequency of the Pi signal is pH dependant (110, 
111) and comes from many physically separated brain compartments with different pH. 
Thus the Pi signal is complex and a single component is not sufficient for analysis.  
Phosphocreatine was fitted with a single component. 
 
3.1.4 Maps of ADC and FA 
The diffusion tensor was measured using single-shot spin-echo diffusion-weighted 
echo-planar imaging (11 coronal slices, echo time (TE) 76 msec; acquisition bandwidth 
200 kHz; slice thickness 2 mm; field of view 4 x 5 cm; image matrix 128 x 128; 10 
averages). Diffusion weighting was applied using a Stejskal Tanner gradient scheme. A 
single image with no diffusion weighting (b = 0 sec mm-2) was acquired along with 6 
images with diffusion weighting b = 1155 sec mm-2 and diffusion encoding directions 
uniformly distributed. The diffusion tensor was estimated using analytical expressions 
(112), and from this, ADC and FA maps were calculated for each pixel (Fig. 3.1-4). To 
compare regional ADC variations, regions of interest (RoIs) were placed in the cortical 
and deep grey matter, and peripheral and central white matter, corresponding to the 
RoIs for the histo-pathological assessment; the actual RoI placement was performed 
based on maps of ADC and FA using an image processing software (ImageJ, the 
National Institutes of Health, U.S.A.) (Fig. 3.1-4). ADC values were measured in a 
coronal plane which dissects the putamen, globus pallidus and thalamus; additional 
slices were used for the head of the caudate nucleus and hippocampus when 
necessary. 
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Figure 3.1-4: Regions of interest on a schema and maps of ADC and FA 
 
Regions of interest (RoIs) are shown in the cartoon (left) including a, sagittal-top; b, sagittal-bottom; 
c, parietal-top; d, parietal-bottom; e, temporal-top; f, CA1 region of the hippocampus; g, caudate 
nucleus, h, putamen; I, anterior thalamus; j, medial thalamus; k, lateral thalamus; l, sagittal white 
matter, m, parietal white matter; n, temporal white matter; o, superior periventricular white matter; p, 
periventricular white matter; q, inferior periventricular white matter; and r, posterior limb of the 
internal capsule. RoIs were placed guided by maps of ADC (middle) and fractional anisotropy 
(right). 
 
3.1.5 T2 maps 
T2 mapping was performed by acquiring two sets of spin-echo echo-planar images with 
different TEs (TR = 3 s; TE = 66 ms and 110 ms; Bandwidth, 200Hz; 11 coronal  
sections; 2 mm slice thickness; field of view, 4 x 5 cm; matrix, 128 x 128;10 averages). 
The T2 relaxation time was calculated using a program developed in a numerical 
computing software (Matlab, version 6.0, Mathworks, Cambridge, UK) by fitting a 
decreasing exponential to the signal intensity as a function of TE. 
 
3.1.6 Transient cerebral hypoxia-ischaemia, resuscitation and 
quantification of acute energy depletion 
After the completion of the baseline data acquisition, a transient hypoxic-ischaemic 
insult was given to the piglet while 31P MRS spectra were acquired every 4 minutes for 
the real time visual monitoring of the cerebral energy deficit using the β-NTP amplitude. 
The inspired oxygen fraction (FiO2) was reduced to 0.10-0.12 simultaneously with 
bilateral carotid-artery occluder inflation. When the β-NTP amplitude had decreased to 
30% of baseline, this amplitude was maintained for 20 minutes by titrating FiO2. After 
the insult, the animal was resuscitated by deflating the occluder and increasing FiO2 to 
achieve normal oxygen saturation. 
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Although we aimed to yield similar insult severities between subjects by utilising the 
feedback from simultaneously obtained 31P MRS spectra, the insult severity and 
subsequent cerebral damage still differed between subjects, presumably due to 
technical variations in hypoxia-ischaemia and biological characteristics in the response 
to the insult. To assess the impact of variations in the insult severity, the cerebral "acute 
energy depletion" was retrospectively calculated from the difference between the ratio 
β-NTP/EPP and its baseline, pre-insult level integrated during hypoxia-ischaemia and 
the first 60 minutes of resuscitation (Fig. 3.1-5) (42). 
 
Figure 3.1-5: Schematic diagram summarising the quantification of the 
acute insult severity 
 
The time integral of the acute energy depletion was calculated during hypoxia-ischaemia and the 
first 60 minutes of the resuscitation. The energy depletion during the early resuscitation was 
included because the tissue energy derangement lasts until high-energy phosphates are fully 
restored by successful resuscitation. 
 
The degree of acute cerebral energy depletion was quantified as the time integral of the 
fall in β-NTP/EPP relative to mean baseline during transient hypoxia-ischaemia and the 
first 60 minutes of resuscitation. The early resuscitation period was included on the 
basis that the degree of cellular injury is related not only to the duration and amount of 
NTP depletion during transient hypoxia-ischaemia but also to that during resuscitation 
when energy generation has not yet fully recovered (42).  
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3.1.7 Temperature control and hypothermia 
The rectal temperature of the piglet was continuously monitored throughout the 
experiment using a thermistor probe (Arbo N44-91, Kendall, Powell, TN, U.S.A.), which 
was maintained within the normal range (38.5-39.0°C) for piglets using either a heated 
operating table and an overhead warmer during surgical procedures, or a thin mattress 
of plastic tubing through which water at a controlled temperature passed was used 
covering the ventral half of the trunk and the limbs during magnetic resonance studies. 
For groups of piglet which underwent delayed therapeutic hypothermia, the mattress 
temperature was lowered between 2 and 26 hours following the end of 
hypoxia-ischaemia to induce whole body cooling at the appropriate target rectal 
temperatures. Animals were then re-warmed slowly at less than 1°C per hour, and the 
normal core temperature was maintained until the end of the experiment. 
 
3.1.8 Monitoring and treatment of seizure 
Continuous monitoring of electroencephalogram was not available for the current study 
due to technical reasons. Possible seizure activities were suspected if there was a 
sudden change in the heart rate, arterial blood pressure, SaO2, breathing pattern and 
the motion artefact on the magnetic resonance signal. The isoflurane concentration was 
transiently increased to 2-3% and mechanical causes such as tube obstruction were 
excluded. If all other possible causes of physiological instability were excluded, the 
event was recorded as a seizure. An injection of phenobarbital (20mg/kg) was given 
intravenously, which was followed by additional doses (10mg/kg) up to twice when the 
initial dose was ineffective or when seizures were recurrent. 
 
3.1.9 Quantification of latent phase and secondary energy failure 
The latent-phase was defined as the period between NTP/EPP ascending to within its 
99% confidence interval of the baseline value during metabolic recovery after 
hypoxia-ischaemia and it later falling below again indicating the start of overt secondary 
energy failure (47). Secondary-energy-failure severity was quantified in each piglet as 
the minimum NTP/EPP during the period 6 to 48 hours post hypoxia-ischaemia 
determined by fitting a cubic polynomial to the time-series data in order to avoid 
systematic bias to lower NTP/EPP due to random error, confirming secondary energy 
failure when NTP/EPP had fallen to less than 60% of baseline. For the study series 
which used variable study durations, the severity of secondary energy failure was 
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defined based on the minimum NRP/EPP during 8 to 24 hours after hypoxia-ischaemia 
(see section 3.3.5.4 in page 67 for detail). 
 
3.1.10  Histopathology 
After the completion of the planned data acquisition and incubation time, animals were 
humanely sacrificed under terminal anaesthesia by an overdose of pentobarbital 
injection. Each brain was fixed by perfusion through the heart with 4% cold 
paraformaldehyde in phosphate saline buffer, dissected out, post-fixed for further 24 
hours within 2% paraformaldehyde, cut in 5mm thick coronal slices, and prepared for 
embedding in paraffin wax. Sections (6µm thick) were stained routinely with 
haematoxylin and eosin (H & E), Luxol-fast blue-cresyl violet (LFB/Nissl), and 
immuno-histochemistry using antibodies to glial fibrillary acidic protein (GFAP, 1: 500, 
Dako Cytomation, Glostrup, Denmark) for the activation of astrocytes, and CD68 (H-255, 
1: 200, Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.) for cells of 
microglial/macrophage lineage. The terminal deoxynucleotide transferase nick end 
labelling (TUNEL, Roche Applied Science, Indianapolis, IN) was also used to identify 
cell death with apoptotic features. Quantitative analyses of the neuronal damage were 
performed using H & E stained sections from the following regions:  
 
(i) the superior and inferior frontal, superior and inferior parietal, insular, temporal, 
and parahippocampal cortex and the corresponding white matter 
(ii) the CA1-4 regions and the dentate gyrus of the hippocampus 
(iii) the putamen, globus pallidus, and anterior, medial, lateral dorsal, and the ventral 
nuclei of the thalamus 
(iv) the periventricular white matter and the posterior limb of the internal capsule  
(v) the cerebellar hemisphere 
 
For the analysis, up to four brain sections (generally 1 to 3 sections for regions i, ii, iii 
and iv; and another section for cerebellum) were carefully chosen to represent 
afore-mentioned regions. In the neo-cortical regions, observations were taken from both 
top of the gyrus and the bottom of the sulcus, respectively. The brain stem and 
hypothalamic nuclei were qualitatively but not quantitatively examined as these regions 
of the brain appeared to be much less affected in our model (113). The detailed cerebral 
regions assessed within each study are presented in the sections 3.2 and 3.3.  
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Figure 3.1-6: Region of interest for histo-pathological assessment in the 
cortical grey matter 
 
In the neo-cortical grey matter, 
assessment was performed over 
multiple views to include all cortical 
layers except for the molecular layer. 
Circles are views on the microscope; 
rectangles are the area where counts for 
neuronal assessment were performed.  
 
 
 
 
 
 
 
 
 
The neuronal changes on H & E stained samples in each region were scored in 6 
grades (0-5) of severity according to the morphological changes in staining (nuclear 
hyperchromasia and cytoplasmic eosinophilia) and shape (cytoplasmic/nuclear 
shrinkage) as follows: 0 normal, 1 very mild changes in staining, 2 mild neuronal change 
in staining and shape, 3 moderate neuronal change in staining and shape, 4 acute 
neuronal death (karyolysis or karyorrhexis), 5 complete neuronal loss (Table 3.1-1). 
Two experienced investigators examined the brain samples blind to the experimental 
group. For quantification, at least 250 neurons per region in the neo-cortical grey matter, 
deep grey matter, and the cerebellar granule cell layers and 100 neurons in the 
remaining regions were assessed in each animal, using ×200 magnification and paying 
attention to include each neuronal layer or region equally (typically 2 views for the 
bottom of sulci and 3 to 5 views for the top of giri; see Fig. 3.1-6). In the cerebellum the 
neuronal appearance was separately evaluated in Purkinje and granule cells, due to the 
marked susceptibility of Purkinje cells. For further analysis, neuronal counts which 
scored 0 or 1, 2 or 3, and 4 or 5 were combined to give percentages of ‘viable’, 
‘intermediate’, and ‘dead’ neurons, respectively. 
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Table 3.1-1: Definition of pathological scoring for neuronal damages 
Score Neuronal Appearance Neuronal Status 
0 no significant changes 
Viable 
1 mild neuronal change in staining 
2 mild neuronal change in staining and shape 
Intermediate 
3 moderate neuronal change in staining and shape 
4 acute neuronal death 
Dead 
5 
neuronal death with complete neuronal loss or tissue 
destruction 
Neuronal changes in staining include nuclear hyper basophilia, condensation of chromatin, and 
cytoplasmic eosinophilia. Changes in shape include cytoplasmic and nuclear shrinkage and 
deformation. Percentages of neurons with each score were recorded in each region. For further 
analysis, scores 0 and 1, 2 and 3, and 4 and 5 were combined to give percentages of ‘viable’, 
intermediate, and ‘dead’ neurons, respectively. 
 
Brain samples stained using LFB/Nissl, immuno-histochemical and TUNEL stains were 
assessed qualitatively and descriptively for the first study, or “Associations between 
insult severity and therapeutic time window duration”, whereas quantitative or 
rank-ordinal assessments were performed for the third study, or “Temporal and spatial 
evolution of secondary energy failure and cerebral injury” (see sections 3.2.3. and 3.4.3. 
in page 63 and 70 for detail).   
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3.2 Associations between insult severity and therapeutic time 
window duration 
 
3.2.1 Subjects and study groups 
Forty-two healthy Large-White piglets of either sex born at term (115 (2) days, mean 
(standard deviation)) weighing 1495 (170) g were studied within 24hours of birth. 
Baseline data were acquired after stabilization of the animal in the spectrometer. Piglets 
were then randomised into 5 groups:  
(i) sham operation and normothermia (rectal temperature 38.5-39oC; n=10) 
(ii) sham operation and transient whole body cooling at rectal temperature 33°C 
(n=3) 
(iii) transient hypoxia-ischaemia and normothermia, (HI-n, n=12) 
(iv) transient hypoxia-ischaemia and delayed transient whole body cooling at rectal 
temperature 35°C (HI-35, n=7) 
(v) transient hypoxia-ischaemia and delayed transient whole body cooling at rectal 
temperature 33°C (HI-33, n=10). 
After randomisation, piglets in groups (iii)-(v) were exposed to a hypoxic-ischaemic 
insult. The groups (ii), (iv) and (v) were cooled to the target rectal temperature between 
2 and 26 hours after resuscitation, which was followed by gradual rewarming with the 
rate of approximately 0.5oC/hour. Experiments were terminated 48 hours after the 
baseline data acquisition for groups (i) and (ii), or 48 hours after the commencement of 
resuscitation for groups (iii), (iv) and (v). 
 
3.2.2 Acquisition of magnetic resonance data 
The 31P MRS spectra were obtained approximately every 4 hours after the 
commencement of resuscitation. The final spectra were acquired within 2 hours of 
termination (Fig. 3.2-1).  
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Figure 3.2-1: NTP/EPP changes of representative piglets over 48 hours 
 
Cerebral NTP/EPP of representative piglets from the HI-n (♦), HI-35 (*) and HI-33 (Δ) groups at 
baseline, during transient hypoxia-ischaemia, and for 48 h following resuscitation. The vertical line 
shows the commencement of resuscitation and the horizontal line shows the lower 99% confidence 
interval of the baseline NTP/EPP. 
 
3.2.3 Histopathology 
H & E stained sections were used for the assessment of the neuronal injury. For specific 
comparison with MRS measures, an observer blind to the experimental piglet group 
assessed neuronal morphological changes in 10 brain regions in the surface-coil 
sensitive volume (6 cortical grey matter regions from 3 gyri and 3 sulci in the inferior 
frontal, superior and inferior parietal cortex, and 4 deep grey matter regions from the 
putamen and anterior, medial, and lateral dorsal thalamic nuclei) and the average 
percentages of dead neurons were calculated (Fig. 3.2-2). 
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Figure 3.2-2: Schematic diagram depicting the histo-pathological regions 
of interest in a coronal slice of the piglet brain 
 
 
Cartoon depicting regions assessed 
histo-pathologically, including the inferior 
frontal (a, b), superior (c, d) and inferior (e, f) 
parietal cortex, and 4 deep grey-matter from 
the putamen (g) and anterior (h), medial (i), 
and lateral dorsal (j) thalamic nuclei. 
For this study, unlike our previous studies, 
temporal cortex, hippocampus and several 
other regions in the deep brain structure 
were not considered because of the 
corresponding brain regions covered by the 
MRS coil (see Fig. 1.5-3 for detail). 
 
 
3.2.4 Statistical analysis 
Neuroprotective effect of transient whole body cooling to 33°C and 35°C has been 
reported previously (47, 49). In this current study, we only considered the groups HI-n, 
HI-35, and HI-33. To examine the dependences of the latent-phase duration, severity of 
secondary energy failure, and neuronal mortality on acute energy depletion and rectal 
temperature separately, multivariate analysis (analysis of covariance) and the 
Bonferroni test were used. In order to avoid the use of independent variables which may 
co-correlate, relationships between measures after hypoxia-ischaemia (i.e. latent-phase 
duration, severity of secondary energy failure, and neuronal death) were assessed 
univariately (analysis of variance) using the combined temperature groups i.e. ignoring 
the target rectal temperature. Statistical probabilities (p) were presented with 
corrections for multiple cerebral regions and the target rectal temperatures. 
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3.3 Energy metabolism during the latent phase and early 
evolutional period or secondary energy failure 
 
3.3.1 Subjects and procedures 
Twenty-three Large-White piglets of either sex (body weight 1640 (220) g, mean 
(standard deviation)) were surgically prepared within 24 hours after birth under general 
anaesthesia and received continuous physiological monitoring and intensive life support 
throughout the experimental procedure as described previously. The animals were then 
inserted into the bore of the magnet scanner and were subjected to transient 
hypoxia-ischaemia after the baseline data acquisition. In this study, cooling was not 
applied and all subjects were kept normothermic throughout the experiment. Three 
sham-operated piglets were also studied for at least 24 hours without giving the 
hypoxic-ischaemic insult. 
 
3.3.2 Hypoxic-ischaemic insult 
Following baseline 31P MRS acquisition, transient global cerebral hypoxia-ischaemia 
was induced in 20 piglets by reducing the inspired oxygen fraction (FiO2) to 12% and 
simultaneously inflating bilateral carotid artery occluders. During hypoxia-ischaemia,31P 
spectra were acquired every four minutes. After the β-NTP peak amplitude had fallen to 
30% of baseline, FiO2 was adjusted to maintain this β-NTP level for 0 to 24 minutes to 
yield a range of insult severities. Resuscitation was then commenced by deflating the 
occluders and increasing FiO2. 
 
3.3.3 Acquisition of magnetic resonance biomarkers 
During hypoxia-ischaemia and resuscitation, 31P MRS spectra were acquired every 4 
minutes. An hour after the commencement of resuscitation, in addition to whole brain 
31P MRS spectra, maps of ADC and T2 relaxation time were acquired serially 
approximately every three to four hours. Because of technical reasons, T2 maps were 
not available for the first 8 piglets, and both ADC and T2 maps were not obtained in one 
sham operated animal. 
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3.3.4 Time course 
In order to correlate serially acquired magnetic resonance biomarkers, especially of the 
ones acquired shortly before termination, with histo-pathological cerebral injury, 
experiments were terminated at various time points when NTP/EPP had fallen to less 
than 60% of baseline thus confirming secondary energy failure (n = 11) with the 
maximum duration of 48 hours after hypoxia-ischaemia. Several subjects were 
terminated preliminarily because of technical problems or unpredictable clinical 
consequences (see the Result section for detail).  
 
3.3.5 Statistical analysis 
In this study, only 31P MRS data were used (see the next study in the chapter 3.4 for the 
analyses on ADC and T2 maps). 
 
3.3.5.1 Sham-operated control animals 
Because of the small number of control subjects, their MRS measures were presented 
without statistical analysis. 
 
3.3.5.2 Animals in the study group 
Because we applied hypoxia-ischaemia of different durations in this study to yield a 
range of insult severities, several subjects developed relatively more severe 
encephalopathy and cardiopulmonary impairments. One experiment was terminated 14 
hours after hypoxia-ischaemia because of an extremely short latent phase (in the 
“severe secondary energy failure” group). The following were excluded from analysis: 
one animal which experienced extremely severe hypoxia-ischaemia and NTP/EPP 
remained < 60% of baseline even after 4 hours of hypoxic-ischaemic insult, and 1 
animal which developed lethal arrhythmia and required cardiac massage 6 hours after 
hypoxia-ischaemia.  
 
3.3.5.3 Serial metabolite ratios and rates of metabolic change  
 (over all subjects) 
Mixed models with fixed (time and metabolite ratios) and random (subject and time) 
effects were used to determine the rates of change of NTP/EPP, PCr/EPP and Pi/EPP 
within the periods (i) first 10 minutes of hypoxia-ischaemia, (ii) rest of hypoxia-ischaemia 
(excluding first 10 minutes), (iii) 0-2 hours, (iv) 2-8 hours, (v) 8-16 hours and (vi) 16-24 
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hours after hypoxia-ischaemia. Although we aimed to acquire at least 2 spectra for each 
of the time intervals (iii) to (vi), in 3, 2, and 4 animals, only a single spectrum was 
acquired at respectively 2-8, 8-16 and 16-24 hours after the insult. For the mixed model, 
the missing measurements at 2-8 and 8-16 hours (regarded as “missing completely at 
random”), but not at 16-24 hours (when the paucity of data resulted from early 
termination), were estimated by linear interpolation from the existing measurement in 
that time interval and the next available measurement: the mixed model during 16-24 
hours used only the 14 remaining piglets. 31P-MRS measures at baseline and later time 
intervals were compared using repeated measure analysis of variance: for this analysis, 
only 17 piglets were included during the period 16-24 hours due to one early 
termination.  
 
3.3.5.4 Secondary energy failure severity groups 
A surrogate for eventual cerebral injury, the severity of secondary energy failure was 
quantified in each piglet as the minimum NTP/EPP 8-24 hours after hypoxia-ischaemia 
determined by fitting a cubic polynomial to the NTP/EPP time-series in order to avoid 
bias to lower NTP/EPP by random error. Using this severity index for secondary energy 
failure, piglets were classified into 3 groups: (a) “no secondary energy failure” (n = 5, 
minimum NTP/EPP ≥ 85% of individual baseline), (b) “moderate secondary energy 
failure” (n = 8, 60% ≤ minimum NTP/EPP < 85%) and (c) “severe secondary energy 
failure” (n = 5, minimum NTP/EPP < 60%). Metabolite ratios were compared with 
baseline values in each group and between groups using the analysis of variance.  
 
3.3.5.5 Baseline metabolism, insult severity and PCr recovery  
 (over all subjects) 
In our analysis, a positive relationship was observed between PCr/EPP 2 to 8 hours 
after hypoxia-ischaemia and secondary energy failure severity. To identify possible 
determinants of this relationship, both simple and multiple linear regression models 
were used with the index of acute energy depletion (insult severity) and/or baseline 
31P-MRS measures as independent variables. Due to the variation in the head size of 
the piglet, we anticipated inconsistent 31P MRS coverage of the brain; if cerebral 
metabolite ratios varied regionally, this might result in dependences of baseline 
metabolite ratios on body weight: this possibility was investigated using a simple linear 
regression model.  
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3.3.5.6 Statistical probability correction 
Statistical results from comparisons in high energy phosphates between groups defined 
by the severity of secondary energy failure were corrected for multiple comparisons 
between different time intervals and between different groups using Bonferroni test.   
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3.4 Temporal and spatial evolution of secondary energy failure 
and cerebral injury 
 
3.4.1 Subjects and procedures 
The same subjects and magnetic resonance data with the second study “Energy 
metabolism during the latent phase and early evolutional period or secondary energy 
failure” were used (see the chapter 3.3 for detail).  
 
3.4.2 Magnetic resonance data processing 
RoIs on the maps of ADC were placed guided by both maps of ADC and fractional 
anisotropy using the ImageJ software (see Figure 3.1-5 for the representative maps with 
RoIs). In the cortical grey matter, three gyri (sagittal, parietal and temporal) and two 
sulci (sagittal and parietal) were chosen as well as the hippocampus (CA1). The 
caudate nucleus, putamen, thalami (anterior, medial and lateral) were also assessed. 
For the white matter, three regions of the peripheral white matter (sagittal, parietal and 
temporal lobes) and four regions of central white matter (superior and medial 
periventricular white matter and posterior limb of the internal capsule) were investigated. 
These RoIs were transferred to T2 maps after inspections for motion artefacts and 
accuracy of positions for RoIs. 
 
Figure 3.4-1: Brain regions of interest for histo-pathological assessment  
 
Diagram depicting the regions placed on the ADC and T2 
maps, and histo-pathological samples. a sagittal-top, b 
sagittal-bottom, c parietal-top, d parietal-bottom, e 
temporal-top, f CA1 region of the hippocampus, g caudate 
nucleus, h putamen, i anterior thalamus, j medial thalamus, 
k lateral thalamus, l sagittal white matter, m parietal white 
matter, n temporal white matter, o superior periventricular 
white matter, p periventricular white matter, and q posterior 
limb of the internal capsule. See Figure 3.1-5 for the 
representative maps of ADC and fractional anisotropy with 
RoIs. 
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3.4.3 Histo-pathological assessment 
Paraffinised coronal brain samples were carefully assessed and the ones closest to the 
MRI slices used for quantitative analysis were chosen. Six µm thick coronal brain 
sections were prepared for stains such as H & E, LFB/Nissl, GFAP, CD68, TUNEL and 
β-APP. RoIs on ADC and T2 maps were then transferred to the brain sections on the 
slide glass by marking the corresponding region using a fibre tipped pen (Fig. 3.4-1). 
Neuronal damage was assessed for each RoI using H & E stained samples based on 
the scale indicated in the Table 3.1-1, page 61, which gave percentages of neuronal 
death. The damage in the white matter was assessed using H & E and LFB/Nissl stains, 
which were classified into four grades of 0 to 3 (Table 3.4-1). On GFAP stained samples, 
the activation of astrocytes within the cortical grey matter and white matter was 
assessed respectively, and scores of 0 to 3 were assigned for each region. CD68 
positive microglia and vessels were counted respectively, and the numbers per a view at 
the x400 magnification were recorded. Similarly, TUNEL positive cells with 
fragmentation of nuclei were counted to give the number of apoptotic cell death per a 
view at the x400 magnification. For the assessment of grey matter regions, each 
neuronal layer or region was equally examined by typically including 2 to 5 views for the 
cerebral cortex and 1 to 3 regions for the deep grey matter; Fig. 3.1-6, page 60), 
whereas 1 to 2 representative views were assessed for the white matter regions.   
 
Table 3.4-1: Injury scales for histo-pathological assessment in the white 
matter 
 
Stains 
Scores 
0 1 2 3 
H & E and 
LFB/Nissl* 
No damage Focal injury without 
destruction in 
axonal integration 
Up to moderate 
destruction with 
substantial 
disintegration in 
axon and myelin  
Severe destruction 
with total loss of 
structural 
integration   
GFAP Mild expression in 
the process and 
plasma membrane 
of astrocytes 
Moderate 
expression 
Strong expression Marked expression 
β-APP* No positive fibres Solitary/scattered 
positive fibres 
 
Grouped positive 
fibres with mild to 
moderate density 
Profound fibres 
with strong stains 
*Evaluation on LFB/Nissl andβ-APP stains focused on axonal injury. Evaluation of neuronal injury 
on H & E, CD68 expressions on microglia and vessels, and TUNEL positive cells with morphological 
features of apoptosis were performed numerically by counting affected cells.  
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3.4.4 Statistical analysis 
3.4.4.1 Sham-operated control animals 
Because of the small number of control subjects, findings in magnetic resonance 
biomarkers were presented without statistical analysis. 
 
3.4.4.2 Animals in the study group 
Magnetic resonance biomarkers were sorted along the time line either (i) prospectively 
starting from the pre-insult baseline, 60 minutes to <3 hours, 3 to < 6 hours, 6 to < 12 
hours, 12 to < 18 hours, 18 to < 24 hours, 24 to < 30 hours, 30 to < 36 hours, 36 to < 42 
hours and 42 to 48 hours after the commencement of resuscitation, or (ii) 
retrospectively starting from 0 to < 3 hours, 3 to < 6 hours, 6 to < 12 hours,12 to < 18 
hours,18 to < 24 hours, 24 to < 30 hours, 30 to < 36 hours,36 to < 42 hours, and 42 to 
48 hours before termination. When there were multiple data within the same time period, 
the average of these were used; missing values were estimated by linear interpolation 
from existing measurements only when there were valid data in both the previous 
(excluding the baseline) and the following time intervals. 
To investigate the variation in ADC and T2 maps within region groups of the cortical 
grey matter (excluding the hippocampus), deep grey matter, peripheral white matter, 
and the central white matter, and also between these region groups (mean values within 
groups were used), the baseline and serial data were assessed using the analysis of 
variance. Because experiments were terminated at different time intervals after 
hypoxia-ischaemia (and hence before termination), the number of subjects considered 
at each time interval differed; to minimise the influence of the sample size to the 
statistical result, analysis was performed on magnetic resonance biomarkers obtained 
(i) equal to or less than 24 hours after hypoxia-ischaemia and (ii) equal to or shorter 
than 24 hours before termination. Associations between global (31P MRS) and regional 
(ADC and T2 maps) magnetic resonance biomarkers obtained at each time interval 
after hypoxia-ischaemia and regional histo-pathological damages were assessed using 
general linear models for either numeric or rank ordinal data with adjustment for the 
insult severity (acute energy depletion) and the experimental duration. The predictive 
value of magnetic resonance biomarkers analysed according to (i) the time after 
resuscitation and (ii) the time before termination were assessed using either the 
Pearson product moment correlation coefficient or the Spearman rank correlation 
coefficient.  
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3.4.4.3 Statistical probability correction 
P-values from comparisons in magnetic resonance biomarkers between different time 
intervals (vs. baseline) were corrected for multiple comparisons using the Dunnett test. 
Results from comparisons in ADC and T2 relaxation time within and between region 
groups at each time interval after resuscitation were corrected using the Bonferroni test. 
For comparisons between magnetic resonance biomarkers and regional 
histo-pathological brain injury, which involved six magnetic resonance biomarkers and 
eight histo-pathological assessments in over seventeen cerebral regions, p-values were 
shown without correction to avoid type-II errors. 
 
  
 73 
Chapter 4: Results 
Values are shown as mean (standard deviation) unless stated otherwise.  
 
4.1 Associations between insult severity and therapeutic time 
window duration 
 
Results from comparisons between temperature groups in the severity of secondary 
energy failure and histo-pathological outcome have been reported elsewhere (47, 49). 
Briefly, therapeutic hypothermia to 35oC and 33oC prolonged the latent phase duration 
(Fig. 1.6-1 in page 47), ameliorated the severity of secondary energy failure (Fig. 4.1-1), 
and reduced the neuronal death in both cortical grey and deep grey matter (47); the 
pattern of cerebral protection differed between 35oC and 33oC, with the former 
protecting the deep grey matter predominantly while the latter preserving the cortical 
grey matter better (Figure 1.6-2 in page 50) (49).  
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Figure 4.1-1: Cerebral high-energy phosphates before, during and after 
hypoxia-ischaemia 
 
Cerebral PCr/Pi (A, C, and E) and NTP/EPP (B, D, and F) for each piglet at baseline, during transient 
HI, and for 48 hours after resuscitation in the HI-n (A and B), HI-35 (C and D), and HI-33 
(E and F) groups. In 1 HI-33 piglet, no data were acquired beyond 36 hours because of spectrometer 
failure. Graphs demonstrate significant intrinsic biological variability despite similar 
HI insult severities. PCr/Pi tended to be preserved in cooled piglets. A significant decline in 
NTP/EPP was only seen in the HI-n group. Abbreviations: HI, hypoxia-ischaemia. HI-n, HI and 
normothermia. HI-35, HI and delayed whole body cooling to 33oC. HI-33, HI and delayed whole body 
cooling to 35oC. From “Delayed whole-body cooling to 33 or 35°C and the development of impaired 
energy generation consequential to transient cerebral hypoxia-ischemia in the newborn piglet” by 
O’Brien FE, Iwata O, Thornton JS, De Vita E, Sellwood MW, Iwata S, Sakata YS, Charman S, Ordidge 
R, Cady EB, Wyatt JS, Robertson NJ. Pediatrics. 2006 May;117(5)1549-59. 
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4.1.1 Summary 
In this chapter, results of the first part of the study, “Associations between insult severity 
and therapeutic time window duration” are presented. A more severe hypoxic-ischaemic 
insult was associated with a shorter latent-phase (p = 0.002), worse secondary energy 
failure (p = 0.023), and more neuronal death in the cortical grey matter (p = 0.016). The 
latent phase duration was inversely related to insult severity, suggesting the brevity of 
the therapeutic time window following severe cerebral hypoxia-ischaemia. 
 
4.1.2 Experimental courses and general findings 
In seven animals, experimentation terminated early: 2 due to NTP depletion persisting 
more than 2 hours after hypoxia-ischaemia (1 HI-n and 1 HI-33); 2 due to equipment 
problems (2 HI-n); and 3 piglets died as a direct consequence of hypoxia-ischaemia (2 
HI-n at 18 and 28 hours and 1 HI-33 at 20 hours after the insult). All other piglets 
survived to 48 hours after hypoxia-ischaemia. Two brains were damaged during 
removal or histological processing (1 HI-n and 1 HI-33). Results from all these animals 
were not included in the analysis. Consequently the numbers of piglets analysed were: 
6 HI-n; 7 HI-35; and 7 HI-33; in one HI-33 piglet MRS data were only available up to 36 
hours due to spectrometer failure. There were no significant differences in the body 
weight, age, heart rate, blood pressure, or other variables between study groups before 
hypoxia-ischaemia. 
 
4.1.3 Severity of hypoxia-ischaemia, duration of latent phase and 
subsequent injury indices in each temperature group 
We aimed for hypoxic-ischaemic insults of similar severity between subjects. However, 
amongst the piglets, acute energy depletion ranged widely due to variations in the 
biological responses to both transient hypoxia-ischaemia and resuscitation. The mean 
acute energy depletion was 0.048 (0.021) hours for HI-n; 0.070 (0.024) hours for HI-35; 
and 0.086 (0.032) hours for HI-33 but statistically invariant (p = 0.116). When the 
magnetic resonance biomarkers were compared between temperature groups with the 
acute energy depletion as a covariate, HI-35 had a longer latent-phase (p < 0.001), less 
severe secondary energy failure (p = 0.032), and less neuronal death (cortical grey 
matter p = 0.001, deep grey matter p = 0.020); and HI-33 had a longer latent phase (p = 
0.014), less severe secondary energy failure, and less neuronal death only in cortical 
grey matter (p < 0.001), compared to HI-n (Table 4.1-1). There was less neuronal death 
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in the cortical grey matter in HI-33 compared to HI-35 (p = 0.022), however, the duration 
of the latent phase, severity of secondary energy failure, and the neuronal death in the 
deep grey matter were similar in both cooled groups. 
 
Table 4.1-1: Magnetic resonance and histo-pathological injury indices in 
each temperature group  
  HI-n HI-35 HI-33 
Latent phase duration 
in hours 
17.5  
(10.0, 24.9) 
41.4  
(35.1, 47.7)*** 
34.3  
(27.5, 41.1)* 
Minimum NTP/EPP 
(6 – 48 hours) 
0.106  
(0.090, 0.122) 
0.136  
(0.122, 0.150)* 
0.135  
(0.120, 0.151) 
 
Neuronal 
death (%) 
Cortical grey matter 
 
85.7  
(69.6, 101.8) 
39.6  
(26.1, 53.1)** 
10.8  
(-3.8, 25.4)***† 
Deep grey matter  66.5  
(44.4, 89.6) 
22.1  
(2.8, 41.5)* 
37.4  
(16.4, 58.3) 
Values are mean (upper and lower 95% confidence interval) corrected for the mean acute energy 
depletion = 0.069 hours. 
*, ** and ***: HI-n vs. HI-35 or HI-33, p < 0.05, 0.005 and 0.001 respectively;  
†: HI-35 vs. HI-33, p < 0.05; p values were corrected for multiple comparisons using Bonferroni test. 
 
4.1.4 Association between the insult severity and the latent phase duration 
A more severe hypoxic-ischaemic insult (greater acute energy depletion) was 
associated with a shorter latent phase (Fig. 4.1-2) (r2 = 0.55, p = 0.002, corrected for 
temperature groups).  
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Figure 4.1-2: Correlation between the latent phase duration and the insult 
severity 
 
Acute insult severity represented 
by the acute energy depletion 
index was inversely correlated 
with the duration of the latent 
phase. Symbols: HI-n (♦), HI-35 (*), 
HI-33 (Δ). r2 = 0.55, p = 0.002, 
analysis of covariance. 
Regression line not indicated 
because the analysis was 
performed with correction for 
temperature groups. 
 
 
 
4.1.5 Association between the insult severity and the severity of 
secondary energy failure 
The severity of secondary energy failure represented by lower NTP/EPP was correlated 
with the insult severity (Fig. 4.1-3) (r2 = 0.44, p = 0.023, corrected for temperature 
groups). 
 
Figure 4.1-3: Association between the severity of acute insult and 
secondary energy failure 
 
 
Severity of secondary energy failure 
was dependent on the severity of 
acute insult represented by the acute 
energy depletion. Symbols: HI-n (♦), 
HI-35 (*), HI-33 (Δ). r2 = 0.44, p = 0.023, 
analysis of covariance. Regression 
line not indicated because the 
analysis was performed with 
correction for temperature groups. 
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4.1.6 Association between the insult severity and neuronal death 
Neuronal death in the cortical grey matter, but not in the deep grey matter, depended on 
the insult severity (Fig. 4.1-4) (r2 = 0.75, p = 0.016, corrected for temperature groups). 
 
Figure 4.1-4: Correlation between the insult severity and neuronal death in 
the cortical grey matter 
 
Histo-pathologically assessed neuronal 
death in the cortical grey matter was 
dependent on the acute insult severity. 
Symbols: HI-n (♦), HI-35 (*), HI-33 (Δ). r2 = 
0.75, p = 0.016, analysis of covariance. 
Regression line not indicated because the 
analysis was performed with correction for 
temperature groups. 
 
 
 
 
4.1.7 Association between the latent phase duration and the severity of 
secondary energy failure 
A longer latent phase duration was associated with a less severe secondary energy 
failure (Fig. 4.1-5) (r2 = 0.78, p < 0.001). 
 
Figure 4.1-5: Correlation between the latent phase duration and the 
severity of secondary energy failure 
 
The latent phase duration was linearly 
correlated with the severity of secondary 
energy failure.  
Symbols: HI-n (♦), HI-35 (*), HI-33 (Δ). r2 = 
0.78, p < 0.001.Regression line is from 
combined temperature groups. 
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4.1.8 Association between the latent phase duration and neuronal death 
A longer latent phase was associated with fewer neuronal death in the cortical grey 
matter (r2 = 0.26, p = 0.023) and deep grey matter (r2 = 0.43, p = 0.002) (Fig. 4.1-6).  
 
Figure 4.1-6: Dependences of neuronal death on the latent phase duration 
(A) Cortical grey matter 
 
 
The latent phase duration was linearly 
correlated with the neuronal death in 
the cortical grey matter. Symbols: HI-n 
(♦), HI-35 (*), HI-33 (Δ). r2 = 0.26, 
p=0.023. Regression line is from 
combined temperature groups. 
 
 
 
 
 
 
 
(B) Deep grey matter 
 
The latent phase duration was 
linearly correlated with the 
neuronal death in the deep grey 
matter. Symbols: HI-n (♦), HI-35 (*), 
HI-33 (Δ). r2 = 0.43, p = 0.002. 
Regression line is from combined 
temperature groups. 
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4.1.9 Association between the severity of secondary energy failure and 
neuronal death 
More severe secondary energy failure was associated with greater neuronal death in 
both cortical grey matter (r2 = 0.27, p = 0.020) and deep grey matter (r2 = 0.36, p = 
0.005) (Fig. 4.1-7).  
 
Figure 4.1-7: Dependence of neuronal death on the severity of secondary 
energy failure 
(A) Cortical grey matter 
 
The severity of secondary energy 
failure was linearly correlated with 
neuronal death in the cortical grey 
matter. Symbols: HI-n (♦), HI-35 (*), 
HI-33 (Δ). r2=0.27, p=0.020.Regression 
line is from combined temperature 
groups. 
 
 
 
 
 
 
(B) Deep grey matter 
 
The severity of secondary energy 
failure was linearly correlated with 
neuronal death in the deep grey 
matter. Symbols: HI-n (♦), HI-35 (*), 
HI-33 (Δ). r2 = 0.36, p = 0.005, 
corrected for temperature groups. 
Regressions are from combined 
temperature groups.  
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4.2 Energy metabolism during the latent phase and early 
evolutional period or secondary energy failure 
 
4.2.1 Summary 
In this chapter, results of the second part of this study are presented. Following 
resuscitation, in subjects with favourable outcome, PCr recovered to higher than its 
baseline level (overshoot). In subjects with unfavourable outcome, maximum PCr 
recovery was lower than baseline and lower than in subjects with favourable and 
intermediate outcomes. Recovery PCr correlated linearly and negatively with acute 
insult severity, suggesting that recovery metabolism 2 to 8 hours after 
hypoxia-ischaemia may provide an early biomarker of injury severity. 
 
4.2.2 Temporal changes in energy metabolites after hypoxia-ischaemia 
4.2.2.1 Sham-operated animals 
Sham operated animals showed no apparent temporal change in NTP/EPP, PCr/EPP 
and Pi/EPP (Table 4.2-1). 
 
Table 4.2-1: Temporal changes in 31P MRS biomarkers in sham operated 
animals  
  
 
Piglet 
Baseline Time from baseline (h) 
 0-2 2-8 8-16 16-24 
N
TP
/E
PP
 1 0.26 0.25 0.23 0.25 0.23 
2 0.21 0.21 0.21 0.20 0.20 
3 0.20 0.20 0.20 0.21 0.19 
PC
r/E
PP
 1 0.18 0.18 0.18 0.18 0.17 
2 0.22 0.21 0.21 0.22 0.22 
3 0.23 0.23 0.23 0.24 0.24 
Pi
/E
PP
 1 0.13 0.14 0.17 0.17 0.19 
2 0.18 0.20 0.22 0.20 0.19 
3 0.17 0.17 0.17 0.17 0.20 
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4.2.2.2 Acute insult, recovery and secondary energy failure 
Significant rates of change of NTP/EPP (falling) and Pi/EPP (increasing) were observed 
during both the first 10 minutes (p = 0.006 and p < 0.005 respectively) and the 
remainder of hypoxia-ischaemia (p < 0.005 and p = 0.006 respectively); falling PCr/EPP 
was observed only during the first 10 minutes of hypoxia-ischaemia (Table 3.2-2 and 
Fig. 4.2-1) (p < 0.005). Compared with baseline, mean PCr/EPP was lower during both 
the first 10 minutes and the remainder of hypoxia-ischaemia, whereas mean Pi/EPP 
was higher and mean NTP/EPP lower only during the later period of hypoxia-ischaemia 
(all p < 0.001). 
 
Table 4.2-2: Rates of change in metabolite ratios during and following 
hypoxia-ischaemia 
Abbreviations: SE, standard error. NS, not significant. 
 
  
   During hypoxia-ischaemia Time after hypoxia-ischaemia (h) 
   First 10 minutes Remainder 0-2 2-8 8-16 16-24 
N
TP
/E
PP
 Slope  (x 10-3/h) -174.8 -153.5 52.4 1.6 -2.7 -3.2 
SE (x 10-3/h) 47.6 31.5 7.7 1.17 1.01 1.11 
p  0.006 <0.005 <0.005 NS NS 0.042 
PC
r/E
PP
 Slope (x 10-3/h) -670.0 -15.3 136.9 -0.6 -4.2 -4.7 
SE (x 10-3/h) 115.3 40.2 17.0 0.9 1.2 0.9 
p  <0.005 NS <0.005 NS 0.006 <0.005 
Pi
/E
PP
 Slope (x 10
-3/h) 1118.4 520.3 -323.2 -3.9 15.6 12.3 
SE (x 10-3/h) 255.1 116.9 36.5 2.3 2.8 3.1 
p  <0.005 0.006 <0.005 NS <0.005 0.006 
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Figure 4.2-1: Trajectories of NTP, PCr and Pi over time relative to EPP 
(A) PCr/EPP 
 
(B) NTP/EPP 
 
(C) Pi/EPP 
 
Data are shown for only representative time points during and shortly after hypoxia-ischaemia. 
Variation in the recovery phosphates is evident despite overall incomplete recovery in NTP and Pi 
and complete recovery in PCr. X-axes are the time interval in hours after hypoxia-ischaemia. 
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After commencing resuscitation, significant rates of change of PCr/EPP and NTP/EPP 
(both increasing) and Pi/EPP (falling) were observed during the period 0-2 hours after 
hypoxia-ischaemia (all p < 0.005). Metabolite ratios had recovered closest to their 
baseline values during the period 2-8 hours after hypoxia-ischaemia when mean 
PCr/EPP was similar to baseline but mean NTP/EPP was slightly smaller (p = 0.012) 
and mean Pi/EPP greater (Table 4.2-3 ) (p = 0.027). The earliest time interval displaying 
overt secondary energy failure was 8-16 hours after hypoxia-ischaemia when there 
were significant rates of change for PCr/EPP (falling, p = 0.006) and Pi/EPP (rising, p < 
0.005): a significant NTP/EPP rate of change during secondary energy failure (falling, p 
= 0.042) was first seen at 16-24 hours. During 8-16 hours and 16-24 hours after 
hypoxia-ischaemia, mean PCr/EPP and NTP/EPP were lower and mean Pi/EPP higher 
compared with the baseline (all p < 0.001). 
 
Table 4.2-3: Metabolite ratios before, during and after hypoxia-ischaemia 
  Baseline During hypoxia-ischaemia Time after hypoxia-ischaemia (h) 
   First 10minutes Remainder 0-2 2-8 8-16 16-24 
N
TP
/E
PP
 Mean 0.22 0.21 0.12 0.17 0.19 0.18 0.16 
Standard deviation 0.02 0.02 0.04 0.03 0.02 0.03 0.05 
p:vs. baseline 
 
NS <0.001 <0.001 0.012 <0.001 <0.001 
PC
r/E
PP
 Mean 0.23 0.18 0.064 0.18 0.22 0.19 0.16 
Standard deviation 0.02 0.04 0.029 0.04 0.03 0.04 0.06 
p:vs. baseline 
 
<0.001 <0.001 <0.001 NS <0.001 <0.001 
Pi
/E
PP
 Mean 0.19 0.26 0.65 0.40 0.27 0.33 0.43 
Standard deviation 0.03 0.07 0.13 0.12 0.09 0.13 0.21 
p:vs. baseline 
 
NS <0.001 <0.001 0.027 <0.001 <0.001 
NS, not significant. 
 
4.2.3 Energy metabolism at 2-8 hours after hypoxia-ischaemia and the 
severity of secondary energy failure  
Compared with baseline, recovery PCr/EPP 2-8 hours after hypoxia-ischaemia was 
higher (overshoot) for subjects with "no" secondary energy failure and was lower for 
subjects with "severe" secondary energy failure (Figs. 4.2-2 and 4.2-3) (p = 0.043 and 
0.008 respectively). In the same time interval, Pi/EPP was higher for subjects with both 
"moderate" and "severe" secondary energy failure compared to baseline (p = 0.006 and 
0.013 respectively), however, NTP/EPP was similar to baseline in each group.   
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Figure 4.2-2: Metabolite ratios 2-8 hours after hypoxia-ischaemia relative 
to individual baselines 
 
PCr/EPP in subjects which never developed secondary energy failure showed overshoot compared 
to the baseline level. Metabolite ratios differed between three outcome groups for PCr/EPP and 
Pi/EPP but the trend did not reach statistical significance for NTP/EPP. Symbols: box - first and 
third quartiles, bold line - median, perpendicular line - range without outliers, open circle - extreme 
outlier less than 1.5 times the interquartile range from the first quartile. 
 
Figure 4.2-3: Representative 31P MRS spectra from three outcome groups 
 
Subtle PCr recovery overshoot relative to NTP peaks is notable in subjects which did not develop 
secondary energy failure (SEF). 
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Subjects with "no" or “moderate" secondary energy failure had higher PCr/EPP (p < 
0.001 and p = 0.001 respectively) and lower Pi/EPP (p = 0.002 and 0.019 respectively) 
compared with subjects with “severe" secondary energy failure; NTP/EPP showed no 
intergroup differences (Fig. 4.2-4). 
 
Figure 4.2-4: PCr/EPP 2-8 hours after hypoxia-ischaemia 
 
PCr/EPP 2-8 hours after hypoxia-ischaemia for “no secondary energy failure (SEF)”, “moderate 
SEF”, and “severe SEF”. The groups with no or moderate SEF consistently showed higher PCr/EPP 
compared with the severe SEF group. Symbols: box - first and third quartiles, bold line - median, 
perpendicular line - range. 
 
4.2.4 Baseline metabolism, insult severity, and PCr at 2-8 hours after 
hypoxia-ischaemia 
PCr/EPP 2-8 hours after hypoxia-ischaemia correlated linearly with both the acute 
energy depletion index and baseline PCr/NTP with simple linear regression analysis (p 
= 0.024 and 0.049 respectively): correlation significance was higher with multivariate 
analysis which incorporated the interaction between the acute energy depletion index 
and baseline PCr/NTP (p = 0.008 and 0.015 respectively). Baseline PCr/NTP was not 
associated with the body weight (Figs. 4.2-5 and 4.2-6). 
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Figure 4.2-5: Baseline and early 31P MRS biomarkers and PCr recovery 
 
PCr/EPP 2 to 8 hours after hypoxia-ischaemia and (A) the acute energy depletion index (insult 
severity) and (B) baseline PCr/NTP, both demonstrating significant linear relationships. 
 
Figure 4.2-6: Baseline metabolism and recovery PCr/EPP 
 
Baseline PCr/EPP (A, p < 0.05) but not NTP/EPP (B) showed linear correlation with recovery 
PCr/EPP 2 to 8 hours after hypoxia-ischaemia. 
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4.3 Temporal and spatial evolution of secondary energy failure 
and cerebral injury 
 
4.3.1 Summary 
In this chapter, results of the third part of this study are presented. When regional maps 
of ADC were analysed, substantial reductions in ADC values were present in 
susceptible regions, such as parietal watershed cortex, peripheral white matter and 
deep grey matter, as early as 6 hours, correlating with subsequent histo-pathological 
brain injury. Although global PCr/Pi was the most accurate early biomarker for 
histo-pathological brain injury, ADC values also predicted l cerebral injury up to 18 hours 
in advance of termination, which would be useful to optimise neuroprotective treatments 
when 31P MRS biomarkers are not available.  
 
4.3.2 Sham-operated control subjects 
For sham-operated control subjects, no significant temporal changes were observed in 
31P MRS biomarkers and maps of ADC and T2 (see Chapter 4.2.2.1 and Table 4.2-1 for 
temporal changes in 31P MRS biomarkers). 
 
4.3.3 Temporal changes in magnetic resonance biomarkers up to 24 
hours after resuscitation 
 
4.3.3.1 31P MRS biomarkers 
31P MRS metabolites at the baseline were similar to those of sham control subjects. 
Compared to the baseline, lower NTP/EPP and PCr/Pi, and higher Pi/EPP were 
observed between 1 and 24 hours after the commencement of resuscitation, whereas 
the reduction in PCr/EPP was noted between 6 and 24 hours after resuscitation, 
reflecting the gradual decline in PCr/Pi and PCr/EPP and increase in Pi/EPP with time 
(Fig. 4.3-1 and Supplemental Table 1 in page 157). 
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Figure 4.3-1: Temporal changes in global 31P MRS biomarkers  
 
 
Upper panel: Trajectories of NTP/EPP, PCr/EPP, Pi/EPP and PCr/Pi at baseline and after 
resuscitation showing the rapid and dynamic change in PCr/Pi, followed by PCr/EPP and Pi/EPP, 
and then, by NTP/EPP. Lower panel: Temporal change in the mean (standard deviation) 31P MRS 
markers up to 24 hours after resuscitation. Data after 24 hours are not shown because of the 
smaller number of subjects thereafter. 
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4.3.3.2 Maps of ADC 
Reductions in regional ADC values were already apparent during the period of 1 to < 3 
hours after the commencement of resuscitation in all cortical grey matter regions, 
putamen, sagittal white matter, parietal white matter, and posterior limb of internal 
capsule, reflecting a rapid decline in regional ADC values following hypoxia-ischaemia 
(Fig. 4.3-2 and 4.3-3; Supplemental Table 2 in page 158). Significant reductions in ADC 
for the lateral thalamus, temporal white matter, superior periventricular white matter, 
and periventricular white matter were first noted during the period of 6 to12 hours of 
resuscitation. A decline in ADC was also observed in the anterior and medial thalami, 
which did not lead to statistical significance until 12 to 18 hours after resuscitation due to 
wide inter-subject variations.  
 
Figure 4.3-2: Two distinct patterns of ADC changes with time following 
hypoxia-ischaemia 
 
In subject A (upper panel), ADC reduction was initially observed in the striatum spreading to the 
parasagittal cortex/white matter. In subject B (lower panel), initial ADC reduction was prominent in 
the sagittal and parasagittal cortex/white matter. Despite the difference in the progress of brain 
injury, both subjects showed profound ADC changes to 30-50% of the baseline level throughout the 
brain by the time of termination. 
Abbreviation: HI, hypoxia-ischaemia. 
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At baseline, ADC values were similar between regions within the cortical grey matter; in 
the deep grey matter, the lateral thalamus had lower ADC values compared to other 
regions of the caudate nucleus, putamen and medial thalamus, whereas the medial 
thalamus showed lower ADC levels compared to the caudate nucleus and lateral 
thalamus; in the peripheral white matter, ADC was lower in the sagittal and temporal 
regions compared to the parietal region; in the central white matter, the posterior limb of 
the internal capsule had higher ADC values compared to the superior periventricular 
white matter and periventricular white matter. When mean baseline ADC values for the 
region groups of the cortical grey matter, hippocampus, deep grey matter, peripheral 
white matter and the central white matter were compared, the central white matter had 
higher ADC values compared to the cortical grey matter, hippocampus and the 
peripheral white matter, whereas the cortical grey matter and hippocampus had higher 
ADC values than the deep grey matter. During the period of 1 to 6 hours after 
hypoxia-ischaemia and the commencement of resuscitation, ADC levels in the sagittal 
cortex was lower than in the temporal cortex, however, no other difference in ADC 
values within the region groups was observed up to 24 hours after resuscitation. The 
mean ADC values for each region group observed at the baseline disappeared after 
hypoxia-ischaemia and resuscitation. 
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Figure 4.3-3: Temporal changes of ADC in representative regions 
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Left panel: Trajectories showing inter-regional variation in the timing of ADC decline from all 
subjects with valid ADC data. Rapid decrease in ADC was observed in the parietal cortex and white 
matter, putamen, and the posterior limb of the internal capsule whereas the change was slow in the 
temporal grey and white matters and the superior periventricular white matter. Right panel: 
Temporal change in the mean (standard deviation) ADC values up to 24 hours after resuscitation in 
representative regions. Data after 24 hours are not shown because of the smaller number of 
subjects thereafter. 
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4.3.3.3 T2 maps 
The T2 relaxation time showed overall trends to increase after resuscitation, however, 
statistically significant increase relative to the baseline value was noted in limited 
regions of the cortical grey matter (mainly in the bottom of the sulci), hippocampus, 
lateral thalamus and the parietal white matter (Fig. 4.3-4 and Supplemental Table 3 in 
page 162).  
 
Figure 4.3-4: Temporal changes of T2 maps  
 
Spatial and temporal change in T2 relaxation time following most severe HI, showing progressive 
increase in T2 involving the whole brain. Short T2 and prolonged T2 are shown in dark purple and 
lighter purple, respectively, whereas extremely long T2 from cerebrospinal fluid is shown in red and 
yellow.  
Abbreviation: HI, hypoxia-ischaemia. 
 
At baseline, the T2 relaxation time was similar within the region groups of the cortical 
grey matter and the deep grey matter; in the peripheral white matter, the T2 relaxation 
time was shorter in the temporal white matter compared to the sagittal and parietal white 
matter; in the central white matter, the periventricular white matter had the longest T2 
relaxation time, which was followed by the superior periventricular white matter and then, 
by the posterior limb of the internal capsule. When the mean baseline T2 relaxation time 
was compared between the region groups, the cortical grey matter and the 
hippocampus both had longer T2 relaxation times compared to the peripheral white 
matter and the central white matter; the T2 relaxation time was longer for the deep grey 
matter compared to the central white matter. After resuscitation, despite the overall 
temporal increase in the T2 relaxation time, the regional pattern of the T2 relaxation 
time remained unchanged in most regions.  
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Figure 4.3-5: Temporal changes of T2 relaxation time in representative 
regions 
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Left panel: Trajectories of regional T2 relaxation time from all subjects with valid T2 data, showing 
trends towards gradual increase in T2 with time although the dynamic range appears to be smaller 
compared to 31P MRS markers and ADC. Right panel: Temporal change in the mean (standard 
deviation) T2 relaxation time up to 24 hours after resuscitation. Data after 24 hours are not shown 
because of the smaller number of subjects thereafter. 
 
 
 
 
4.3.3.4 Histopathological brain injury 
For sham-operated control animals, no significant damage was noted for brain samples 
stained using H & E stains, LFB/Nissl stain and β-APP immuno-histochemical stain 
(Figs. 4.3-5 and 4.3-6); a small number of TUNEL-positive neurons were observed in 
the cerebral cortex and hippocampus with nuclear shrinkage, condensation, or 
fragmentation suggestive of apoptotic cell death; CD68-positive vessels and microglial 
cells were occasionally observed in the white matter and cortical/deep grey matter. 
A wide range of histo-pathological brain injury and immuno-histochemical reactions 
were observed for brain samples of subjects which experienced transient 
hypoxia-ischaemia. The most extensive damage on H & E-stained samples was 
observed in the watershed zones in the para-sagittal and parietal cortex, and the 
hippocampus; extension of the damage towards the deep grey matter was highly 
heterogeneous between subjects. Generally, severe grey matter injury observed on H & 
E-stained samples was accompanied by a greater number of TUNEL-positive neurons 
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and CD68-positive endothelial/microglial cells. Similarly, more severe white matter 
injury was associated with relatively more profound changes in β-APP espression. 
GFAP immuno-histochemical stain showed high level of expression in both 
sham-operated control and study groups unassociated with the insult severity and 
experimental duration, which were not considered further in the current analysis. 
 
Figure 4.3-6: Representative histo-pathological findings-1  
 
Representative brain samples stained using H & E stains (A-C), LFB/Nissl stain (D-E) and GFAP 
immuno-histochemical stain (F), showing normal white matter structure (A); severe destruction in 
microanatomical architecture in both the white matter and cortical grey matter (B); moderate 
pyramidal cell damage in the hippocampus (C); mild (D) and moderate (E) axonal injury; and 
increased GFAP expression in the white matter (F).  
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Figure 4.3-7: Representative histo-pathological findings-2  
 
Representative brain samples stained using β-APP (A-C), CD68 immuno-histochemical stain (D-E) 
and TUNEL stain (F) with mild (A), moderate (B) and strong (C) expression of β-APP in the white 
matter; CD68 positive microglia (D) and vessel (E) in the parietal cortex; and TUNEL positive 
neurons with nuclear fragmentation (F) in the sagittal cortex.  
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4.3.4 Serial magnetic resonance biomarkers obtained 1 to 24 hours after 
resuscitation and histo-pathological brain injury  
 (adjusted for the insult severity and experimental duration) 
 
4.3.4.1 Insult severity, experimental duration, magnetic resonance 
biomarkers, and histo-pathological brain injury 
Greater insult severity represented by the acute energy depletion index was associated 
with higher Pi/EPP at 3 to < 6 hours after resuscitation and with lower PCr/EPP at 18 to 
< 24 hours after resuscitation (Supplemental Table 4 A in page 166). Greater insults 
showed only modest influence on ADC values obtained 1 to < 12 hours after 
resuscitation in both the grey and white matters. Associations between the insult 
severity and T2 relaxation times were observed only for limited regions and time 
intervals. The severity of acute insult showed limited associations with 
histo-pathological brain injury even when adjusted for the time period between 
hypoxia-ischaemia and termination; greater insult severity led to greater number of 
CD68 positive microglia and vessels in the deep grey matter and the central white 
matter, and the white matter injury assessed on LFB/Nissl (Supplemental Table 4 B and 
C in pages 168-169). 
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4.3.4.2  31P MRS biomarkers (1 to 24 hours after resuscitation) and brain 
injury 
During the periods 1 to < 3 hours and 3 to < 6 hours after resuscitation, only inconsistent 
correlations between global 31P MRS biomarkers and regional histo-pathological injury 
were observed except that lower PCr/Pi in the white matter was associated with worse 
injury on H & E stains and more CD68 positive microglia and vessels in the 
corresponding regions (Fig. 4.3-7 and Supplemental Table 5 in page 170). During the 
periods 6 to < 12 hours, 12 to < 18 hours, and 18 to < 24 hours after resuscitation, 
consistent correlations were observed between global 31P MRS biomarkers and the 
percentage of neuronal death in the cortical and deep grey matters, and white matter 
injury assessed on H & E stains and β–APP stain. Only modest correlations were 
observed between global 31P MRS biomarkers and CD68 positive microglia and vessels. 
Of global 31P MRS biomarkers, there were trends that NTP/EPP showed less prominent 
associations with histo-pathological outcomes, whereas PCr/Pi showed most prominent 
associations. Between the periods of 6 to < 12 hours, 12 to < 18 hours, and 18 to < 24 
hours after resuscitation, there was no obvious trend towards specific timing for the 
optimal prediction of the histo-pathological outcome, however, modest relationships 
between abnormal 31P MRS biomarkers and percentages of TUNEL positive apoptotic 
cells were observed only for the period of 6 to < 12 hours after resuscitation. 
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Figure 4.3-8: Associations between 31P MRS biomarkers obtained 1-24 
hours after resuscitation and histo-pathological brain injury   
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Scatter graphs showing associations between 31P MRS markers obtained 1 to < 3 (x), 6 to < 12 (▲) 
and 6 to < 24 hours (●) after resuscitation and histo-pathological brain injury assessed using H & E 
stains in representative regions. There was a trend towards tighter linear relationships between 
histo-pathological outcomes and 31P MRS biomarkers obtained at later time intervals (see 
Supplemental Table 5 in page 170 for statistical findings and data at other time intervals).   
 103 
4.3.4.3 Maps of ADC (1 to 24 hours after resuscitation) and brain injury 
During the periods 1 to < 3 hours and 3 to <6 hours after resuscitation, regional ADC 
values did not show consistent correlations with histo-pathological cerebral injury except 
that lower ADC levels during these periods were modestly correlated with numbers of 
CD68 positive microglia and vessels (Fig. 4.3-8 and Supplemental Table 6 in page 183). 
During the periods 6 to <12 hours, 12 to <18 hours, and 18 to <24 hours after 
resuscitation, regional ADC reductions showed modest associations with percentages 
of neuronal death in the cortical and deep grey matters, white matter damage assessed 
using H & E stains, and CD68 positive microglia and vessels. 
 
Figure 4.3-9: Associations between maps of ADC obtained 1-24 hours 
after resuscitation and histo-pathological brain injury   
 
Scatter graphs showing associations between ADC obtained 1 to < 3 (x), 6 to < 12 (▲) and 6 to < 24 
hours (●) after resuscitation and histo-pathological brain injury assessed using H & E stains in 
representative regions. Even subtle reductions in ADC shortly after resuscitation corresponded to a 
considerable fraction of neuronal death in the grey matter (see Supplemental Table 6 in page 183 for 
statistical findings and data at other time intervals).  
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4.3.4.4 T2 maps (1 to 24 hours after resuscitation) and brain injury 
Regional T2 relaxation times did not show consistent associations with 
histo-pathological brain damage regardless of the timing of data acquisition and the type 
of histo-pathological assessment (Fig. 4.3-9 and Supplemental Table 7 in page 189). 
However, the longer T2 relaxation time in the cortical grey matter regions showed 
modest relationship with increased TUNEL positive apoptotic cellular death in the 
corresponding regions. 
 
Figure 4.3-10: Associations between T2 maps obtained 1-24 hours after 
resuscitation and histo-pathological brain injury   
 
Scatter graphs showing associations between T2 relaxation times obtained 1 to < 3 (x), 6 to < 12 (▲) 
and 6 to < 24 hours (●) after resuscitation and histo-pathological brain injury assessed using H & E 
stains in representative regions. Regional T2 relaxation times showed relatively less prominent 
relationships with histo-pathological outcomes (see Supplemental Table 7 in page 189 for statistical 
findings and data at other time intervals). 
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4.3.5 Serial magnetic resonance biomarkers obtained shortly before to 24 
hours before termination and histo-pathological brain injury 
 
4.3.5.1  31P MRS biomarkers (1 to 24 hours before termination) and brain 
injury 
Consistent predictive values of 31P MRS biomarkers for percentages of neuronal death 
and white matter injury assessed on H & E stains were observed as early as 18 to 24 
hours before the termination of the study, which became more consistent and robust in 
intervals closer to the time of termination; PCr/Pi showed optimal prediction of regional 
histological damage, whereas the predictive value of NTP/EPP was suboptimal to other 
31P MRS biomarkers (Fig. 4.3-10 and Supplemental Table 8 in page 195). During the 
period 12 to < 18 hours before termination, predictive values of 31P MRS biomarkers 
were further observed for the TUNEL positive apoptotic cellular death in the cortical 
grey matter, CD68 positive microglia and vessels in the cortical grey matter and the 
peripheral white matter, and β-APP positive axonal changes in the white matter. There 
was a trend towards more precise prediction of histo-pathological outcomes with time 
intervals closer to termination, except for the TUNEL positive apoptotic cellular death in 
the cortical grey matter, the optimal prediction of which was observed during the period 
of 12 to < 18 hours before termination. 
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Figure 4.3-11: Associations between 31P MRS biomarkers obtained 1-24 
hours before termination and histo-pathological brain injury   
 
 107 
 
 
Scatter graphs showing associations between 31P MRS markers obtained 1 to < 3 (●), 6 to < 12 (▲) 
and 6 to < 24 hours (x) before termination and histo-pathological brain injury assessed using H & E 
stains in representative regions. Tighter linear relationships with histo-pathological outcomes were 
observed for biomarkers obtained shortly before termination (see Supplemental Table 8 in page 195 
for statistical findings and data at other time intervals).  
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4.3.5.2 Maps of ADC (1 to 24 hours before termination) and brain injury  
Regional ADC values started showing consistent predictive values for the percentage of 
neuronal death in the cortical and deep grey matters, white matter injury assessed on H 
& E stains and LFB, and CD68 positive microglia and vessels in the cortical grey matter 
and the peripheral white matter during the period of 12 to < 18 hours before termination 
and the time intervals closer to termination (Fig. 4.3-11 and Supplemental Table 9 in 
page 208). Regional ADC in the white matter also predicted β-APP positive axonal 
changes after time intervals of 6 to < 12 hours before termination. 
 
Figure 4.3-12: Associations between maps of ADC obtained 1-24 hours 
before termination and histo-pathological brain injury   
 
Scatter graphs showing associations between ADC obtained 1 to < 3 (●), 6 to < 12 (▲) and 6 to < 24 
hours (x) before termination and histo-pathological brain injury assessed using H & E stains in 
representative regions. Subtle reduction in ADC just prior to termination corresponded to a 
considerable fraction of neuronal death in the parietal cortex. Tighter linear relationships were 
observed between histo-pathological outcomes and ADC obtained closer to termination (see 
Supplemental Table 9 in page 208 for statistical findings and data at other time intervals). 
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4.3.5.3 T2 maps (1 to 24 hours before termination) and brain injury 
Predictive values of regional T2 relaxation times were limited and inconsistent. However, 
longer T2 relaxation times in the white matter showed modest predictive value for worse 
white matter injury assessed on H & E stains during the time intervals of 18 to < 24 
hours before and closer to the time of termination (Fig. 4.3-12 and Supplemental Table 
10 in page 214). Longer T2 relaxation times were also associated with greater 
percentages of TUNEL positive apoptotic cellular death in the cortical grey matter during 
the period 18 to < 24 hours before termination and time intervals closer to termination. 
 
Figure 4.3-13: Associations between T2 maps obtained 1-24 hours before 
termination and histo-pathological brain injury   
 
Scatter graphs showing associations between T2 relaxation times obtained 1 to < 3 (●), 6 to < 12 
(▲) and 6 to < 24 hours (x) before termination and histo-pathological brain injury assessed using H 
& E stains in representative regions. Regional T2 relaxation times showed relatively less prominent 
relationships with histo-pathological outcomes (see Supplemental Table 10 in page 214 for 
statistical findings and data at other time intervals). 
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Chapter 5: Discussion 
 
5.1 Associations between insult severity and therapeutic time 
window duration 
 
5.1.1 Summary 
We have proved the hypotheses that a more severe hypoxic-ischaemic insult leads to a 
shorter latent phase, more severe secondary energy failure and greater neuronal death. 
The findings of this study are discussed in this chapter. 
 
5.1.2 Key findings from the study 
In a newborn piglet model of asphyxial encephalopathy, we have demonstrated that the 
more severe the cerebral energy depletion during transient hypoxia-ischaemia was, the 
shorter the subsequent latent-phase was, the worse the severity of secondary energy 
failure was, and the more extensive neuronal death in the cortical grey matter was. The 
duration of the latent phase itself showed significant relationships with the severity of 
secondary energy failure and the eventual extent of neuronal injury in both the cortical 
grey matter and the deep grey matter. Further, we confirmed that a higher neuronal 
mortality was associated with more severe secondary energy failure. Previously the 
association between the duration of therapeutic time window and the severity of acute 
hypoxia-ischaemia had been deduced indirectly on the basis of faster development in 
the histo-pathological injury with more severe hypoxia-ischaemia (114, 115). However, 
using quantitative measures and multivariate analysis, we have demonstrated here that 
the duration of the latent phase was shorter following more severe insults, and that this 
period, which is likely to include the therapeutic time window, can be lengthened by 
therapeutic hypothermia.   
 
5.1.3 Acute energy depletion and evolution of secondary energy failure 
Secondary energy failure has been observed in several different species at various 
maturational stages as reduced high energy phosphates (e.g. PCr and NTP). Our group 
has mainly used NTP/EPP and PCr/Pi as indices of high-energy phosphate reserves. In 
this current analysis, we used NTP/EPP as a robust index of the severity for secondary 
energy failure, because PCr/Pi would be affected by factors including the flux within the 
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mitochondrial electron transport chain and re-phosphorylation of adenosine 
diphosphate via creatine kinase; furthermore, PCr/Pi can fall before ATP because, with 
unimpaired substrate delivery, anaerobic glycolysis can maintain ATP (47).  
Using MRS and biochemical methods, previous studies quantified the absolute 
concentrations of high energy phosphates (45, 78) and of total adenine nucleotides and 
total creatine (79) respectively. These studies have demonstrated falls in total mobile 
phosphates, EPP, total adenine nucleotides and total creatine at the similar timing to the 
reduction in NTP/EPP and PCr/Pi. Although energy metabolism apparently recovers 
within approximately an hour after the primary insult, injury cascades have already been 
activated at the cellular level even at this stage (50-54). Vannucci and colleagues 
observed linear relationships between histological tissue injury and high energy 
phosphate concentrations at 6 to 18 hours after resuscitation, with greater significance 
at 24 to 48 hours, suggesting that secondary energy failure was consequential to 
evolving cellular destruction rather than causal of cellular death in so far surviving tissue 
(79). Although it is agreeable that secondary energy failure as observed by 31P MRS is 
likely to be a phenomenon directly associated with a delayed, irreversible metabolic 
crisis, it may not closely match the temporal evolution of cell death itself. Our present 
study in a piglet model suggests that considerable histological cell death may already 
be present during the latent phase (i.e. before overt secondary energy failure). This 
suggests that, during the early phase of secondary energy failure, co-existing earlier 
and progressing histological damage may not relate directly to the surviving 
exchangeable phosphate pool, and that the latent phase may simply represent 
damaged but surviving tissue maintaining normal high energy phosphate levels via 
salvage systems, because 31P MRS is likely to be "blind" to dead cells, from where all 
mobile phosphate has leaked out. Hence we believe that the latent phase represents 
normal high energy phosphate levels in surviving tissue; it is during the latent phase that 
therapeutic interventions are most likely to preserve tissue vitality - but only that of 
tissue which has survived to this stage. 
 
5.1.4 Level of acute energy depletion and the effect of hypothermic 
neuroprotection 
There is some evidence suggesting that hypothermia is less neuroprotective in the most 
severely asphyxiated subjects. In a study of adult traumatic brain injury, moderate 
systemic hypothermia improved the outcome of patients with an initial Glasgow Coma 
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Scale of 5-7 but not for those with 3-4 (116). A study of selective head cooling for infants 
with neonatal encephalopathy showed improved survival with lessened severe disability 
only in infants whose aEEG demonstrated moderate (but not most severe) background 
abnormalities before cooling (8). In our current study, a more severe acute insult 
(greater acute energy depletion) led to a shorter latent phase. If therapy is only effective 
during the latent phase, then the brevity of that stage in the most severely injured 
patients may explain the reduced hypothermic neuroprotection. 
 
5.1.5 Evolution of secondary energy failure and neuroprotective 
treatments 
The therapeutic time window for potentially neuroprotective interventions may vary 
depending on the treatment, as particular neuroprotective agents ameliorate different 
cytotoxic stages (11, 101, 117). Hence the latent phase duration may not directly 
correspond with the window of opportunity for neuroprotection following 
hypoxia-ischaemia. However, once secondary energy failure is established, therapeutic 
interventions may provide no or minimal benefit, because deleterious reactions expands 
rapidly to the downstream cascades of cerebral injury by the end of the latent phase, 
suggesting that the earlier the intervention is, the greater the benefit of neuroprotective 
treatments are.  
Diffusion-weighted imaging of hypoxic-ischaemic cerebral injury has demonstrated 
temporal and anatomical variations in brain water ADC which correlated with NTP/EPP 
(62). Albeit slightly biased towards cortical grey matter, we used effectively whole brain 
31P MRS to monitor the latent phase and the evolution of secondary energy failure: 
hence, we could not discern regional differences in the latent phase. However, the 
regional ADC differences suggest that the therapeutic time window may also vary 
between regions. Our study was not designed to elucidate the optimal therapeutic time 
window for hypothermic neuroprotection. Further studies, utilising a wide range of 
hypothermic delays and durations, are needed to achieve this. Our study was also not 
designed to address the direct relationship between the insult severity and hypothermic 
neuroprotection. However, only in both cooled groups was there a suggestion in cortical 
grey matter that the most severe insults were associated with greater neuronal death 
and more moderate insults with less: further studies are required to investigate the 
relationship between the severity of hypoxia-ischaemia and the efficacy of cooling. 
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5.1.6 Clinical implications 
In infants with neonatal encephalopathy consequential to perinatal hypoxia-ischaemia, 
the exact timing, duration, and magnitude of the intrapartum events are unknown. Using 
our translational model of perinatal asphyxial encephalopathy, the insult severity of 
which can be quantified, we have shown that the latent phase shortens as insult severity 
increases. Thus the time between birth and the onset of secondary energy failure may 
constitute a retrospective index of the severity in intrapartum hypoxa-ischaemia.  
Recently, large scale clinical trials of therapeutic hypothermia following perinatal 
hypoxia-ischaemia have confirmed that intervention within the first 6 hours after birth 
reduces death and severe disability at 18 months after birth (12). The possibility of only 
a brief latent phase in the most severely injured patients, who had very abnormal 
background activity on the pre-randomisation aEEG, may explain the reduced 
hypothermic neuroprotection in such infants (8). These trials, whilst results are 
encouraging, highlight the need to select candidates for intervention, excluding those 
who are unlikely to benefit, and also to tailor specific treatments to individual infants in 
order to fully optimise neuroprotection.  
Very early 31P MRS may help define the severities of a preceding hypoxic-ischaemic 
insult and the consequential secondary energy failure (54), however, given the clinical 
problems associated with very early application of this modality to encephalopathic 
infants, it is important that experimental research focuses on relationships between 
quantitative 31P MRS and other magnetic resonance biomarkers, such as 1H MRS and 
ADC, and cotside tools such as aEEG. 
 
5.1.7 Strengths and limitations of the study 
We used acute energy depletion as an index of the insult severity, because our group 
has reported that this index correlates with the severity of secondary energy failure (42) 
and neuronal death (118) in this model. Throughout the present study, we aimed for 
insults of similar severity by using a standardised protocol employing continuous31P 
MRS to monitor β-NTP in real time during the acute hypoxic-ischaemic insult: however, 
there were variations in the biological response to both transient hypoxia-ischaemia and 
resuscitation. Such variability, often encountered in the clinical practice as well, may 
explain a wide range of outcome severities in infants with neonatal encephalopathy 
consequential to perinatal hypoxia-ischaemia. It may be important to understand the 
infant specific biological response to the stress as well as the insult morbidity itself to 
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improve the diagnostic accuracy and neuroprotective effect of therapies. In the currents 
study, we were unable to maintain our model for more than 60 hours in total for ethical 
and practical reasons. Consequentially it is possible that the severity of both secondary 
energy failure and histological injury may have been worse than that measured. It is 
also important to note that, unlike in our model, the precise timing of perinatal 
hypoxia-ischaemia is generally unclear in clinical practice. Further studies in our model 
may help establish biomarkers, which indicate the timing, type and depth of insults.        
Multivariate analysis adjusting for the temperature groups demonstrated correlation 
between neuronal death and acute energy depletion only in cortical grey matter. On-axis 
reception sensitivity of a circular MRS surface coil (radius r) decreases with coil distance 
(d) as r2/(r2 + d2)3/2 with comparable behaviour off-axis (119): elliptical surface-coil 
sensitivity also decreases similarly. Hence, the observed acute energy depletion may 
have been more representative of the insult experienced by the cortical grey matter 
rather than the deep grey matter. Characteristic intrinsic factors of the deep grey matter 
in the developing brain, such as the high metabolic rate and overexpression of 
glutamate receptors and nitric oxide synthase, may render this region highly susceptible 
to perinatal hypoxia-ischaemia, potentially yielding different consequences from the 
cortical grey matter (120-122). In addition, our previous histological analysis on the 
same experimental subjects demonstrated that the optimal protection for the cortical 
grey matter was observed at 33ºC, whereas the deep grey matter was most protected at 
35ºC (49), suggesting potentially different optimal temperature values for 
neuroprotection in different cerebral regions; the relationship between the insult severity 
and the outcome measure might also be affected by cooling. 
 
5.1.8 Conclusions 
We have shown that increasing insult severity is associated with shortening of the 
subsequent latent phase, and more severe secondary energy failure and neuronal 
damage in the cortical grey matter. The severity of secondary energy failure correlated 
linearly with neuronal mortality. The brevity of the latent phase in subjects with severe 
perinatal hypoxia-ischaemia may explain the apparently reduced hypothermic 
neuroprotection in the most severely asphyxiated newborn infants. Further work is 
needed to investigate the relationship between the severity of the insult and the efficacy 
of cooling. It is also important to develop cotside tools providing early measures which 
correlate with the impairment of brain energy generation. 
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5.2 Energy metabolism during the latent phase and early 
evolutional period or secondary energy failure 
 
5.2.1 Summary 
We have proved the hypothesis that subtle variation in global energy metabolites during 
the latent phase is associated with the severity of secondary energy failure even before 
the overt evolution of secondary energy failure. The findings of this study are discussed 
in this chapter. 
 
5.2.2 Key findings from the study 
Following resuscitation, in subjects with favourable outcome, PCr/EPP recovered to 
higher than its baseline level (overshoot); in subjects with unfavourable outcome, 
maximum recovery in PCr/EPP was lower than baseline and lower than in subjects with 
favourable and intermediate outcomes. Recovery PCr/EPP correlated linearly and 
negatively with both acute insult severity and baseline PCr/NTP. These results suggest 
that recovery in energy metabolites shortly after resuscitation may provide an early 
biomarker for the tissue viability. PCr recovery overshoot may indicate a protective 
response to hypoxia-ischaemia leading to cell recovery, survival and protection against 
subsequent stress. In addition, baseline cerebral metabolism (PCr/NTP) may identify 
vulnerable subjects and cerebral regions prior to invasive surgery. 
 
5.2.3 Changes in high energy phosphates during transient 
hypoxia-ischaemia, latent phase and secondary energy failure 
A range of compensatory systems exist to maintain the tissue metabolism under the 
shortage or lack in energy substrates. For example, the creatine kinase reaction can 
generate ATP from PCr and adenosine diphosphate at sites of high energy demand 
(123) constituting a temporal and spatial buffering system for cellular energy stores (124, 
125). In our study, a rapid reduction in PCr/EPP was observed only during the first 10 
minutes of hypoxia-ischaemia, whereas NTP/EPP declined slowly throughout the insult, 
suggesting that NTP was initially maintained at the expense of PCr via the creatine 
kinase reaction. We observed a similar sequence in the reduction of PCr/EPP and 
NTP/EPP during secondary energy failure, suggesting that creatine kinase was 
employed to initially but temporarily maintain the NTP level even during this secondary 
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phase of metabolic derangement. Studies by our group and others have suggested that 
secondary energy failure occurs concomitantly with irreversible, terminal stage tissue 
injury (45, 53, 78, 79). Although this phase may not directly reflect the consequence of 
on-going cellular death, our current results also suggest that secondary energy failure is 
a consequence of a substantial tissue fraction, which survived acute hypoxia-ischaemia 
only to later undergo further metabolic derangement, eventually leading to more cell 
death and tissue loss. Further studies need to address mitochondrial functions during 
evolutional phases of secondary energy failure. 
 
5.2.4 Cerebral stress response after the commencement of resuscitation 
and PCr recovery overshoot 
When all experimental subjects were analysed together, resuscitation led to the 
recovery in PCr/EPP to the baseline level 2-8 hours following transient 
hypoxia-ischaemia, whereas neither NTP/EPP nor Pi/EPP fully recovered. Group 
analysis revealed that the “full recovery” of PCr/EPP was due to the combined effects of 
incomplete recovery in the “severe" secondary energy failure group and recovery 
beyond baseline levels for “no" secondary energy failure: in the latter piglet group, 
PCr/EPP 2-8 hours after resuscitation was higher than at the baseline and higher than 
for subjects with “severe" secondary energy failure. Even during the latent phase, the 
neurotoxic cascade (the death programme) and the recovery process induced by 
reperfusion (the rescue programme) compete to determine the extent of the eventual 
cerebral injury (51-53, 72, 126-128).  
 
Brief PCr recovery overshoot, quantified either as the absolute PCr concentration or 
measured relative to NTP, is considered to be one of such stress responses widely 
recognised in skeletal muscle (129, 130) and myocardium (131-136). However, it 
remains unclear if this phenomenon is beneficial, detrimental, or inconsequential. In 
skeletal muscle, endurance training up-regulates PCr recovery and improves exercise 
performance (129), whereas in cardiac muscle, PCr recovery overshoot following 
ischaemia and reperfusion has been related both to adversities including depressed 
contractile function (“myocardial stunning”), poor ATP restoration, and worse 
histological injury (132, 137), and to favourable remote effects such as more efficient 
energy consumption and tolerance to forthcoming potentially lethal hypoxia-ischaemia 
(“ischaemic preconditioning”) (133-135). Although cerebral PCr recovery overshoot 
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following hypoxia-ischaemia has not been described previously, several stimuli such as 
hypothermia and creatine supplementation, both of which are potent neuroprotective 
treatments, induce an elevation in cerebral PCr (138-140). In our current study, the 
recovery in PCr/EPP above the baseline level occurred only in the subject with "no" 
secondary energy failure, and the PCr/EPP level correlated linearly and negatively with 
the insult severity, suggesting that PCr recovery overshoot in brain is a welcome 
response to hypoxia-ischaemia potentially heralding cell recovery and survival. Given 
that induced high cerebral PCr (e.g. incurred by hypothermia or creatine 
supplementation) is associated with increased resistance to hypoxia-ischaemia, 
cerebral PCr recovery overshoot following mild hypoxia-ischaemia might also protect 
against subsequent potentially lethal stressors.  
 
Our study was not designed to investigate the mechanism of PCr recovery above 
baseline in the developing brain. However in the skeletal muscle, this stress response is 
attributed to delayed downgrading of oxidative phosphorylation from the activated high 
demand status (130). In myocardium, a potential explanation is mitochondrial PCr 
synthesis proceeds unperturbed but deficiency in creatine kinase specific within 
cytoplasm due to oxygen radical toxicity reduces PCr utilisation (131, 137). Another 
possibility is that cardiac function is down regulated either passively due to severe 
damage or actively as a “hibernation period” for the stressed tissue (141). A transient 
reduction of intracellular adenine nucleotides by loss into the interstitial and vascular 
space observed in myocardium following hypoxia-ischaemia could also explain why 
neither NTP/EPP nor Pi/EPP regained baseline levels after the insult (142, 143). Indeed, 
in the developing brain, a transient, reversible reduction in total cerebral adenine 
nucleotides has been observed following hypoxia-ischaemia although the relationship 
with PCr recovery level was not investigated (79, 128). However given the prolonged 
PCr recovery above baseline observed in the current study, it is possible that the 
underlying mechanism may be different from that in the skeletal and cardiac muscle.  
 
We also observed that lower baseline PCr/NTP was associated with higher recovery 
PCr/EPP. Although we used term born piglets of similar size and maturation, high brain 
PCr/NTP under normal physiological conditions may imply differences in maturity, 
metabolic activity and subsequent vulnerability to hypoxia-ischaemia. Interestingly, 
pre-existing low PCr (relative to NTP or creatine) leads to a greater increase in PCr 
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following exercise (skeletal muscle) and creatine supplementation (skeletal muscle and 
brain) (130, 144, 145). Further studies are required to elucidate the relationship 
between cerebral PCr recovery overshoot and background metabolism. 
 
5.2.5 Clinical implications 
Early prediction of the extent of cerebral injury following transient hypoxia-ischaemia is 
desirable for the refining and appropriate targeting of neuroprotective therapies in the 
newborn. Our current results suggest that subtle changes in the global brain PCr/EPP 
and Pi/EPP during the latent phase (2-8 hours after resuscitation) can discriminate 
subjects which will later develop minimal, moderate and severe secondary energy 
failure. 
 
5.2.6 Limitations and advantages of the study 
The number of subjects (particularly controls) and the interval of serial MRS acquisitions 
were limited for ethical and practical reasons. Our group has reported previously that 
PCr remains unchanged relative to the total mobile phosphate over 48 hours in sham 
operated subjects (42). This mirrors human studies in which PCr, Pi, NTP, and total 
mobile phosphate concentrations changed only gradually up to the age of 20 months 
old (146). The duration of our present study was shorter compared to those in our 
previous reports, which kept the piglet within the bore over 48 hours after resuscitation 
(42, 47): it is possible that subjects with no or moderate secondary energy failure may 
have eventually developed severe secondary energy failure with longer observations.  
 
5.2.7 Future studies 
We have demonstrated, for the first time, the presence of cerebral PCr recovery 
overshoot after hypoxia-ischaemia. Although this phenomenon appeared to be a 
favourable event leading to the optimal metabolic function during the sub-acute phase, 
detailed associations between injury reactions and energy metabolism need to be 
delineated (i) to improve understanding of injury cascade, (ii) to develop more precise 
diagnostic tools, and (iii) to increase the beneficial effect of neuroprotective treatments. 
  
 119 
5.2.8 Conclusions 
PCr recovery overshoot has been reported elsewhere in skeletal muscle after exercise 
and in myocardium after reperfusion. The presence of cerebral PCr recovery above 
baseline in a newborn porcine model of asphyxial encephalopathy was demonstrated 
using serial 31P MRS: piglets in which secondary energy failure did not develop 
displayed supra-baseline recovery in PCr/EPP. Our findings give novel insight into the 
cerebral stress response to hypoxia-ischaemia and suggest that, as well as Pi/EPP, 
cerebral PCr/EPP might be an early favourable biomarker before the evolution of 
secondary energy failure following perinatal hypoxia-ischaemia. 
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5.3 Temporal and spatial evolution of secondary energy failure 
and cerebral injury 
 
5.3.1 Summary 
We have proved the hypothesis that evolution of secondary energy failure observed 
using ADC maps was spatially heterogeneous, and that early regional ADC values 
predicted tissue damage up to 18 hours in advance of termination. Although the 
predictive value of magnetic resonance biomarkers for histo-pathological brain injury 
appeared to be optimal with global PCr/Pi, regional ADC provided equivalent predictive 
values to global PCr/EPP and Pi/EPP, and may be clinically useful as an alternative to 
31P MRS biomarkers. The findings of this study are discussed in this chapter. 
 
5.3.2 Key findings from the study 
Global cerebral energy metabolite levels observed using 31P MRS were confirmed to be 
a robust biomarker for histo-pathological brain damage, with PCr/Pi providing the 
optimal estimation of existing and forthcoming brain damage. Although regional ADC 
values failed to demonstrate superior predictive value to global PCr/Pi, ADC showed 
significant regional heterogeneity during the evolutional phase of secondary energy 
failure. Given that global 31P MRS biomarkers predominantly reflected tissue changes in 
the superficial architecture corresponding to regions covered by the surface coil, maps 
of ADC may additionally provide spatial information especially in deep brain structures. 
Maps of T2 relaxation time showed only limited predictive value of brain damage, 
however, its temporal increase was predominantly associated with apoptotic cellular 
death. Given that T2 relaxation time is mainly determined by changes in the 
water-macromolecule ratio within the tissue (69), T2 prolongation may well be observed 
for tissue injury where other types of cellular death is predominant. Further investigation 
is required to confirm whether our current finding was caused by chance or by 
characteristic changes in tissue integrity associated with apoptotic cellular death.  
 
5.3.3 Diagnostic value of global and regional magnetic resonance 
biomarkers for histo-pathological brain injury 
We have confirmed that ADC values can provide precise estimation of 
histo-pathological brain injury up to 18 hours in advance of termination, the predictive 
 121 
value of which appeared to be relatively more robust compared to the global NTP/EPP. 
However, unlike our initial hypothesis, the maps of ADC failed to demonstrate superior 
predictive values for histo-pathological brain damage to global PCr/Pi despite the 
advantage in the spatial information. Our group has utilised the31P MRS variables by 
quantifying the concentration of energetic metabolites relative to EPP. The reduction in 
PCr/EPP and the increase in Pi/EPP precede the decline in NTP/EPP, as the ATP 
concentration is maintained by utilising the PCr pool via the creatine kinase reaction 
(124, 125). Although the reduction in NTP/EPP is more likely to be linked with the 
terminal energy derangement of the cerebral tissue (147), this may not provide highly 
sensitive early marker of delayed tissue injury. Given that PCr/EPP and Pi/EPP have 
been demonstrated to be more sensitive early markers compared to NTP/EPP (54), the 
metabolite ratio between PCr and Pi may reasonably provide an even more sensitive 
biomarker to on-going tissue injury during the acute phase. Further studies are required 
to compare the predictive value of PCr/Pi, ADC and lactate relative to N-acetylaspartate 
(Lac/NAA) obtained using 1H MRS, the last of which is currently recognised to be the 
most sensitive and specific magnetic resonance biomarker for the neurodevelopmental 
outcome after perinatal hypoxia-ischaemia in the clinical practice (58). 
 
Despite the excellent predictive value of global PCr/Pi for the endpoint brain injury, 
currently few research and clinical institutions can obtain 31P MRS from the newborn 
brain because of its high demand for the hardware, expertise and skilled personnel as 
well as the lack in the spatial information and the relatively long acquisition time. In 
contrast, ADC maps can be acquired in most clinical MRI scanners, rendering this 
modality one of most useful early biomarker to support tailored neuroprotective 
treatments after perinatal hypoxia-ischaemia. Although there remained uncertainty 
around the optimal timing of the scan and the interpretation into clinical outcome 
especially because of the pseudo-normalisation of ADC several days after 
hypoxia-ischaemia, our current study demonstrated that, during the evolutional phase of 
secondary energy failure, regional ADC values can be used to estimate the 
histo-pathological brain injury in the corresponding region both at the time of and up to 
18 hours after the MRI study. To clinically apply early prediction of cerebral injury 
following hypoxia-ischaemia using the maps of ADC, further translational studies are 
required to give ranges in ADC values corresponding to normal and abnormal outcomes 
for each region, infant’s maturational stage, and time after birth. Experimental studies 
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with longer observational intervals are required to delineate the optimal time window for 
ADC to predict the associated brain injury.  
Our current study was initially designed to assess correlations between 
histo-pathological brain injury and serially obtained magnetic resonance biomarkers at 
specific time intervals before termination of each study, so that clinicians may be able to 
monitor and predict the type and depth of tissue damage both at the moment of and 
after hours of the magnetic resonance data acquisition. However, we also analysed the 
time-series data according to the elapsed time after resuscitation, which may provide 
useful information for clinical assessment of injury severity. When the analysis was 
performed with adjustment for the insult severity and the survival time after resuscitation, 
both global 31P MRS biomarkers and regional ADC values showed modest correlation 
with the end point brain injury, however, the level and pattern of positive findings were 
less robust compared to the former approach, which was based on the data classified 
according to specific time intervals before termination. The difference in the findings 
might be explained by previous studies which have found that brain injury on 
histopathology increases with longer survival times within the first few days after the 
acute event (148, 149); other bias might also influence the predictive value of magnetic 
resonance biomarkers, as, in our study, the dependence of histo-pathological outcomes 
on the insult severity and the time interval after resuscitation was relatively weak. One 
limitation of the current study is that, although we intended to correlate serial magnetic 
resonance biomarkers with histo-pathological samples harvested at different time points 
with different levels of energy failure, we did not have sufficient numbers at each time 
point for robust analysis. Future studies need to assign multiple subjects to several 
predetermined termination points to remove the probable bias in our current study.   
 
5.3.4 Spatial changes of ADC during the evolutional process of secondary 
energy failure 
A previous study from our group demonstrated that, in a similar piglet model of perinatal 
asphyxial encephalopathy, ADC changes in the superficial cerebral cortex and white 
matter precisely surrogate the decline in high energy phosphates quantified using 31P 
MRS (62). Based on this observation, in this current study, we used the maps of ADC to 
monitor regional evolution of secondary energy failure in the piglet model. Consistent to 
this assumption, both global NTP/EPP and ADC values in the cortical grey matter and 
peripheral white matter were lower than baseline from 1 to < 3 hours after resuscitation. 
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Serial observations in regional ADC values suggested that the evolutional timing of 
secondary energy failure was spatially heterogeneous, presumably reflecting the 
inter-subject and inter-regional variations in the reaction to both hypoxia-ischaemia and 
resuscitation. Rapid reduction in ADC values in the cerebral cortex and peripheral white 
matter was observed predominantly in the sagittal and parietal watershed regions 
between anterior and middle cerebral arteries; these changes were followed by gradual 
ADC declines in the temporal lobe, deep grey matter and central white matter after 6 to 
<12 hours of resuscitation. ADC values at baseline were highest in the central white 
matter and lowest in the deep grey matter, the contrast of which was lost shortly after 
hypoxia-ischaemia, supporting the rapid change in the water diffusion within the 
susceptible cerebral regions of the watershed cortex, white matter and the posterior 
limb of the internal capsule. Future studies need to address the relationship between 
types and depth of insult, and spatial pattern of ADC decline with time. 
 
5.3.5 T2 maps during acute phase after perinatal hypoxia-ischaemia 
In contrast to the information obtained from global 31P MRS and ADC, T2 maps showed 
only weak predictive values of histo-pathological brain injury. At baseline, there was a 
considerable inter-regional variation in the T2 relaxation time as estimated from the 
contrast on T2 weighted imaging from the newborn brain. However, such an 
inter-regional variability was lost shortly after hypoxia-ischaemia and resuscitation. 
Although we rarely observe marked reductions in T2 contrast within a few days of 
perinatal hypoxia-ischaemia in clinical cases, quantitative approach may enable to 
identify subtle reductions in T2 contrast objectively. Relatively small temporal changes 
of this variable following hypoxia-ischaemia may render this measure suboptimal 
surrogate biomarker for the tissue injury, however, it was interesting that the T2 
relaxation time was predominantly associated with apoptotic cell death. Although further 
studies are needed to elucidate the exact micro-structural change of apoptotic cell death 
associated with T2 prolongation, in future, T2 maps may additionally provide specific 
information about delayed and prolonged tissue damage via apoptosis when it is used 
in combination with other magnetic resonance biomarkers. 
 
5.3.6 Clinical implications 
Monitoring of the regional evolution of secondary energy failure using the maps of ADC 
may help predict histo-pathological brain injury corresponding to both the same timing of 
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and up to 18 hours after the imaging acquisition. For example, if regional ADC suggests 
the survival of considerable fraction of neurons at the time of scan, and the likelihood of 
profound cerebral injury after 18 hours without efficient treatment, one may be able to 
introduce invasive but efficient neuroprotective treatments even out of generally 
accepted window of opportunity for the treatment. Clinically reliable threshold levels of 
ADC drops need to be established, with which one can predict later brain injury before 
overt, global drops in ADC are observed reflecting the development of secondary 
energy failure. 
 
5.3.7 Limitations of the study 
The current study used variable experimental durations after resuscitation to investigate 
the relationship between histo-pathological brain injury and magnetic resonance 
biomarkers obtained a certain time interval before termination, and hence, we were 
unable to identify specific biomarkers and timings for acquisition, which provide optimal 
predictive value for the endpoint histo-pathological brain injury. Because most animals 
were sacrificed between 24 and 48 hours after the commencement of resuscitation, we 
were unable to assess the predictive value of magnetic resonance biomarkers both later 
than 24 hours after resuscitation and earlier than 24 hours before termination. T2 maps 
were obtained within a limited number of subjects, which may in part be responsible for 
their lack in predictive values for histo-pathological brain injury using this modality. In 
addition, we were unable to include temporal and spatial changes in FA for the current 
analysis, which might provide optimal diagnostic utility in the white matter.  
Acquisition intervals for magnetic resonance biomarkers were limited for technical 
reasons, resulting in uncertainty around the optimal timing in acquiring magnetic 
resonance biomarkers to predict the outcome. Our assumption that regional variations 
of ADC following hypoxia-ischaemia reflect local energy metabolism might be wrong 
given the superior predictive value of global PCr/Pi compared to regional ADC for 
regional histo-pathological injury. It was of note that the correlation between ADC and 
histo-pathological injury was relatively weak in small deep structures such as the 
caudate nucleus and the posterior limb of the internal capsule, which could be attributed 
to the inaccuracy in calculating ADC values in small RoIs. Further studies are needed 
using 31P MRS imaging to identify associations between regional energy metabolism, 
ADC values, long term MRS and histological outcome (150).   
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5.3.8 Future studies 
Clinical studies have to establish the relationship between ADC changes at different 
time point after resuscitation and eventual patters and depths of injury using both 
conventional and volumetric MRI as endpoint markers. Although T2 maps provided 
much less information in predicting the tissue damage, difference in the temporal 
changes with a range of apoptotic cell death may be worth investigation to see whether 
these maps are useful to discriminate specific types of cellular death and their early 
signs especially in conjunction with other magnetic resonance biomarkers. 
 
5.3.9 Conclusions 
Findings in the maps of ADC following transient hypoxia-ischaemia, although highly 
sensitive during the acute phase, have thus far considered as a difficult variable to 
interpret into clinical information because of their dynamic temporal changes after 
hypoxia-ischaemia (64). However, our current study highlighted that absolute ADC 
values obtained during the evolutional phase of secondary energy failure can precisely 
predict the tissue damage at and up to 18 hours after the data acquisition; analysis with 
the time-series data after resuscitation showed modest predictive values of 31P MRS 
and ADC for the end point brain injury as early as 3 to 6 hours after resuscitation. Future 
studies have to validate the level of ADC change corresponding to mild, moderate and 
severe tissue damage for each time point after hypoxia-ischaemia, so that the natural 
course can be predicted with early, subtle changes in regional ADC values. 
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Chapter 6: Overall conclusion and implication of the findings 
from this thesis 
 
6.1 Conclusions 
 
A more severe acute insult led to a shorter latent phase duration, more severe 
secondary energy failure and more deleterious brain damage. Although energy 
metabolism recovers to the normal level at a glance, subtle increase in PCr and Pi 
relative to EPP may identify subjects with favourable and unfavourable outcomes in 
energy metabolism. During the evolutional phase of secondary energy failure, global 
PCr/Pi was the most sensitive early marker which provided robust prediction of endpoint 
histo-pathological brain injury up to 24 hours in advance of termination. Regional ADC, 
although inferior to global PCr/Pi, also demonstrated sufficient predictive values for the 
endpoint brain injury with spatial resolution. Evolution of secondary energy failure was 
heterogeneous between subjects and cerebral regions, according to the variations in 
the severity of hypoxia-ischaemia, susceptibility of specific subjects and regions, and 
the response to resuscitation.  
 
Maps of ADC have been utilised as a reliable surrogate biomarker for high energy 
phosphates; in our study, regional ADC obtained up to 18 hours before termination 
predicted later neuronal, glial and axonal injury. Regional ADC also predicted the 
endpoint neuronal injury and microglial reaction as early as 12 hours after resuscitation, 
the period of which is within the latent phase for most subjects when assessed by global 
NTP/EPP. Thus far, ADC values following hypoxia-ischaemia have been considered to 
be of limited utility because of their dynamic and multiphasic changes after the acute 
event (64). However, our current findings suggested that, when obtained during the 
evolutional phase of secondary energy failure i.e. within up to 48 hours after 
resuscitation, ADC values may provide highly useful information to predict the pattern 
and severity of tissue damages. Further evidence is required to establish ADC ranges 
corresponding to specific outcomes at different stages after hypoxia-ischaemia. 
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6.2 Latent phase, secondary energy failure and tissue 
homeostasis 
 
The discovery of secondary energy failure following hypoxia-ischaemia in late 1980s to 
1990s (42-44) gave an illusion to clinicians and investigators as if cerebral energy 
metabolism recovers to the normal function after successful resuscitation. However, 
despite sufficient supply in oxygen and energy substrates to the brain, the latent phase 
is followed by an overt loss of high energy phosphate after 8 to 24 hours of resuscitation. 
Recent experimental and clinical studies which addressed the evolutional period of 
secondary energy failure suggested the presence of substantial metabolic derangement 
and tissue destruction has been confirmed even before or during the early evolutional 
stage of secondary energy failure (45, 53, 78, 79), highlighting the importance of 
understanding injury reactions which are processed during the latent phase. Given the 
wide range of deleterious chemical reactions which are activated shortly after 
reoxygenation and reperfusion (41, 151), it is more likely that, following severe 
hypoxia-ischaemia but before the evolution of overt secondary energy failure, cerebral 
tissue is maintaining a normal balance between energetic metabolites only by 
maximising salvage systems to compensate for damaged cytoplasmic organelle such 
as mitochondria and endoplasmic reticulum (41, 101). Subtle increase in PCr and Pi, 
and subnormal ADC levels observed during the latent phase may be the signs 
suggestive of on-going competitions between deleterious injury program and protection 
program. 
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6.3 Magnetic resonance biomarkers and histo-pathological 
findings 
 
Global 31P MRS biomarkers and regional ADC showed good predictive values for later 
histo-pathological brain injury over most cerebral regions. However, the association 
between these biomarkers and CD68 expression was mainly observed within superficial 
part of the brain, presumably because of the higher incidence of CD68 positive 
microglia and vessels in the cortical grey matter compared to the deep grey matter.  
Although the spatial information provided by ADC maps may improve the quality of 
diagnosis to identify regionally heterogeneous evolution of secondary energy failure, 
agreements between regional ADC values and histo-pathological injury appeared to be 
relatively worse in small deep regions such as the caudate nucleus and the posterior 
limb of the internal capsule, suggesting that the placement of small RoIs for ADC maps 
(and potentially for T2 maps) is technically unreliable. Our current findings need to be 
confirmed in future experimental studies using consistent study durations. Although the 
regional T2 relaxation time was insensitive to most cerebral injury observed during the 
acute phase, it showed specific sensitivity to apoptotic cell death in the cortical grey 
matter; these maps may be used to predict prolonged tissue damage via apoptosis 
when they are combined with other magnetic resonance biomarkers. 
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6.4 Monitoring of secondary energy failure 
 
Because of spatially highly heterogeneous evolution of secondary energy failure, the 
maps of ADC appear to be more suitable to monitor the energy metabolism after 
hypoxia-ischaemia. Thus far, it remains unclear why temporal changes in ADC mimics 
those in high energy phosphates; it is presumed that the maintenance of the normal 
spatial distribution for intracellular and extracellular water is of high energy demand, and 
that, with energy deficit of even short period, significant reductions in water diffusion can 
be observed (152). In our current study, early absolute ADC values obtained within 48 
hours of birth predicted the natural histo-pathological outcome even without referring to 
the baseline data. Early reductions in regional ADC to subnormal levels are suggestive 
of later development of substantial cerebral injury.  
Although the predictive value of global 31P MRS biomarkers, especially PCr/Pi, was 
optimal, these markers have significant clinical limitations, because currently, only few 
institutions have access to a spectrometer which can obtain 31P MRS from the newborn 
brain. In contrast, ADC maps are available using most existing MRI scanners within a 
short period. Further experimental studies may help promote ADC maps during the 
evolutional phase of secondary energy failure into a handy, standard biomarker after 
perinatal hypoxia-ischaemia. Studies in 31P MRS also need to establish absolute 
quantification of phosphates from the whole brain to discriminate the tissue loss from 
reductions in phosphates, and also to give temporal changes in regional 31P MRS 
measures using MRS imaging.  
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6.5 Secondary energy failure and cerebral protection 
 
Our current findings suggested that the severity of acute insult is positively correlated 
with the brevity of the latent phase duration, which is likely to include the therapeutic 
time window for hypothermia and most other neuroprotective treatments. 
Neuroprotective interventions should be commenced as early as possible given the 
evidence to support the process of deleterious chemical reactions even during the latent 
phase (11). For subjects who experienced the most severe hypoxia-ischaemia, very 
early interventions such as pre-hospital cooling may increase the opportunity to respond 
the treatment (153). Maps of ADC, by providing the spatial pattern of metabolic 
derangement, may help improve the choice of treatments, as we have previously 
reported that different body temperatures are likely to lead to spatially different 
protection patterns of the cerebral tissue (49). Similarly, if early evolution of apoptotic 
cell death is noticed using T2 maps, additional pharmacological treatments targeting 
pro-apoptotic proteins can be applied as a tailored treatment (41, 154). 
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6.6 Strength and limitation 
 
We were able to obtain a range of magnetic resonance biomarkers including 31P MRS 
and maps of ADC and T2 relaxation time. However, because of the limited acquisition 
cycle, we were unable to include 1H MRS, which has been demonstrated to be the 
optimal clinical biomarker to predict the neurodevelopmental outcome after perinatal 
hypoxia-ischaemia (58). For the current study, we were able to use an established piglet 
model of perinatal asphyxial encephalopathy (42, 47, 49, 155, 156). This model was 
established as a clinically relevant translational model where intensive life support can 
be provided mimicking the clinical intensive cares for sick newborn infants. Bridging 
biomarkers such as near infrared spectroscopy, aEEG, MRS and MRI can be obtained 
and validated for the potential use in the human newborn infants. In addition, the use of 
a large animal enabled us to compare magnetic resonance biomarkers and 
histo-pathological outcomes in different cerebral regions. In contrast, because our 
model induces terminal anaesthesia, we were unable to assess the neurological 
functioning associated with spatial injury patterns observed on magnetic resonance 
biomarkers and histo-pathologically assessed brain injury. In addition, our model still 
varies from human newborn infants who experienced perinatal hypoxia-ischaemia, 
where the onset, pattern, repetition and depth of hypoxia-ischaemia are various and 
difficult to extrapolate. Another limitation is that, for the ethical and practical reason, we 
were unable to maintain the model longer than 48 hours after the commencement of 
resuscitation, resulting in the lack of observations on magnetic resonance biomarkers 
during the period when ADC values are likely to start to pseudo-normalise.  
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6.7 Future studies 
 
Although our current findings suggested the benefit of using regional ADC as a 
surrogate biomarker for cerebral tissue energy metabolism and subsequent tissue 
damage, further validation studies in both preclinical and clinical settings are required (i) 
to confirm the relationship between regional ADC and phosphate levels assessed using 
MRS imaging; (ii) to elucidate typical fractional ADC reductions from the institutional 
standard corresponding to normal, mild, moderate and severe later tissue destructions; 
and (iii) to confirm the optimal placement of RoIs which provides reproducible measures 
of ADC in each region. In addition to the standardisation of normal and abnormal ranges 
of ADC for each maturational stage, it is also of great interest to investigate whether 1H 
MRS or 1H MRS imaging can provide better surrogate biomarker for tissue energy 
derangement and ultimate tissue injury. Given that temporal changes in 1H MRS 
metabolites such as lactate/NAA show monotonic increase after severe 
hypoxia-ischaemia, this measure can be useful biomarker especially during the period 
when ADC shows pseudo-normalisation (58).   
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6.8 Implication of the findings from this thesis 
 
Infants with most severe neonatal encephalopathy may benefit from induction of 
therapeutic interventions as early as possible because of the extremely short 
therapeutic time window. Normal energetic metabolites obtained later than 24 hours of 
hypoxia-ischaemia may be indicative of relatively longer latent phase and optimal 
metabolic and histo-pathological outcomes. By identifying subtle abnormalities in global 
cerebral PCr/Pi as well as regional ADC, the severity of secondary energy failure and 
histo-pathological cerebral injury can be predicted. Future studies need to address the 
threshold of magnetic resonance biomarkers suggestive of later severe cerebral injury 
and the timing when the predictive value of ADC is lost due to pseudo-normalisation.  
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Supplemental Table 4.3-1: Temporal changes in 31P MRS biomarkers after hypoxia-ischaemia 
  Time after resuscitation (h) 
  Baseline 1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
 (n) (18)  (18)  (18)  (18)  (17)  (14)  (9)  (7)  (5)  (4)  
NTP/EPP Mean 0.21  0.19  0.19  0.18  0.18  0.15  0.15  0.14  0.18  0.15  
 SD 0.03  0.03  0.02  0.03  0.04  0.07  0.04  0.05  0.03  0.06  
 p   0.003  0.003  <0.001  <0.001  0.004  0.002  0.005  0.043  0.111  
PCr/EPP Mean 0.23  0.21  0.21  0.18  0.17  0.14  0.13  0.13  0.13  0.12  
 SD 0.02  0.04  0.03  0.05  0.05  0.06  0.06  0.04  0.03  0.05  
 p   0.188  0.061  0.001  0.001  0.001  0.004  0.010  0.020  0.044  
Pi/EPP Mean 0.19  0.30  0.27  0.34  0.37  0.49  0.48  0.51  0.43  0.51  
 SD 0.03  0.11  0.08  0.14  0.15  0.24  0.20  0.19  0.09  0.23  
 p   <0.001  0.001  <0.001  <0.001  0.001  0.003  0.007  0.010  0.065  
PCr/Pi Mean 1.22  0.84  0.87  0.66  0.60  0.43  0.40  0.31  0.34  0.30  
 SD 0.29  0.40  0.32  0.38  0.38  0.37  0.39  0.20  0.14  0.19  
 p   <0.001  0.001  <0.001  <0.001  <0.001  0.001  0.002  0.007  0.006  
Statistical significance was assumed with p-values < 0.01 (Dunnett test). 
P-values for the periods after 24 hours are presented only for reference because of the limited number of surviving subjects.  
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Supplemental Table 4.3-2: Temporal changes in regional ADC after hypoxia-ischaemia 
   Time after resuscitation (h) 
   Baseline 1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
C
or
tic
al
 g
re
y 
m
at
te
r 
Sagittal top 
n 18  18  18  17  16  11  9  5 b 5 b 4  
Mean 1.114  0.950  0.832  0.778  0.742  0.685  0.653  0.595  0.562  0.650  
SD 0.099  0.241  0.285  0.323  0.352  0.262  0.229  0.130  0.130  0.101  
p   0.009  0.001  <0.001  0.001  0.001  <0.001  0.001  <0.001  0.001  
Sagittal bottom 
n 18  18 a 18 a 17  16  11  9  5 c 5 c 4 a 
Mean 1.087  0.858  0.771  0.713  0.680  0.570  0.552  0.546  0.499  0.480  
SD 0.072  0.247  0.249  0.259  0.284  0.252  0.225  0.148  0.072  0.096  
p   0.001  <0.001  <0.001  <0.001  <0.001  <0.001  0.002  <0.001  <0.001  
Parietal top 
n 18  18  18  17  16  11  9  5 a 5 a 4  
Mean 1.124  0.950  0.832  0.789  0.766  0.738  0.625  0.625  0.621  0.564  
SD 0.087  0.187  0.273  0.306  0.299  0.264  0.254  0.127  0.096  0.062  
p   0.001  <0.001  <0.001  <0.001  0.001  <0.001  0.001  <0.001  0.001  
Parietal bottom 
n 18  18  18  17  16  11  9  5 d 5 d 4  
Mean 1.121  0.915  0.819  0.746  0.706  0.616  0.554  0.567  0.543  0.538  
SD 0.090  0.213  0.274  0.324  0.319  0.287  0.225  0.125  0.090  0.122  
p   0.001  <0.001  <0.001  <0.001  <0.001  <0.001  <0.001  <0.001  0.001  
Temporal 
n 16  16 a 16 a 15  13  9  8  5 a 5 a 3 a 
Mean 1.162  1.082  1.040  0.967  0.915  0.827  0.849  0.936 b 0.900 b 0.697  
SD 0.085  0.091  0.178  0.213  0.233  0.219  0.229  0.210 c 0.246 c 0.179  
p   <0.001  0.010  0.004  0.003  0.001  0.005  0.069 d 0.071 d 0.044  
Group mean 
Mean 1.120 A 0.950  0.859  0.802  0.769  0.693  0.652  0.654  0.625  0.583  
SD 0.70 D 0.170  0.222  0.254  0.257  0.226  0.195  0.096  0.097  0.074  
p   0.001  <0.001  <0.001  <0.001  <0.001  <0.001  0.001  0.001  <0.001  
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   Time after resuscitation (h) 
   Baseline 1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
Hippocampus 
n 8 B 8  8  7  5  3  2  2  2  2  
mean 1.139  1.063  0.952  0.997  0.889  0.809  0.848  0.832  0.688  0.705  
SD 0.059  0.153  0.192  0.234  0.240  0.166  0.031  0.010  0.261  0.197  
p   0.162  0.034  0.104  0.055  0.052  0.045  0.009  0.230  0.183  
D
ee
p 
gr
ey
 m
at
te
r 
Caudate 
nucleus 
n 15 a 15  15  14  12  9  8  5  5  3  
Mean 1.100 e 0.990  0.864  0.829  0.802  0.702  0.741  0.788  0.730  0.559  
SD 0.072  0.156  0.257  0.253  0.264  0.246  0.160  0.187  0.204  0.217  
p   0.017  0.002  0.001  0.003  0.001  0.001  0.042  0.033  0.096  
Putamen 
n 15 f 15  15  14  12  9  8  5  5  3  
Mean 1.074  0.927  0.769  0.715  0.690  0.675  0.653  0.636  0.620  0.510  
SD 0.076  0.213  0.248  0.283  0.263  0.275  0.183  0.208  0.201  0.179  
p   0.006  <0.001  <0.001  <0.001  0.004  <0.001  0.010  0.009  0.037  
Anterior 
thalamus 
n 15 g 15  15  14  12  9  8  5  5  3  
Mean 1.076  0.985  0.905  0.899  0.864  0.812  0.798  0.741  0.684  0.679  
SD 0.065  0.149  0.255  0.306  0.230  0.262  0.208  0.197  0.218  0.193  
p   0.012  0.014  0.038  0.006  0.006  0.005  0.016  0.013  0.087  
Lateral 
thalamus 
n 15 b 15  15  14  12  9  8  5  5  3  
Mean 0.952 e 0.855  0.745  0.738  0.714  0.707  0.612  0.592  0.591  0.473  
SD 0.057 f 0.172  0.276  0.265  0.237  0.243  0.209  0.259  0.252  0.083  
p  g 0.029  0.008  0.005  0.003  0.009  0.001  0.030  0.028  0.007  
Medial 
thalamus 
n 15 a 15  15  14  12  9  8  5  5  3  
Mean 1.030 b 1.006  0.966  0.950  0.875  0.774  0.740  0.654  0.608  0.554  
SD 0.057  0.091  0.190  0.188  0.203  0.225  0.188  0.236  0.246  0.132  
p   0.370  0.237  0.150  0.015  0.008  0.001  0.022  0.017  0.013  
Group mean Mean 1.046 A 0.952  0.850  0.826  0.789  0.734  0.709  0.682  0.647  0.555  
SD 0.046 B 0.126  0.213  0.218  0.215  0.225  0.168  0.201  0.210  0.155  
p   0.006  0.002  0.002  0.001  0.002  <0.001  0.015  0.013  0.036  
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   Time after resuscitation (h) 
   Baseline 1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
Pe
rip
he
ra
l w
hi
te
 m
at
te
r 
Sagittal  
n 16 a 16  16  15  14  11  9  5  5  4  
Mean 1.076  0.874  0.758  0.720  0.698  0.565  0.546  0.502  0.484  0.550  
SD 0.065  0.243  0.285  0.301  0.291  0.265  0.233  0.050  0.050  0.076  
p   0.006  0.001  0.001  0.001  <0.001  <0.001  <0.001  <0.001  0.001  
Parietal  
n 15 a 15  15  14  13  11  9  5  5  4  
Mean 1.159 e 0.950  0.861  0.800  0.753  0.702  0.664  0.683  0.627  0.601  
SD 0.0.67  0.242  0.289  0.336  0.311  0.280  0.242  0.185  0.097  0.146  
p   0.003  0.001  0.002  0.001  <0.001  <0.001  0.006  0.001  0.009  
Temporal  
n 16 e 16  16  15  14  11  9  5  5  4  
Mean 1.008  0.894  0.786  0.749  0.700  0.677  0.641  0.632  0.570  0.601  
SD 0.124  0.226  0.280  0.310  0.273  0.289  0.307  0.264  2.18  1.75  
p   0.022  0.003  0.005  0.003  0.009  0.009  0.030  0.004  0.003  
Group mean 
Mean 1.079 C 0.909  0.806  0.762  0.724  0.648  0.617  0.606  5.60  5.84  
SD 0.063 E 0.218  0.254  0.288  0.280  0.260  0.238  0.132  0.83  0.88  
p   0.005  0.001  0.001  0.001  0.001  0.001  0.003  <0.001  0.002  
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   Time after resuscitation (h) 
   Baseline 1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
C
en
tra
l w
hi
te
r m
at
te
r 
Superior 
periventricular 
n 15 e 15  15  14  11  9  8  5  5  4  
Mean 0.912  0.850  0.728  0.638  0.590  0.502  0.504  0.530  5.53  5.72  
SD 0.095  0.137  0.214  0.192  0.209  0.153  0.164  0.180  1.90  1.28  
p   0.036  0.003  <0.001  0.002  <0.001  0.001  0.017  0.022  0.026  
Periventricular 
n 14 b 14  14  13  11  9  8  5  5  4  
Mean 0.976  0.897  0.778  0.690  0.640  0.649  0.600  0.628  0.687  0.701  
SD 0.126  0.113  0.231  0.220  0.230  0.227  0.230  0.250  0.219  0.166  
p   0.010  0.002  <0.001  0.002  0.003  0.002  0.041  0.052  0.068  
Posterior limb 
of internal 
capsule 
n 12 b 12  12  11  10  8  6  4  4  3  
Mean 1.152 e 0.882  0.736  0.665  0.671  0.558  0.499  0.570  0.448  0.526  
SD 0.141  0.297  0.297  0.365  0.329  0.197  0.205  0.189  0.066  0.090  
p   0.004  0.001  0.003  0.003  0.001  0.003  0.025  0.001  0.002  
Group mean Mean 0.994 C 0.875  0.755  0.674  0.651  0.569  0.526  0.564  0.563  0.607  
 SD 0.081 D 0.155  0.221  0.232  0.251  0.170  0.171  0.187  0.135  0.120  
 p  E 0.004  0.001  0.001  0.001  <0.001  <0.001  0.007  0.002  0.012  
 
ADC values shown as 10-3･mm2･sec-1. 
a-g: statistical significance from within group comparisons with p < 0.05 (a), p < 0.01 (b –d) and p < 0.01 (e-g) 
A-E: statistical significance from between group mean comparisons with p < 0.01 (A-C) and p < 0.001 (D-E) 
Statistical significance was assumed with p-values < 0.01 (Dunnett test). 
P-values for the periods after 24 hours are presented only for reference because of the limited number of surviving subjects.  
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Supplemental Table 4.3-3: Temporal changes in regional T2 relaxation time after hypoxia-ischaemia 
   Time after resuscitation (h) 
   Baseline 1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
C
or
tic
al
 g
re
y 
m
at
te
r 
Sagittal top 
n 11  11  11  10  9  8  6  3  3  2  
Mean 66.62  71.62  75.30  78.52  78.26  85.54  98.96  91.91  92.88  100.83  
SD 8.45  11.10  14.68  14.16  16.58  20.02  22.03  25.03  19.20  14.24  
p   0.026  0.021  0.006  0.032  0.026  0.031  0.243  0.083  0.034  
Sagittal bottom 
n 11  11  11  10  9  8  6  3  3  2 a 
Mean 66.04  70.07  72.87  75.77  75.28  83.24  91.00  83.35  82.11  90.36  
SD 9.71  9.98  10.81  12.82  16.19  18.22  16.29  16.78  15.77  6.29  
p   0.002  <0.001  0.001  0.030  0.003  0.005  0.169  0.106  0.098  
Parietal top 
n 11  11  11  10  9  8  6  3  3  2  
Mean 67.54  68.20  69.82  75.53  75.20  80.12  94.06  91.90  90.83  96.73  
SD 11.55  11.72  9.96  14.86  17.02  16.93  18.84  22.39  23.19  7.77  
p   0.650  0.421  0.025  0.096  0.041  0.004  0.049  0.059  0.004  
Parietal bottom 
n 11  11  11  10  9  8  6  3  3  2  
Mean 68.77  69.65  72.16  73.68  74.73  77.88  90.77  83.23  82.48  90.74  
SD 9.81  9.70  9.40  9.76  10.63  14.33  15.81  18.31  17.78  17.44  
p   0.383  0.017  0.001  0.001  0.011  0.002  0.063  0.042  0.148  
Temporal 
n 11  11  11  10  7  6  4  2  2  0 a 
Mean 73.10  77.53  77.75  78.01  79.45  85.84  96.90  79.52  88.12    
SD 11.41  12.16  14.33  11.59  16.82  17.06  24.23  20.16  27.09    
p   0.020  0.009  0.016  0.583  0.308  0.240  0.913  0.436    
Group mean 
Mean 68.41 E 71.41 E 73.58 E 76.30 C 76.13 A 81.85 A 94.21 A 86.99 A 87.26  94.66  
SD 9.69 F 10.43 F 10.93 F 11.98 E 14.42 C 16.48 C 17.86 C 19.42  18.59  11.43  
p   0.005  0.002  0.001  0.017  0.012  0.010  0.145  0.074  0.026  
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   Time after resuscitation (h) 
   Baseline 1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
Hippocampus 
n 11 C 11 G 11 A 10 A 8 B 7 B 5  3  3  1  
mean 65.19 G 69.74 H 68.77 G 71.76 D 76.37 D 81.43 D 83.59  73.48  74.82  78.80  
SD 8.36  8.90  7.47  8.33  13.49  15.62  16.21  11.60  10.94    
p   0.043  0.048  0.003  0.001  0.006  0.020  0.105  0.052    
D
ee
p 
gr
ey
 m
at
te
r 
Caudate 
nucleus 
n 11  11  11  10  8  7  5  3  3  1  
Mean 63.93  67.11  69.69  69.88  72.77  76.30  79.51  68.84  72.10  65.70  
SD 10.88  12.72  11.77  10.74  11.23  15.62  11.93  5.57  5.60    
p   0.201  0.055  0.022  0.043  0.088  0.045  0.422  0.169    
Putamen 
N 11  11 a 11  10  8  7  5  3  3  1  
Mean 62.93  65.65  68.14  68.94  71.45  80.49  80.04  70.70  75.23  67.74  
SD 8.80  7.77  8.21  8.19  8.72  13.76  16.10  8.29  6.88    
p   0.064  0.030  0.051  0.034  0.010  0.163  0.542  0.241    
Anterior 
thalamus 
n 11  11 a 11  10  8  7  5  3  3  1  
Mean 54.73  57.86  61.72  63.22  65.24  64.52  73.73  65.64  66.20  59.37  
SD 8.83  7.15  11.39  12.36  12.39  8.74  11.69  4.83  4.25    
p   0.003  0.017  0.035  0.073  0.050  0.040  0.115  0.061    
Lateral thalamus 
n 11  11  11  10  8  7  5  3  3  1  
Mean 59.16  62.93  63.58  66.35  69.10  74.61  75.28  70.20  70.22  71.68  
SD 9.72  9.15  9.66  10.53  10.08  11.34  5.64  3.62  1.53    
p   0.004  0.003  0.002  0.022  0.007  0.034  0.188  0.188    
Medial thalamus 
n 11  11  11  10  9  8  5  3  3  2  
Mean 62.47  64.57  67.70  66.29  66.35  68.64  71.24  77.99  75.09  81.57  
SD 5.68  3.62  6.80  6.70  7.54  8.15  9.68  19.33  15.37  21.74  
p   0.210  0.096  0.266  0.254  0.118  0.117  0.304  0.304  0.572  
Group mean Mean 60.64 A 63.63 C 66.17 C 66.93  68.51  71.50  75.35  70.68  71.77  69.24  
SD 7.26  6.92  7.81  8.64  8.56  10.56  8.63  7.53  4.56  4.31  
p   0.001  0.001  0.011  0.008  0.004  0.050  0.279  0.167  0.776  
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   Time after resuscitation (h) 
   Baseline 1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
Pe
rip
he
ra
l w
hi
te
 m
at
te
r 
Sagittal  
n 9 c 9 e 9 a 8 e 7  7  4  3  3 c 2  
Mean 58.73  57.16  58.72 e 62.94  56.90  59.72  66.55  69.20  69.25  75.87  
SD 9.51  6.90  6.76 f 7.88  9.76  10.89  18.25  21.68  14.76  19.36  
p   0.588  0.999  0.444  0.549  0.952  0.921  0.517  0.334  0.603  
Parietal  
n 11 e 11 f 11 a 10 f 9 c 8 c 5 a 3 a 3 d 2 a 
Mean 56.19  60.75  64.28  64.72  64.22  67.66  71.81  78.64  77.90  87.33  
SD 3.24  5.28  5.36  6.04  7.70  7.65  12.08  19.17  12.48  16.29  
p   0.005  <0.001  0.001  0.006  0.002  0.019  0.127  0.052  0.229  
Temporal  
n 11 c 11 e 11 e 10 e 8 c 7 c 5 a 3 a 3 c 2 a 
Mean 46.41 e 46.75 f 50.17 f 50.84 f 54.43  55.07  55.22  49.85  48.29 d 48.51  
SD 3.50  3.11  5.69  6.45  6.35  9.20  11.62  7.35  6.18  8.70  
p   0.566  0.120  0.139  0.032  0.042  0.187  0.626  0.776  0.781  
Group mean 
Mean 53.54 C 54.92 E 57.64 A 59.14 A 58.81 A 61.21 A 64.79 A 65.90  65.15  70.57  
SD 3.33 E 3.74 G 5.39 E 6.12 C 6.65 B 7.42 B 11.93  15.78  10.83  14.79  
p   0.258  0.082  0.033  0.069  0.014  0.131  0.302  0.192  0.425  
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   Time after resuscitation (h) 
   Baseline 1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
C
en
tra
l w
hi
te
r m
at
te
r 
Superior 
periventricular 
n 11 e 11 e 11 e 10 e 8 e 7 c 4  3  3  2 a 
Mean 49.86  49.22  50.51  52.39  52.92  54.71  54.27  50.21  49.91  48.01 b 
SD 7.56  6.27  5.37  6.07  5.64  6.93  8.35  6.45  4.93  7.42  
p   0.495  0.765  0.234  0.044  0.046  0.266  0.773  0.758  0.738  
Periventricular  
n 3 e 3 e 3 e 3 e 3 e 3 c 2  1  1  1 a 
Mean 67.91 f 70.63 f 70.44 f 71.30 f 76.84 f 78.91 d 80.64  81.90  79.03  83.82  
SD 3.18  1.05  2.77  7.41  2.99  5.72  1.28        
p   0.310  0.357  0.537  0.074  0.114  0.120        
Posterior limb of 
internal capsule 
n 11 f 11 f 11 f 10 f 9 f 8 d 5  3  3  2 b 
Mean 48.56  50.23  53.31  56.00  55.20  57.26  63.23  62.14  61.81  64.26  
SD 3.67  4.95  7.06  7.77  9.43  10.49  14.87  23.09  10.25  6.44  
p   0.044  0.049  0.019  0.058  0.016  0.054  0.334  0.065  0.042  
Group mean 
Mean 51.08 A 51.86 C 53.53 C 55.66 D 55.55 C 57.97 C 61.74 C 57.30 A 57.73  59.93  
SD 4.43 F 4.07 F 6.06 F 7.05 E 8.63 D 9.21 D 10.96  15.46  8.79  12.30  
p  G 0.170 H 0.223 G 0.069  0.142  0.036  0.036  0.399  0.117  0.222  
T2 relaxation times are shown as milliseconds. 
a-f: statistical significance from within group comparisons with p < 0.05 (a-b), p < 0.01 (c–d) and p < 0.001 (e-f) 
A-H: statistical significance from between group comparisons with p < 0.05 (A-B), p < 0.01 (C-D) and p < 0.001 (E-H) 
Statistical significance was assumed with p-values < 0.01 (Dunnett test). 
P-values for the periods after 24 hours are presented only for reference because of the limited number of surviving subjects.  
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Supplemental Table 4.3-4: Influence of insult severity and survival time to magnetic resonance biomarkers and 
histo-pathological brain injury 
A. Influence of insult severity (acute energy depletion) to temporal changes in MR biomarkers 
        Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
NTP/EPP -0.40  0.103  -0.34  0.163  -0.34  0.172  -0.19  0.462  -0.41  0.142  -0.73  0.027  -0.73  0.061  -0.86  0.065  -0.50  0.498  
PCr/EPP -0.34  0.172  -0.44  0.070  -0.29  0.236  -0.31  0.219  -0.53  0.049  -0.69  0.038  -0.83  0.021  -0.96  0.011  -0.91  0.092  
Pi/EPP 0.33  0.178  0.50  0.035  0.33  0.185  0.23  0.376  0.45  0.106  0.67  0.046  0.79  0.033  0.84  0.076  0.60  0.397  
PCr/Pi -0.35  0.151  0.00  0.060  -0.42  0.081  -0.37  0.148  -0.46  0.099  -0.56  0.119  -0.77  0.042  -0.87  0.056  -0.83  0.167  
AD
C
 
Sagittal CTX-top -0.62  0.006  -0.46  0.056  -0.27  0.304  -0.11  0.692  -0.33  0.328  -0.59  0.092  -0.73  0.159  -0.26  0.672  -0.80  0.205  
Sagittal CTX-bottom -0.75  0.000 -0.65  0.004  -0.50  0.041  -0.37  0.164  -0.32  0.335  -0.51  0.159  -0.77  0.130  -0.70  0.189  -0.78  0.219  
Parietal CTX-top -0.27  0.288  -0.42  0.080  -0.26  0.306  -0.14  0.619  0.13  0.704  0.04  0.924  0.66  0.225  0.28  0.644  0.45  0.548  
Parietal CTX-bottom -0.56  0.015  -0.59  0.010  -0.52  0.033  -0.38  0.142  -0.20  0.549  -0.50  0.171  -0.96  0.010  -0.95  0.013  -0.99  0.008  
Temporal CTX 0.01  0.973  -0.29  0.275  -0.15  0.598  -0.10  0.747  -0.38  0.312  -0.70  0.052  -0.79  0.052  -0.89  0.044  -1.00  0.055  
Hippocampus -0.70  0.054  -0.57  0.139  -0.20  0.674  -0.14  0.829  0.69  0.512          
Caudate nucleus -0.40  0.139  -0.32  0.239  0.02  0.953  0.08  0.805  -0.62  0.074  -0.82  0.013  -0.94  0.018  -0.80  0.105  -0.76  0.450  
Putamen -0.50  0.059  -0.54  0.036  -0.48  0.083  -0.54  0.069  -0.56  0.121  -0.39  0.345  -0.45  0.444  -0.45  0.443  -1.00  0.051  
Anterior thalamus -0.33  0.230  -0.43  0.115  -0.33  0.243  -0.39  0.209  -0.60  0.086  -0.89  0.003  -0.40  0.509  -0.60  0.289  -0.90  0.283  
Lateral thalamus -0.59  0.021  -0.54  0.040  -0.53  0.052  -0.54  0.072  -0.85  0.004  -0.59  0.126  -0.66  0.229  -0.62  0.270  -0.98  0.129  
Medial thalamus -0.62  0.013  -0.51  0.051  -0.39  0.167  -0.39  0.207  -0.74  0.023  -0.73  0.039  -0.40  0.501  -0.37  0.540  -0.68  0.521  
Sagittal WM -0.53  0.035  -0.61  0.013  -0.49  0.063  -0.36  0.205  -0.44  0.181  -0.35  0.359  -0.23  0.711  -0.10  0.878  -0.75  0.246  
Parietal WM -0.43  0.042  -0.47  0.075  -0.32  0.264  -0.19  0.527  -0.29  0.384  -0.38  0.312  -0.58  0.302  -0.82  0.087  -0.54  0.462  
Temporal WM -0.34  0.200  -0.34  0.200  -0.22  0.432  -0.23  0.432  -0.07  0.828  -0.09  0.826  0.17  0.787  0.36  0.555  0.34  0.657  
Superior periventricular WM -0.57  0.025  -0.59  0.021  -0.50  0.071  -0.51  0.106  -0.23  0.548  -0.18  0.663  -0.30  0.623  -0.34  0.574  -0.58  0.419  
Periventricular WM -0.25  0.391  -0.31  0.285  -0.08  0.786  -0.31  0.353  -0.29  0.447  -0.19  0.655  -0.52  0.368  -0.56  0.330  -0.37  0.629  
PLIC -0.55  0.062  -0.48  0.114  -0.34  0.306  -0.35  0.323  -31.0
  
0.455  -0.21  0.687  -0.66  0.344  0.51  0.491  -0.87  0.327  
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        Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
T2
 
Sagittal CTX-top -0.13  0.694  0.21  0.564  0.21  0.564  0.23  0.551  0.01  0.984  0.16  0.763  0.41  0.728  -0.11  0.931    
Sagittal CTX-bottom -0.03  0.942  -0.02  0.946  0.19  0.595  0.30  0.428  0.01  0.989  0.17  0.741  0.75  0.459  0.49  0.673    
Parietal CTX-top -0.10  0.776  0.29  0.394  0.13  0.720  0.25  0.519  -0.12  0.780  0.14  0.796  0.41  0.733  0.33  0.783    
Parietal CTX-bottom -0.08  0.806  -0.05  0.874  -0.08  0.837  0.07  0.865  -0.02  0.687  -0.01  0.981  0.24  0.846  0.04  0.976    
Temporal CTX -0.26  0.443  -0.44  0.181  -0.17  0.633  0.09  0.850  0.29  0.580  0.46  0.541        
Hippocampus 0.11  0.752  -0.16  0.630  0.11  0.773  0.29  0.488  0.21  0.654  0.24  0.697  0.88  0.316  0.69  0.520    
Caudate nucleus -0.27  0.429  -0.37  0.261  0.02  0.957  0.25  0.549  0.16  0.737  0.40  0.506  0.61  0.582  0.01  0.991    
Putamen -0.36  0.282  -0.13  0.706  0.24  0.500  0.56  0.147  0.69  0.087  0.07  0.908  1.00  0.015  0.97  0.163    
Anterior thalamus -0.23  0.500  0.14  0.684  0.32  0.374  0.75  0.032  0.59  0.166  -0.03  0.962  0.60  0.592  -0.60  0.588    
Lateral thalamus -0.30  0.377  -0.31  0.349  -0.01  0.987  0.51  0.195  0.40  0.380  0.33  0.587  0.59  0.596  0.02  0.990    
Medial thalamus 0.59  0.058  0.81  0.003  0.79  0.007  0.63  0.068  0.38  0.349  0.93  0.020  1.00  0.018  1.00  0.022    
Sagittal WM 0.20  0.607  0.67  0.046  0.65  0.083  0.57  0.178  0.08  0.873  0.93  0.066  0.96  0.192  0.95  0.207    
Parietal WM 0.52  0.102  0.75  0.009  0.60  0.066  0.44  0.239  0.67  0.067  0.96  0.009  0.98  0.138  0.98  0.135    
Temporal WM -0.24  0.472  0.50  0.119  0.33  0.349  0.43  0.283  0.15  0.750  0.45  0.448  0.97  0.163  0.95  0.204    
Superior periventricular WM 0.05  0.880  0.40  0.227  0.31  0.388  0.06  0.892  -0.10  0.835  -0.17  0.827  0.60  0.593  0.42  0.724    
Periventricular WM 0.60  0.588  0.27  0.827  0.45  0.703  0.53  0.646  0.64  0.559          
PLIC 0.37  0.263  0.51  0.112  0.49  0.146  0.35  0.360  0.23  0.577  0.94  0.020  1.00  0.058  0.89  0.304    
Statistical significance was assumed with p-values < 0.01 (Dunnett test). 
P-values for the periods after 24 hours are presented only for reference because of the limited number of surviving subjects.  
Abbreviations: CTX, cerebral cortex; WM, white matter; PCIC, posterior limb of the internal capsule. 
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B. Influence of insult severity (acute energy depletion) to histo-pathological brain injury 
 Brain damage in the grey matter 
 Neuronal death (H&E) TUNEL (+) apoptosis CD68 (+) microglia CD68(+) vessel  
 r p r p r p r p   
Sagittal top 0.39 0.110 -0.13 0.600 0.05 0.859 0.03 0.909   
Sagittal bottom 0.39 0.110 -0.16 0.536 0.41 0.095 0.29 0.242   
Parietal top 0.30 0.227 -0.09 0.721 0.11 0.663 -0.04 0.874   
Parietal bottom 0.44 0.068 -0.14 0.588 -0.16 0.520 -0.19 0.462   
Temporal  0.44 0.068 -0.14 0.588 -0.16 0.520 -0.19 0.462   
Hippocampus -0.01 0.986 -0.30 0.432 0.48 0.195 0.68 0.046   
Caudate nucleus 0.29 0.316 -0.33 0.247 0.73 0.002 0.74 0.002   
Putamen 0.20 0.502 -0.13 0.651 0.63 0.011 0.40 0.136   
Anterior thalamus 0.44 0.113 -0.36 0.210 0.67 0.006 0.74 0.002   
Lateral thalamus 0.01 0.982 -0.26 0.341 0.82 <0.001 0.82 <0.001   
Medial thalamus 0.07 0.792 -0.13 0.659 0.59 0.025 0.84 <0.001   
 Brain damage in the white matter 
 H & E  LFB CD68 (+) microglia CD68 (+) vessel β-APP 
 r p r p r p r p r p 
Sagittal  0.54 0.024 -0.73 0.001 -0.01 0.965 0.39 0.125 0.06 0.830 
Parietal  0.40 0.125 -0.75 0.001 0.21 0.430 0.36 0.169 0.18 0.494 
Temporal  0.33 0.206 -0.63 0.009 0.11 0.698 0.46 0.076 0.02 0.950 
Superior Periventricular 0.37 0.146 -0.05 0.846 0.66 0.004 0.64 0.006 0.30 0.246 
Periventricular 0.45 0.079 -0.03 0.918 0.58 0.018 0.43 0.097 0.28 0.302 
PLIC 0.36 0.251 0.03 0.931 0.00 0.994 0.22 0.549 0.18 0.623 
Sagittal  0.54 0.024 -0.73 0.001 -0.01 0.965 0.39 0.125 0.06 0.830 
Abbreviation: PCIC, posterior limb of the internal capsule. 
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C. Influence of survival time after resuscitation to histo-pathological brain injury 
 Brain damage in the grey matter 
 Neuronal death (H&E) TUNEL (+) apoptosis CD68 (+) microglia CD68(+) vessel  
 r p r p r p r p   
Sagittal top 0.08 0.740 0.20 0.423 -0.16 0.535 -0.24 0.335   
Sagittal bottom 0.23 0.352 0.45 0.063 -0.54 0.021 -0.41 0.089   
Parietal top 0.23 0.365 0.26 0.294 -0.42 0.083 -0.42 0.087   
Parietal bottom 0.20 0.420 0.30 0.227 -0.19 0.449 -0.21 0.400   
Temporal  0.04 0.876 0.40 0.126 -0.33 0.207 -0.33 0.214   
Hippocampus 0.24 0.533 0.17 0.672 -0.47 0.208 -0.48 0.196   
Caudate nucleus -0.19 0.519 0.47 0.092 -0.32 0.246 -0.30 0.278   
Putamen -0.32 0.259 0.36 0.207 -0.44 0.098 -0.11 0.703   
Anterior thalamus 0.04 0.900 0.48 0.086 -0.25 0.370 -0.28 0.307   
Lateral thalamus 0.06 0.829 -0.07 0.792 -0.44 0.099 -0.46 0.085   
Medial thalamus 0.17 0.553 0.14 0.626 -0.53 0.054 -0.38 0.177   
 Brain damage in the white matter 
 H & E  LFB CD68 (+) microglia CD68 (+) vessel β-APP 
 r p r p r p r p r p 
Sagittal  0.06 0.830 0.34 0.179 -0.18 0.486 -0.29 0.255 0.20 0.437 
Parietal  0.18 0.510 0.22 0.404 -0.23 0.386 -0.58 0.018 -0.07 0.792 
Temporal  0.16 0.566 0.37 0.159 -0.34 0.192 -0.32 0.233 -0.22 0.414 
Superior Periventricular 0.16 0.545 0.08 0.768 -0.35 0.165 -0.22 0.399 0.07 0.783 
Periventricular 0.19 0.492 0.11 0.676 -0.47 0.067 -0.22 0.420 0.13 0.629 
PLIC 0.10 0.757 0.03 0.931 -0.03 0.940 -0.09 0.803 0.63 0.049 
Sagittal 0.06 0.830 0.34 0.179 -0.18 0.486 -0.29 0.255 0.20 0.437 
P values are presented without correction for multiple comparisons. 
Abbreviation: PCIC, posterior limb of the internal capsule. 
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Supplemental Table 4.3-5: 31P MRS biomarkers and histo-pathological injury  
 (adjusted for AED and survival time after resuscitation) 
A. 31P MRS biomarkers 1-48 h after resuscitation and neuronal death assessed using H & E stains 
        Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
N
TP
/E
P
P
 
Sagittal top 0.03  0.874  1.18  0.296  5.86  0.030  6.93  0.021  8.37  0.016  3.06  0.141  0.22  0.672  0.89  0.519  0.21  0.726  
Sagittal bottom 0.03  0.867  0.47  0.503  0.83  0.379  1.14  0.305  1.65  0.228  3.73  0.111  0.24  0.657  0.47  0.618  0.08  0.824  
Parietal top 0.08  0.783  1.65  0.219  1.40  0.257  1.79  0.204  2.07  0.181  2.00  0.216  0.10  0.773  0.12  0.787  0.00  0.994  
Parietal bottom 0.07  0.799  1.42  0.254  0.69  0.421  1.46  0.249  1.89  0.200  1.08  0.346  0.06  0.821  4.55  0.279  76.27  0.073  
Temporal  0.41  0.536  0.12  0.732  4.38  0.058  5.28  0.042  6.05  0.036  2.04  0.226  1.14  0.363  1.16  0.476  0.30  0.683  
Hippocampus 0.07  0.806  0.56  0.488  8.20  0.035  14.29  0.019  4.53  0.123  
        
Caudate nucleus 0.27  0.615  0.73  0.413  5.54  0.040  7.21  0.025  5.53  0.047  1.13  0.366  3.68  0.195  1.29  0.459  0.34  0.666  
Putamen 0.05  0.821  0.57  0.466  2.80  0.125  2.72  0.130  1.46  0.258  1.54  0.283  0.99  0.393  1.25  0.465  0.32  0.672  
Anterior thalamus 2.51  0.144  4.95  0.050  5.67  0.039  6.30  0.031 7.60  0.022  4.76  0.095  0.84  0.427  2.88  0.339  0.75  0.546  
Lateral thalamus 0.33  0.580  0.54  0.479  3.21  0.101  0.94  0.354  1.23  0.296  0.29  0.618  0.10  0.773  1.56  0.429  0.41  0.636  
Medial thalamus 0.04  0.852  0.01  0.915  12.57  0.005  7.21  0.023  8.26  0.018  1.76  0.256  0.22  0.668  1.33  0.455  0.35  0.661  
PC
r/E
PP
 
Sagittal top 1.11  0.311  1.25  0.283  11.78  0.004  21.56  <0.00
 
23.81  0.001  4.31  0.093  15.25  0.030  0.89  0.518  0.01  0.925  
Sagittal bottom 1.02  0.329  1.36  0.263  5.23  0.038  5.00  0.044  6.22  0.032  29.56  0.003  1.22  0.349  0.47  0.617  0.00  0.976  
Parietal top 0.91  0.357  0.68  0.424  5.09  0.041  7.44  0.017  7.00  0.025  6.18  0.055  7.47  0.072  0.12  0.786  0.10  0.807  
Parietal bottom 1.89  0.191  1.62  0.223  5.03  0.042  6.29  0.026  6.50  0.029  4.31  0.093  5.71  0.097  4.50  0.280  24.53  0.127  
Temporal  0.09  0.773  0.01  0.936  3.15  0.101  3.78  0.078  5.51  0.043  0.53  0.506  0.33  0.608  1.17  0.475  0.03  0.882  
Hippocampus 2.56  0.171  4.09  0.099  16.79  0.009  11.67  0.027  9.86  0.052  
        
Caudate nucleus 0.88  0.372  0.30  0.593  8.06  0.018  16.22  0.003  7.46  0.026  0.32  0.611  35.87  0.027  1.30  0.458  0.05  0.865  
Putamen 0.33  0.580  0.16  0.699  1.50  0.249  3.41  0.095  1.14  0.313  0.36  0.583  1.21  0.352  1.26  0.464  0.04  0.871  
Anterior thalamus 8.57  0.015  4.03  0.072  9.18  0.013  13.59  0.004  11.21  0.009  11.49  0.028  0.49  0.533  2.90  0.338  0.18  0.745  
Lateral thalamus 0.00  0.982  0.07  0.794  1.68  0.221  2.88  0.120  2.62  0.140  0.32  0.603  9.81  0.052  1.58  0.428  0.07  0.835  
Medial thalamus 0.13  0.729  0.15  0.705  3.71  0.080  5.20  0.046  9.32  0.014  1.12  0.349  1.49  0.310  1.34  0.454  0.05  0.861  
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  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
Pi
/E
P
P
 
Sagittal top 2.01  0.178  2.08  0.171  10.87  0.005  14.21  0.002  17.16  0.002  5.26  0.070  0.46  0.544  3.55  0.311  0.14  0.772  
Sagittal bottom 0.74  0.403  1.88  0.192  4.68  0.048  3.59  0.081  4.56  0.058  8.65  0.032  0.10  0.775  1.78  0.410  0.04  0.871  
Parietal top 1.67  0.217  1.72  0.211  4.69  0.048  5.48  0.036  5.66  0.039  5.88  0.060  0.42  0.562  0.61  0.579  0.00  0.960  
Parietal bottom 2.72  0.121  2.96  0.107  3.80  0.072  4.37  0.057  5.20  0.046  3.81  0.108  0.35  0.597  1.08  0.487  587.6
  
0.026  
Temporal  0.13  0.729  0.49  0.496  3.50  0.086  5.31  0.042  6.66  0.030  0.90  0.397  0.49  0.535  4.98  0.268  0.20 0.729  
Hippocampus 2.31  0.189  1.79  0.239  7.81  0.038  6.63  0.062  6.16  0.089  
        
Caudate nucleus 2.12  0.176  0.77  0.401  5.15  0.047  10.86  0.009  7.08  0.029  2.12  0.242  8.20  0.103  5.77  0.251  0.24  0.712  
Putamen 1.68  0.224  0.29  0.605  1.42  0.262  3.26  0.101  1.40  0.267  0.83  0.415  0.55  0.513  5.49  0.257  0.23  0.718  
Anterior thalamus 7.03  0.024  6.01  0.034  7.00  0.025  13.35  0.004  9.44  0.013  2.70  0.176  0.35  0.597  23.02  0.131  0.56  0.592  
Lateral thalamus 0.26  0.620  0.00  0.949  2.80  0.122  2.59  0.139  2.39  0.157  0.73  0.440  0.35  0.597  7.62  0.221  0.30  0.682  
Medial thalamus 0.28  0.605  0.06  0.815  6.30  0.029  6.11  0.033  9.42  0.013  0.81  0.418  0.12  0.748  6.01  0.247  0.24  0.708  
PC
r/P
i 
Sagittal top 2.13  0.166  2.56  0.132  21.56  0.000 31.99  0.000 51.20  0.000
 
6.50  0.051  13.59  0.035  7.49  0.223  0.76  0.543  
Sagittal bottom 1.81  0.199  3.84  0.070  10.23  0.006  6.90  0.021  19.77  0.001  56.40  0.001  1.50  0.308  3.26  0.322  0.40  0.642  
Parietal top 2.33  0.149  2.88  0.112  11.23  0.005  10.88  0.006  22.33  0.001  9.40  0.028  3.29  0.168  1.06  0.491  0.09  0.811  
Parietal bottom 3.97  0.066  4.62  0.050  11.30  0.005  10.00  0.007  18.50  0.002  7.37  0.042  2.44  0.216  0.62  0.575  5.57  0.255  
Temporal  0.15  0.706  0.45  0.515  7.12  0.020  8.25  0.015  9.59  0.013  4.72  0.096  1.16  0.361  11.78  0.181  1.00  0.501  
Hippocampus 4.77  0.081  3.00  0.144  22.28  0.005  26.82  0.007  3.98  0.140  
        
Caudate nucleus 2.68  0.133  0.51  0.493  13.50  0.004  35.49  0.000  10.78  0.011  4.70  0.119  237.9
  
0.004  14.52  0.163  1.11  0.483  
Putamen 1.69  0.223  0.03  0.859  3.22  0.103  6.80  0.026  2.40  0.155  6.35  0.065  3.55 0.156  13.51  0.169  1.07  0.489  
Anterior thalamus 7.67  0.020  5.41  0.042  9.80  0.011  9.09  0.013  9.68  0.012  1.08  0.357  0.36  0.591  217.2
  
0.043  2.43  0.363  
Lateral thalamus 0.00  0.987  0.06  0.806  3.10  0.106  3.33  0.098  7.11  0.026  1.26  0.325  5.96  0.092  22.07 0.134  1.34  0.454  
Medial thalamus 0.36  0.562  0.04  0.849  6.52  0.027  7.84  0.019  12.26  0.007  12.74  0.023  4.47  0.125  15.39  0.159  1.14  0.479  
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B. 31P MRS biomarkers 1-48 h after resuscitation and TUNEL positive apoptotic cell death 
        Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
N
TP
/E
P
P
 
Sagittal top 0.05  0.820  0.20  0.664  2.56  0.132  0.94  0.350  1.12  0.316  1.93  0.224  0.00  0.990  0.00  0.975  0.14  0.769  
Sagittal bottom 0.06  0.817  0.15  0.700  9.28  0.009  3.60  0.080  1.47  0.253  4.96  0.076  0.47  0.541  1.32  0.456  0.34  0.663  
Parietal top 0.05  0.822  0.08  0.781  5.89  0.029  1.67  0.219  0.62  0.450  3.22  0.133  0.00  0.968  0.00  0.993  0.12  0.786  
Parietal bottom 0.01  0.919  0.40  0.538  6.07  0.027  3.19  0.097  1.07  0.326  5.49  0.066  0.09  0.780  10.84  0.188  1142.
  
0.019  
Temporal  0.28  0.607  0.29  0.600  1.78  0.206  0.53  0.483  0.53  0.484  0.05  0.833  0.27  0.638  0.88  0.520  0.21  0.726  
Hippocampus 4.54  0.086  0.07  0.796  0.53  0.500  3.97  0.117  7.39  0.073          
Caudate nucleus 0.03  0.871  0.00  0.959  1.21  0.297  0.40  0.543  0.82  0.393  0.01  0.921  0.17  0.717  0.03  0.885  0.02  0.908  
Putamen 0.00  0.965  0.07  0.798  13.43  0.004  2.47  0.147  1.69  0.226  2.55  0.186  0.06  0.828  0.49  0.612  1.83  0.406  
Anterior thalamus 0.15  0.710  0.95  0.353  0.04  0.844  0.11  0.752  0.05  0.830  0.83  0.414  0.40  0.570  0.00  0.984  0.13  0.778  
Lateral thalamus 0.06  0.815  0.03  0.862  2.56  0.138  1.51  0.247  4.26  0.069  0.11  0.755  0.00  0.999  0.37  0.651  1.42  0.445  
Medial thalamus 0.01  0.941  0.09  0.764  4.47  0.061  2.52  0.147  4.22  0.074  0.01  0.915  1.56  0.339      
PC
r/E
PP
 
Sagittal top 0.36  0.558  1.10  0.311  2.60  0.129  1.34  0.267  2.03  0.184  4.48  0.088  0.12  0.751  0.00  0.977  0.64  0.569  
Sagittal bottom 0.98  0.339  2.34  0.148  8.15  0.013  5.09  0.042  3.44  0.093  6.04  0.057  1.84  0.268  1.33  0.455  0.05  0.862  
Parietal top 0.21  0.655  0.82  0.380  4.51  0.052  3.00  0.107  2.17  0.172  5.22  0.071  0.24  0.659  0.00  0.994  0.57  0.587  
Parietal bottom 0.27  0.611  0.85  0.372  6.28  0.025  4.56  0.052  2.98  0.115  8.21  0.035  1.38  0.324  10.69  0.189  7.85  0.218  
Temporal  0.03  0.860  1.45  0.251  2.47  0.142  1.09  0.319  1.29  0.286  0.73  0.442  0.04  0.860  0.89  0.518  0.01  0.926  
Hippocampus 0.14  0.724  0.68  0.446  1.18  0.327  1.78  0.253  2.87  0.189          
Caudate nucleus 0.11  0.749  0.88  0.371  0.70  0.421  0.30  0.595  0.97  0.353  0.19  0.690  0.01  0.940  0.03  0.884  0.24  0.709  
Putamen 0.00  0.977  0.20  0.663  5.53  0.041  4.55  0.059  2.48  0.150  7.35  0.053  0.03  0.875  0.48  0.613  8.88  0.206  
Anterior thalamus 0.86  0.376  0.14  0.712  0.11  0.747  0.04  0.838  0.14  0.717  0.58  0.487  0.10  0.777  0.00  0.985  0.61  0.578  
Lateral thalamus 0.48  0.501  0.56  0.469  1.06  0.325  1.31  0.279  4.91  0.054  0.34  0.594  0.01  0.921  0.37  0.652  6.09  0.245  
Medial thalamus 0.00  0.995  0.37  0.558  2.58  0.139  3.48  0.095  5.74  0.043  0.16  0.718  0.03  0.873      
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  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
Pi
/E
P
P
 
Sagittal top 0.00  0.974  0.13  0.720  4.09  0.063  1.34  0.267  1.92  0.196  3.62  0.115  0.07  0.815  0.09  0.816  0.22  0.723  
Sagittal bottom 0.18  0.682  0.75  0.400  15.05  0.002  4.77  0.048  2.71  0.131  7.39  0.042  1.32  0.334  5.93  0.248  0.24  0.709  
Parietal top 0.05  0.826  0.08  0.786  6.98  0.019  2.13  0.168  1.45  0.257  4.47  0.088  0.11  0.758  0.11  0.799  0.19  0.740  
Parietal bottom 0.00  0.970  0.07  0.800  8.71  0.011  4.03  0.066  2.14  0.174  7.02  0.045  0.44  0.556  1.95  0.396  94.80  0.065  
Temporal  0.42  0.529  0.00  0.991  3.60  0.082  0.82  0.386  0.84  0.384  0.22  0.665  0.02  0.886  3.53  0.311  0.14  0.772  
Hippocampus 0.26  0.632  0.09  0.774  0.68  0.448  4.60  0.098  4.21  0.132          
Caudate nucleus 0.00  0.952  0.16  0.694  1.29  0.282  0.44  0.523  1.04  0.337  0.13  0.740  0.01  0.917  0.31  0.677  0.05  0.862  
Putamen 0.00  0.950  0.00  0.999  10.22  0.010  3.28  0.100  1.93  0.198  1.67  0.266  0.08  0.791  0.08  0.820  2.50  0.359  
Anterior thalamus 0.14  0.720  0.35  0.566  0.01  0.942  0.11  0.748  0.10  0.765  0.75  0.435  0.22  0.672  0.10  0.807  0.20  0.731  
Lateral thalamus 1.06  0.325  0.81  0.387  1.84  0.202  1.58  0.237  5.15  0.049  0.18  0.696  0.00  0.992  0.05  0.859  1.92  0.398  
Medial thalamus 0.01  0.940  0.03  0.877  3.02  0.113  2.42  0.154  4.39  0.070  0.00  0.980  0.59  0.522      
PC
r/P
i 
Sagittal top 0.55  0.470  0.96  0.343  3.07  0.101  1.42  0.254  2.36  0.156  3.03  0.142  0.01  0.930  0.21  0.729  0.01  0.951  
Sagittal bottom 0.75  0.401  1.87  0.193  5.84  0.030  3.87  0.071  3.21  0.104  3.42  0.124  0.49  0.536  15.11  0.160  1.13  0.480  
Parietal top 0.35  0.562  0.63  0.442  3.63  0.078  2.37  0.147  2.17  0.171  2.91  0.149  0.04  0.856  0.24  0.711  0.00  0.969  
Parietal bottom 0.30  0.591  0.83  0.379  4.83  0.045  3.60  0.080  3.44  0.093  4.37  0.091  0.33  0.605  1.11  0.484  14.46  0.164  
Temporal  0.06  0.808  0.21  0.652  0.99  0.339  0.31  0.589  0.81  0.393  0.00  0.968  0.05  0.840  7.45  0.224  0.76  0.544  
Hippocampus 0.01  0.931  0.45  0.534  0.87  0.394  1.22  0.331  1.27  0.342          
Caudate nucleus 0.03  0.874  0.52  0.485  0.63  0.447  0.12  0.736  0.31  0.591  0.08  0.798  0.02  0.911  0.57  0.589  0.02  0.909  
Putamen 0.01  0.927  0.15  0.709  4.32  0.064  2.84  0.123  2.15  0.176  1.23  0.330  0.06  0.818  0.02  0.908  0.57  0.588  
Anterior thalamus 0.30  0.598  0.35  0.568  0.02  0.881  0.06  0.810  0.09  0.772  0.99  0.376  0.14  0.737  0.22  0.720  0.00  0.960  
Lateral thalamus 1.16  0.305  0.58  0.462  2.54  0.139  1.96  0.191  5.19  0.049  0.14  0.729  0.00  0.986  0.01  0.947  0.44  0.627  
Medial thalamus 0.02  0.890  0.00  0.978  2.92  0.118  2.56  0.144  3.91  0.083  0.00  0.974  0.00  0.985      
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C-1. 31P MRS biomarkers 1-48 h after resuscitation and CD68 positive microglia in the grey matter 
        Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
N
TP
/E
P
P
 
Sagittal top 0.84  0.375  0.39  0.544  1.48  0.244  2.06  0.175  1.34  0.274  4.09  0.099  0.41  0.567  0.24  0.708  0.99  0.501  
Sagittal bottom 0.18  0.674  0.87  0.367  5.84  0.030  4.48  0.054  8.35  0.016  4.87  0.078  0.66  0.475  0.27  0.696  0.02  0.903  
Parietal top 2.89  0.111  2.09  0.170  2.88  0.112  2.64  0.128  3.82  0.079  4.10  0.099  0.68  0.471  0.57  0.587  2.16  0.381  
Parietal bottom 0.31  0.584  0.59  0.455  0.49  0.496  1.26  0.283  0.53  0.483  4.02  0.101  1.17  0.359  0.03  0.900  0.27  0.693  
Temporal  1.66  0.222  1.27  0.281  0.18  0.680  0.21  0.656  0.00  0.961  0.71  0.448  0.08  0.801  1.70  0.416  8.55  0.210  
Hippocampus 0.67  0.452  2.42  0.180  1.90  0.226  0.06  0.822  0.17  0.705          
Caudate nucleus 2.20  0.166  0.39  0.545  2.78  0.124  0.29  0.603  0.39  0.547  0.03  0.861  1.30  0.337  0.41  0.639  1.54  0.432  
Putamen 0.01  0.905  3.54  0.087  0.07  0.793  0.03  0.856  0.00  0.968  0.42  0.550  0.60  0.494  4.67  0.276  1.12  0.482  
Anterior thalamus 1.54  0.240  0.36  0.562  1.88  0.197  0.02  0.882  0.30  0.595  0.10  0.769  1.01  0.389  0.57  0.587  2.16  0.381  
Lateral thalamus 2.91  0.116  0.21  0.656  1.46  0.252  0.03  0.873  0.00  0.954  0.10  0.769  1.01  0.389  0.57  0.587  2.16  0.381  
Medial thalamus 0.05  0.820  2.50  0.145  0.18  0.677  0.00  0.971  0.01  0.928  0.62  0.488  0.18  0.713      
PC
r/E
PP
 
Sagittal top 0.80  0.386  0.59  0.454  1.55  0.234  2.63  0.129  4.46  0.061  40.03  0.001  0.07  0.813  0.24  0.709  3.79  0.302  
Sagittal bottom 1.84  0.197  2.69  0.123  8.41  0.012  5.95  0.030  15.41  0.003  15.95  0.010  0.11  0.761  0.27  0.695  0.03  0.898  
Parietal top 5.57  0.033  3.09  0.100  3.43  0.085  3.49  0.084  13.79  0.004  30.25  0.003  0.03  0.867  0.57  0.588  11.68  0.181  
Parietal bottom 1.23  0.286  0.99  0.337  2.53  0.134  3.18  0.098  2.41  0.151  35.93  0.002  0.05  0.832  0.02  0.901  1.04  0.494  
Temporal  1.90  0.194  0.47  0.507  0.19  0.672  0.14  0.717  0.01  0.915  0.52  0.511  0.01  0.930  1.69  0.418  3780.
  
0.010  
Hippocampus 2.49  0.175  2.37  0.184  0.54  0.495  0.02  0.897  0.00  0.998          
Caudate nucleus 0.02  0.884  0.23  0.639  0.12  0.736  0.16  0.695  0.72  0.417  0.06  0.822  0.47  0.542  0.40  0.640  6.82  0.233  
Putamen 1.11  0.316  1.46  0.252  0.09  0.772  0.04  0.845  0.29  0.605  1.37  0.307  0.03  0.864  4.72  0.275  0.30  0.682  
Anterior thalamus 0.03  0.856  0.05  0.821  0.06  0.805  0.02  0.883  0.57  0.470  0.01  0.922  0.04  0.852  0.57  0.588  11.68  0.181  
Lateral thalamus 0.26  0.621  1.14  0.309  0.03  0.870  0.01  0.928  0.00  0.951  0.01  0.922  0.04  0.852  0.57  0.588  11.68  0.181  
Medial thalamus 1.89  0.199  2.49  0.145  0.14  0.713  0.00  0.970  0.32  0.587  1.18  0.357  0.01  0.929      
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  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
Pi
/E
P
P
 
Sagittal top 2.58  0.130  2.05  0.174  3.04  0.103  2.34  0.150  3.35  0.097  9.57  0.027  0.43  0.557  0.02  0.916  1.33  0.455  
Sagittal bottom 0.93  0.351  1.58  0.230  8.07  0.013  6.36  0.026  14.21  0.004  12.24  0.017  0.73  0.455  1.08  0.488  0.01  0.949  
Parietal top 5.76  0.031  4.72  0.048  5.22  0.038  4.18  0.062  10.51  0.009  10.64  0.022  0.79  0.439  0.11  0.795  2.98  0.334  
Parietal bottom 2.01  0.178  2.19  0.161  2.59  0.130  2.31  0.152  1.80  0.209  10.34  0.024  1.19  0.355  0.03  0.892  0.38  0.647  
Temporal  0.99  0.339  0.35  0.567  0.19  0.671  0.31  0.587  0.05  0.834  0.24  0.651  0.04  0.860  0.45  0.625  14.51  0.163  
Hippocampus 1.62  0.259  1.39  0.291  1.96  0.221  0.01  0.910  0.01  0.923          
Caudate nucleus 0.14  0.719  0.00  0.970  1.28  0.283  0.63  0.446  0.98  0.347  0.43  0.547  2.22  0.233  0.06  0.847  2.08  0.386  
Putamen 0.52  0.486  0.27  0.613  0.08  0.777  0.02  0.884  0.30  0.595  0.00  0.963  1.03  0.385  87.84  0.068  0.83  0.529  
Anterior thalamus 0.34  0.570  0.54  0.478  1.39  0.263  0.42  0.532  0.95  0.356  0.29  0.616  1.20  0.353  0.11  0.795  2.98  0.334  
Lateral thalamus 0.01  0.905  0.24  0.632  0.24  0.631  0.16  0.696  0.04  0.853  0.29  0.616  1.20  0.353  0.11  0.795  2.98  0.334  
Medial thalamus 0.93  0.359  1.12  0.314  0.46  0.513  0.14  0.716  0.34  0.577  0.07  0.810  0.38  0.599      
PC
r/P
i 
Sagittal top 6.13  0.027 3.32  0.090  3.84  0.070  3.75  0.075  10.87  0.008  59.63  0.001  0.00  0.981  0.00  0.996  0.29  0.684  
Sagittal bottom 0.93  0.352  2.46  0.139  12.44  0.003  7.80  0.015  13.28  0.005  9.69  0.026  0.45  0.551  1.89  0.401  0.22  0.721  
Parietal top 10.27  0.006  4.49  0.052  3.84  0.070  3.20  0.097  46.23  0.000  44.17  0.001  0.02  0.893  0.03  0.883  0.67  0.563  
Parietal bottom 6.03  0.028  5.49  0.034  6.01  0.028  4.99  0.044  6.41  0.030  54.05  0.001  0.26  0.647  0.10  0.804  0.04  0.876  
Temporal  2.91  0.114  0.30  0.594  0.01  0.922  0.02  0.903  0.16  0.701  0.66  0.461  0.14  0.736  0.24  0.712  1.99  0.392  
Hippocampus 2.27  0.192  1.08  0.345  0.44  0.538  0.00  0.996  0.28  0.633          
Caudate nucleus 0.07  0.802  0.07  0.790  0.69  0.424  0.32  0.582  1.93  0.198  0.08  0.796  0.18  0.700  0.01  0.935  0.48  0.615  
Putamen 1.65  0.226  0.27  0.615  0.02  0.887  0.00  0.992  1.29  0.285  1.75  0.257  0.06  0.828  1009.
  
0.020  3.85  0.300  
Anterior thalamus 0.00  0.996  0.16  0.698  0.54  0.478  0.08  0.779  1.61  0.236  0.05  0.834  0.01  0.911  0.03  0.883  0.67  0.563  
Lateral thalamus 0.33  0.580  0.74  0.408  0.02  0.881  0.01  0.919  0.15  0.703  0.05  0.834  0.01  0.911  0.03  0.883  0.67  0.563  
Medial thalamus 1.73  0.217  0.86  0.375  0.12  0.740  0.03  0.875  1.34  0.280  1.36  0.329  0.06  0.829      
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C-2. 31P MRS biomarkers 1-48 h after resuscitation and CD68 positive microglia in the white matter 
   Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
N
TP
/E
P
P
 
Sagittal 0.63  0.442  0.64  0.439  1.26  0.282  2.92  0.113  1.46  0.254  3.11  0.138  0.00  0.995  2.13  0.383  12.43  0.176  
Parietal 0.89  0.365  0.62  0.445  1.65  0.223  2.33  0.155  1.89  0.203  3.71  0.112  1.36  0.328  0.18  0.745  0.79  0.538  
Temporal 0.03  0.867  0.33  0.577  0.47  0.508  1.73  0.215  2.05  0.186  0.43  0.550  0.20  0.683  6.78  0.233  559.6
  
0.027  
Superior Periventricular 0.34  0.572  0.24  0.632  3.23  0.096  3.86  0.073  2.35  0.156  0.08  0.789  1.28  0.340  0.08  0.824  0.47  0.617  
Periventricular 0.24  0.636  1.82  0.202  0.81  0.386  1.28  0.282  4.25  0.066  0.22  0.655  0.08  0.793  1.42  0.445  6.48  0.238  
PLIC 0.31  0.597  0.94  0.370  1.46  0.272  2.84  0.153  2.95  0.161          
PC
r/E
PP
 
Sagittal 2.83  0.117  2.48  0.140  3.60  0.080  4.25  0.062  4.52  0.059  23.82  0.005  0.00  0.987  2.11  0.384  737.9
  
0.023  
Parietal 0.65  0.435  0.42  0.527  1.45  0.251  2.45  0.146  7.12  0.026  28.07  0.003  0.06  0.827  0.18  0.746  2.88  0.339  
Temporal 14.26  0.003  21.84  0.001  7.57  0.018  4.33  0.062  3.57  0.091  0.86  0.405  0.56  0.508  6.70  0.235  12.96  0.173  
Superior Periventricular 6.46  0.025  8.61  0.012  4.43  0.055  2.37  0.150  2.18  0.171  0.18  0.689  0.06  0.829  0.08  0.825  1.69  0.418  
Periventricular 2.17  0.166  2.51  0.139  0.89  0.363  1.20  0.296  1.26  0.288  0.00  0.985  0.00  0.963  1.41  0.446  268.4
  
0.039  
PLIC 2.74  0.149  6.30  0.046  4.26  0.085  1.51  0.273  7.87  0.049          
Pi
/E
P
P
 
Sagittal 3.86  0.071  3.64  0.079  4.03  0.066  3.53  0.085  3.46  0.092  8.49  0.033  0.01  0.921  0.56  0.591  23.45  0.130  
Parietal 2.20  0.164  1.72  0.214  2.96  0.111  2.60  0.135  5.49  0.044  10.05  0.025  2.00  0.252  0.01  0.953  1.05  0.492  
Temporal 4.05  0.067  10.38  0.007  3.95  0.070  3.23  0.100  2.87  0.125  0.00  0.972  0.58  0.503  1.45  0.442  1072.
  
0.019  
Superior Periventricular 4.10  0.064  3.99  0.067  3.54  0.083  2.40  0.147  2.25  0.165  0.63  0.464  1.97  0.255  0.00  0.968  0.64  0.571  
Periventricular 0.77  0.396  1.63  0.225  0.99  0.339  1.41  0.261  1.81  0.208  0.00  0.949  0.04  0.847  0.37  0.653  10.35  0.192  
PLIC 1.07  0.341  2.77  0.147  3.91  0.095  2.08  0.209  6.67  0.061          
PC
r/P
i 
Sagittal 13.32  0.003  7.48  0.017  7.55  0.017  6.49  0.026  8.82  0.014  35.60  0.002  0.10  0.767  0.31  0.678  2.51  0.358  
Parietal 5.81  0.033  3.03  0.107  4.12  0.065  3.94  0.073  24.03  0.001  42.01  0.001  0.00  0.966  0.00  0.959  0.22  0.721  
Temporal 10.77  0.007  15.53  0.002  5.79  0.033  4.20  0.065  1.89  0.203  0.71  0.447  0.06  0.823  0.83  0.529  8.58  0.209  
Superior Periventricular 5.06  0.042  4.42  0.056  4.03  0.066  3.04  0.107  0.50  0.495  0.21  0.664  0.01  0.934  0.04  0.880  0.11  0.800  
Periventricular 2.01  0.182  1.65  0.224  0.84  0.376  0.78  0.395  0.37  0.558  0.01  0.925  0.09  0.782  0.19  0.741  1.65  0.421  
PLIC 1.66  0.246  4.53  0.077  3.95  0.094  2.03  0.214  8.31  0.045          
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D-1. 31P MRS biomarkers 1-48 h after resuscitation and CD68 positive vessels in the grey matter 
        Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
N
TP
/E
P
P
 
Sagittal top 0.47  0.506  0.61  0.450  1.80  0.201  4.37  0.057  3.51  0.090  3.97  0.103  1.23  0.348  0.57  0.587  2.16  0.381  
Sagittal bottom 0.05  0.830  0.89  0.361  3.65  0.077  3.64  0.079  7.21  0.023  3.19  0.134  1.01  0.388  1.42  0.445  6.48  0.238  
Parietal top 1.14  0.304  1.81  0.200  3.26  0.093  3.67  0.078  5.14  0.047  4.10  0.099  0.43  0.558  0.57  0.587  2.16  0.381  
Parietal bottom 0.34  0.567  0.87  0.366  1.01  0.332  2.14  0.167  1.36  0.271  4.09  0.099  0.24  0.656  1.42  0.445  6.48  0.238  
Temporal  2.14  0.169  0.88  0.366  0.33  0.578  0.21  0.657  0.01  0.943  0.85  0.408  0.08  0.793  1.42  0.445  6.48  0.238  
Hippocampus 1.32  0.303  0.74  0.429  1.95  0.221  0.24  0.651  0.61  0.492          
Caudate nucleus 2.73  0.127  0.00  0.972  2.58  0.137  0.39  0.547  0.09  0.767          
Putamen 0.26  0.621  1.10  0.316  1.30  0.278  1.34  0.274  0.79  0.396  0.12  0.749  1.19  0.354  0.03  0.900  0.27  0.693  
Anterior thalamus 3.06  0.108  0.02  0.892  2.31  0.157  0.03  0.871  0.07  0.798  0.10  0.769  1.01  0.389  0.57  0.587  2.16  0.381  
Lateral thalamus 3.28  0.097  0.16  0.700  1.69  0.220  0.01  0.940  0.03  0.861  0.10  0.769  1.01  0.389  0.57  0.587  2.16  0.381  
Medial thalamus 1.00  0.340  0.92  0.360  0.24  0.632  0.00  0.994  0.01  0.913  0.62  0.488  0.18  0.713      
PC
r/E
PP
 
Sagittal top 2.26  0.155  2.18  0.162  2.64  0.127  3.95  0.068  8.65  0.015  39.08  0.002  0.03  0.880  0.57  0.588  11.68  0.181  
Sagittal bottom 0.14  0.710  0.56  0.467  2.56  0.132  3.27  0.094  17.86  0.002  27.86  0.003  0.20  0.686  1.41  0.446  268.4
  
0.039  
Parietal top 9.05  0.009  7.31  0.017  6.97  0.019  5.78  0.032  16.07  0.002  18.51  0.008  0.03  0.884  0.57  0.588  11.68  0.181  
Parietal bottom 1.43  0.252  1.35  0.264  3.44  0.085  4.47  0.054  4.97  0.050  37.76  0.002  0.17  0.706  1.41  0.446  268.4
  
0.039  
Temporal  1.85  0.198  0.43  0.524  0.15  0.707  0.10  0.762  0.03  0.862  0.72  0.445  0.00  0.963  1.41  0.446  268.4
  
0.039  
Hippocampus 6.19  0.055  5.37  0.068  1.45  0.282  1.17  0.339  0.84  0.426          
Caudate nucleus 0.04  0.851  0.22  0.646  0.01  0.911  0.05  0.834  0.06  0.806          
Putamen 0.96  0.348  1.03  0.332  0.81  0.387  2.45  0.149  0.53  0.485  0.77  0.429  0.05  0.832  0.02  0.901  1.04  0.494  
Anterior thalamus 0.02  0.904  0.10  0.761  0.01  0.923  0.01  0.941  0.11  0.743  0.01  0.922  0.04  0.852  0.57  0.588  11.68  0.181  
Lateral thalamus 0.00  0.970  0.30  0.593  0.00  0.966  0.05  0.827  0.05  0.823  0.01  0.922  0.04  0.852  0.57  0.588  11.68  0.181  
Medial thalamus 2.05  0.183  3.91  0.076  0.61  0.454  0.26  0.621  0.03  0.871  1.18  0.357  0.01  0.929      
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  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
Pi
/E
P
P
 
Sagittal top 4.18  0.060  3.01  0.105  3.09  0.101  3.20  0.097  5.85  0.036  8.26  0.035  1.46  0.313  0.11  0.795  2.98  0.334  
Sagittal bottom 0.55  0.472  1.13  0.305  4.05  0.064  3.65  0.078  13.19  0.005  7.08  0.045  1.06  0.379  0.37  0.653  10.35  0.192  
Parietal top 7.00  0.019  8.57  0.011  7.96  0.014  5.85  0.031  11.63  0.007  9.67  0.027  0.50  0.529  0.11  0.795  2.98  0.334  
Parietal bottom 2.46  0.139  3.23  0.094  4.06  0.063  3.60  0.080  3.73  0.082  10.51  0.023  0.21  0.678  0.37  0.653  10.35  0.192  
Temporal  1.06  0.323  0.29  0.599  0.25  0.629  0.28  0.609  0.00  0.978  0.32  0.600  0.04  0.847  0.37  0.653  10.35  0.192  
Hippocampus 3.82  0.108  3.48  0.121  3.52  0.119  0.53  0.509  0.58  0.503          
Caudate nucleus 0.14  0.711  0.15  0.702  0.56  0.469  0.22  0.652  0.13  0.726          
Putamen 0.76  0.401  0.24  0.633  1.18  0.302  1.26  0.289  0.33  0.580  0.03  0.864  1.87  0.265  0.03  0.892  0.38  0.647  
Anterior thalamus 0.35  0.569  0.08  0.781  1.07  0.323  0.26  0.619  0.28  0.612  0.29  0.616  1.20  0.353  0.11  0.795  2.98  0.334  
Lateral thalamus 0.26  0.620  0.03  0.866  0.70  0.420  0.35  0.569  0.15  0.711  0.29  0.616  1.20  0.353  0.11  0.795  2.98  0.334  
Medial thalamus 0.44  0.521  1.45  0.256  0.07  0.795  0.00  0.991  0.00  0.959  0.07  0.810  0.38  0.599      
PC
r/P
i 
Sagittal top 10.49  0.006  3.95  0.067  3.61  0.078  4.39  0.056  10.95  0.008  61.58  0.001  0.02  0.887  0.03  0.883  0.67  0.563  
Sagittal bottom 0.17  0.690  0.80  0.386  4.03  0.064  3.92  0.069  17.23  0.002  29.78  0.003  0.27  0.642  0.19  0.741  1.65  0.421  
Parietal top 11.98  0.004  8.26  0.012  6.91  0.020  5.39  0.037  22.53  0.001  22.13  0.005  0.03  0.878  0.03  0.883  0.67  0.563  
Parietal bottom 6.26  0.025  6.70  0.021  8.04  0.013  6.74  0.022  12.65  0.005  53.68  0.001  0.49  0.535  0.19  0.741  1.65  0.421  
Temporal  2.85  0.117  0.21  0.654  0.01  0.931  0.01  0.938  0.00  0.995  0.64  0.467  0.09  0.782  0.19  0.741  1.65  0.421  
Hippocampus 4.65  0.084  2.63  0.165  1.12  0.339  0.65  0.464  0.27  0.639          
Caudate nucleus 0.01  0.941  0.44  0.521  0.24  0.632  0.14  0.715  0.18  0.679          
Putamen 1.05  0.328  0.12  0.736  0.90  0.362  1.71  0.220  0.50  0.496  1.08  0.356  0.01  0.913  0.10  0.804  0.04  0.876  
Anterior thalamus 0.00  0.979  0.01  0.918  0.26  0.619  0.03  0.873  0.59  0.463  0.05  0.834  0.01  0.911  0.03  0.883  0.67  0.563  
Lateral thalamus 0.03  0.865  0.06  0.810  0.11  0.751  0.02  0.884  0.39  0.549  0.05  0.834  0.01  0.911  0.03  0.883  0.67  0.563  
Medial thalamus 1.95  0.193  1.96  0.192  0.16  0.697  0.10  0.764  0.01  0.938  1.36  0.329  0.06  0.829      
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D-2. 31P MRS biomarkers 1-48 h after resuscitation and CD68 positive vessels in the white matter 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
N
TP
/E
P
P
 
Sagittal 0.47  0.504  0.95  0.347  1.42  0.255  5.06  0.044  2.21  0.168  1.40  0.290  0.08  0.793  1.42  0.445  6.48  0.238  
Parietal 1.81  0.204  0.46  0.511  5.94  0.031  4.99  0.047  3.39  0.099  3.85  0.107        
Temporal 0.26  0.617  0.20  0.666  0.81  0.385  0.75  0.406  4.48  0.063  0.42  0.550  0.60  0.494  4.67  0.276  1.12  0.482  
Superior Periventricular 0.27  0.610  0.73  0.410  0.55  0.471  0.18  0.679  0.81  0.389  0.03  0.875  0.03  0.871  3.15  0.327  27.38  0.120  
Periventricular 0.03  0.865  2.59  0.133  0.22  0.644  0.34  0.570  0.27  0.616  0.05  0.828  0.08  0.793  1.42  0.445  6.48  0.238  
PLIC 0.30  0.602  0.09  0.777  5.06  0.066  9.55  0.027  6.92  0.058          
PC
r/E
PP
 
Sagittal 3.06  0.104  3.40  0.088  4.35  0.057  4.75  0.050  5.12  0.047  8.30  0.035  0.00  0.963  1.41  0.446  268.4
  
0.039  
Parietal 9.78  0.009  8.27  0.014  12.58  0.004  10.68  0.007  13.07  0.006  34.09  0.002        
Temporal 8.57  0.013  9.13  0.011  1.89  0.195  1.60  0.233  4.07  0.075  1.37  0.307  0.03  0.864  4.72  0.275  0.30  0.682  
Superior Periventricular 1.68  0.217  1.79  0.203  0.18  0.681  0.01  0.927  0.11  0.749  0.63  0.463  0.00  0.955  3.12  0.328  63.96  0.079  
Periventricular 0.03  0.859  0.00  0.983  0.10  0.755  0.26  0.620  1.31  0.280  0.95  0.375  0.00  0.963  1.41  0.446  268.4
  
0.039  
PLIC 3.42  0.114  7.16  0.037  5.26  0.062  2.53  0.172  7.48  0.052          
Pi
/E
P
P
 
Sagittal 2.85  0.115  2.36  0.149  3.40  0.088  4.11  0.065  3.96  0.075  4.11  0.099  0.04  0.847  0.37  0.653  10.35  0.192  
Parietal 7.04  0.021  4.57  0.054  12.01  0.005  7.74  0.018  8.25  0.018  9.73  0.026        
Temporal 4.83  0.048  8.91  0.011  2.44  0.144  1.60  0.232  4.06  0.075  0.00  0.963  1.03  0.385  87.84  0.068  0.83  0.529  
Superior Periventricular 0.28  0.606  1.10  0.313  0.06  0.818  0.01  0.942  0.15  0.707  0.64  0.459  0.10  0.772  0.80  0.535  73.58  0.074  
Periventricular 0.19  0.672  0.00  0.954  0.01  0.941  0.48  0.501  1.02  0.337  0.55  0.490  0.04  0.847  0.37  0.653  10.35  0.192  
PLIC 2.15  0.193  2.10  0.197  4.72  0.073  2.80  0.155  8.56  0.043          
PC
r/P
i 
Sagittal 10.08  0.007  5.66  0.033  7.43  0.017  7.30  0.019  6.16  0.032  10.65  0.022  0.09  0.782  0.19  0.741  1.65  0.421  
Parietal 12.51  0.004  6.98  0.022  19.05  0.001  14.67  0.003  19.55  0.002  55.29  0.001        
Temporal 6.61  0.025  6.27  0.028  1.22  0.290  0.90  0.364  1.18  0.306  1.75  0.257  0.06  0.828  1009.
  
0.020  3.85  0.300  
Superior Periventricular 0.61  0.447  1.72  0.213  0.11  0.748  0.00  0.972  0.01  0.915  0.82  0.408  0.10  0.768  0.45  0.623  3.77  0.303  
Periventricular 0.01  0.917  0.16  0.695  0.21  0.656  0.46  0.513  2.25  0.164  1.19  0.324  0.09  0.782  0.19  0.741  1.65  0.421  
PLIC 5.25  0.062  3.69  0.103  4.67  0.074  4.17  0.097  3.13  0.152          
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E. 31P MRS biomarkers 1-48 h after resuscitation and white matter injury assessed using H & E stains 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
N
TP
/E
P
P
 
Sagittal 0.25  0.628  0.94  0.349  5.36  0.038  7.02  0.021  6.02  0.034  1.39  0.291  0.23  0.664  0.88  0.521  0.21  0.728  
Parietal 0.08  0.785  1.21  0.292  3.28  0.095  5.69  0.036  4.55  0.062  1.39  0.291  0.23  0.664  0.88  0.521  0.21  0.728  
Temporal 0.19  0.674  0.47  0.504  4.83  0.048  3.40  0.092  3.34  0.101  0.01  0.926  0.00  0.986  0.00  0.993  0.11  0.800  
Superior Periventricular 0.00  0.984  0.02  0.891  3.27  0.094  3.64  0.080  4.67  0.056  0.66  0.454  0.00  0.983  0.00  1.000    
Periventricular 0.07  0.799  0.15  0.701  14.52  0.002  8.97  0.012  9.87  0.010  2.02  0.214  0.00  0.999  0.88  0.521  0.21  0.728  
PLIC 0.06  0.816  0.24  0.638  15.19  0.005  10.59  0.014  19.60  0.004  0.30  0.637  1.61  0.425      
PC
r/E
PP
 
Sagittal 3.12  0.101  4.05  0.065  12.06  0.004  19.83  0.001  20.30  0.001  6.60  0.050  0.86  0.421  0.88  0.520  0.01  0.927  
Parietal 3.18  0.100  3.65  0.080  12.73  0.004  20.71  0.001  17.78  0.002  6.60  0.050  0.86  0.421  0.88  0.520  0.01  0.927  
Temporal 6.05  0.030  8.40  0.013  12.76  0.004  11.75  0.006  9.71  0.012  0.00  0.977  0.83  0.430  0.00  0.992  0.52  0.601  
Superior Periventricular 4.54  0.053  5.25  0.039  8.90  0.011  15.01  0.002  11.16  0.007  2.08  0.209  4.01  0.139  0.00  1.000    
Periventricular 1.84  0.200  4.02  0.068  8.05  0.015  9.75  0.010  12.55  0.005  6.12  0.056  1.15  0.362  0.88  0.520  0.01  0.927  
PLIC 0.62  0.454  1.35  0.279  6.44  0.035  4.98  0.061  16.69  0.006  0.17  0.719  1.28  0.461      
Pi
/E
P
P
 
Sagittal 4.51  0.054  3.26  0.094  11.12  0.005  11.27  0.006  12.05  0.006  3.75  0.111  0.02  0.906  3.49  0.313  0.14  0.774  
Parietal 3.23  0.098  2.25  0.160  7.94  0.016  10.66  0.008  9.74  0.012  3.75  0.111  0.02  0.906  3.49  0.313  0.14  0.774  
Temporal 5.65  0.035  5.50  0.037  11.73  0.005  6.71  0.025  6.22  0.034  0.07  0.801  0.09  0.781  0.12  0.785  0.17  0.754  
Superior Periventricular 4.76  0.048  4.56  0.052  9.00  0.010  8.62  0.012  8.19  0.017  1.90  0.227  0.07  0.814      
Periventricular 0.84  0.377  1.42  0.256  15.71  0.002  11.42  0.006  12.15  0.006  5.23  0.071  0.14  0.735  3.49  0.313  0.14  0.774  
PLIC 0.27  0.620  0.83  0.389  8.12  0.021  7.94  0.026  25.27  0.002  2.37  0.264  60.52  0.081      
PC
r/P
i 
Sagittal 7.98  0.014  4.95  0.044  17.70  0.001  20.44  0.001  24.71  0.001  7.09  0.045  0.37  0.586  7.34  0.225  0.75  0.545  
Parietal 7.97  0.015  4.73  0.050  17.65  0.001  21.60  0.001  23.81  0.001  7.09  0.045  0.37  0.586  7.34  0.225  0.75  0.545  
Temporal 6.86  0.022  5.86  0.032  13.45  0.003  11.14  0.007  9.70  0.012  0.01  0.938  0.34  0.598  0.27  0.697  0.00  0.983  
Superior Periventricular 6.37  0.025  4.22  0.061  10.81  0.006  15.32  0.002  14.29  0.004  3.32  0.128  2.60  0.205  0.00  1.000    
Periventricular 1.67  0.221  2.00  0.182  7.58  0.018  7.60  0.019  7.28  0.022  4.98  0.076  0.31  0.617  7.34  0.225  0.75  0.545  
PLIC 0.90  0.370  1.98  0.197  8.84  0.018  5.98  0.044  8.78  0.025  0.03  0.880  12.83  0.173      
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F. 31P MRS biomarkers 1-48 h after resuscitation and white matter injury assessed using LFB/Nissl stains 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
N
TP
/E
P
P
 
Sagittal 0.66  0.431  0.23  0.638  1.36  0.264  3.50  0.086  5.71  0.038  0.02  0.899  1.87  0.265      
Parietal 0.18  0.678  0.36  0.560  3.51  0.085  3.30  0.097  8.13  0.019  0.34  0.585  2.01  0.251  1.42  0.445  6.48  0.238  
Temporal 0.69  0.423  0.19  0.667  1.71  0.215  2.43  0.147  4.37  0.066  0.85  0.408  0.08  0.793  1.42  0.445  6.48  0.238  
Superior Periventricular 1.08  0.318  0.02  0.886  0.92  0.356  4.73  0.050  12.23  0.006          
Periventricular 0.98  0.341  0.01  0.915  0.78  0.395  4.13  0.067  12.23  0.006          
PLIC 0.52  0.491  0.42  0.534  4.43  0.069  2.71  0.144  4.38  0.081  0.02  0.895  4.70  0.275      
PC
r/E
PP
 
Sagittal 0.01  0.914  0.22  0.644  0.07  0.800  0.04  0.849  1.25  0.289  0.01  0.920  0.04  0.854      
Parietal 0.02  0.896  0.00  0.951  0.06  0.813  0.13  0.721  1.87  0.204  0.00  0.947  0.04  0.852  1.41  0.446  268.4
  
0.039  
Temporal 0.04  0.836  0.07  0.795  0.89  0.363  1.31  0.277  1.86  0.205  0.72  0.445  0.00  0.963  1.41  0.446  268.4
  
0.039  
Superior Periventricular 0.58  0.460  0.75  0.404  1.64  0.223  3.02  0.108  4.45  0.061          
Periventricular 0.23  0.640  0.36  0.559  1.11  0.312  2.33  0.155  4.45  0.061          
PLIC 2.76  0.135  3.65  0.093  3.08  0.117  1.50  0.261  6.42  0.044  0.06  0.829  0.49  0.610      
Pi
/E
P
P
 
Sagittal 0.36  0.558  0.02  0.901  0.31  0.586  1.08  0.319  2.83  0.124  0.30  0.605  2.29  0.228      
Parietal 0.07  0.792  0.00  0.996  0.53  0.482  1.27  0.284  4.21  0.070  0.29  0.614  1.89  0.263  0.37  0.653  10.35  0.192  
Temporal 0.03  0.858  0.03  0.872  0.69  0.422  1.56  0.238  2.42  0.154  0.32  0.600  0.04  0.847  0.37  0.653  10.35  0.192  
Superior Periventricular 0.00  0.987  0.47  0.504  0.92  0.354  5.48  0.037  6.47  0.029          
Periventricular 0.01  0.911  0.27  0.613  0.60  0.452  4.51  0.057  6.47  0.029          
PLIC 2.00  0.195  4.11  0.077  4.74  0.061  2.53  0.156  8.23  0.028  0.31  0.633  86.29  0.068      
PC
r/P
i 
Sagittal 0.00  0.986  0.15  0.702  0.17  0.688  0.16  0.695  0.12  0.740  0.02  0.888  0.01  0.916      
Parietal 0.01  0.910  0.02  0.890  0.26  0.618  0.30  0.596  0.38  0.555  0.00  0.977  0.04  0.857  0.19  0.741  1.65  0.421  
Temporal 0.54  0.478  0.19  0.671  1.59  0.232  1.62  0.230  1.02  0.339  0.64  0.467  0.09  0.782  0.19  0.741  1.65  0.421  
Superior Periventricular 0.56  0.469  1.07  0.320  1.84  0.198  2.44  0.144  2.15  0.174          
Periventricular 0.28  0.609  0.65  0.435  1.29  0.278  1.82  0.204  2.15  0.174          
PLIC 2.95  0.124  6.16  0.038  4.81  0.060  2.33  0.171  6.87  0.040  0.11  0.769  722.6
  
0.024      
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G. 31P MRS biomarkers 1-48 h after resuscitation and axonal injury assessed using β-APP immune-histochemical stain 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
N
TP
/E
P
P
 
Sagittal 0.00  0.997  0.09  0.772  2.31  0.153  1.08  0.319  0.95  0.353  6.72  0.049  0.71  0.462  0.57  0.587  2.16  0.381  
Parietal 0.06  0.813  0.19  0.671  4.05  0.067  3.56  0.086  3.44  0.096  4.22  0.095  0.04  0.846  0.00  0.993  0.11  0.800  
Temporal 0.00  0.950  0.28  0.605  3.88  0.072  1.41  0.260  0.62  0.451  2.44  0.193  0.71  0.462  0.57  0.587  2.16  0.381  
Superior Periventricular 0.49  0.497  2.25  0.158  6.51  0.024  4.88  0.047  2.84  0.123  8.52  0.033  1.88  0.264  0.57  0.587  2.16  0.381  
Periventricular 0.01  0.940  0.22  0.649  5.19  0.042  4.02  0.070  4.40  0.062  3.47  0.122  0.05  0.833  0.07  0.838  0.43  0.631  
PLIC 1.32  0.294  3.05  0.131  3.07  0.130  3.37  0.126  0.88  0.401          
PC
r/E
PP
 
Sagittal 0.03  0.871  0.04  0.850  0.80  0.387  0.95  0.349  3.38  0.096  16.37  0.010  2.36  0.222  0.57  0.588  11.68  0.181  
Parietal 0.02  0.882  0.11  0.749  1.19  0.296  1.48  0.249  8.72  0.016  8.55  0.033  0.01  0.913  0.00  0.992  0.52  0.601  
Temporal 2.03  0.179  3.44  0.089  8.33  0.014  4.94  0.048  2.67  0.137  4.68  0.097  2.36  0.222  0.57  0.588  11.68  0.181  
Superior Periventricular 6.54  0.024  8.01  0.014  18.32  0.001  12.05  0.005  9.93  0.010  17.34  0.009  1.53  0.304  0.57  0.588  11.68  0.181  
Periventricular 1.34  0.270  2.90  0.114  7.24  0.020  5.41  0.040  10.87  0.008  12.07  0.018  0.04  0.860  0.07  0.839  1.54  0.432  
PLIC 0.21  0.665  0.02  0.905  0.88  0.384  1.08  0.347  1.08  0.357          
Pi
/E
P
P
 
Sagittal 0.18  0.681  0.21  0.654  2.35  0.149  0.74  0.408  2.40  0.152  17.50  0.009  1.56  0.300  0.11  0.795  2.98  0.334  
Parietal 0.04  0.847  0.01  0.925  2.33  0.153  1.41  0.259  5.96  0.037  6.57  0.050  0.17  0.705  0.12  0.785  0.17  0.754  
Temporal 1.22  0.291  2.12  0.171  9.90  0.008  2.79  0.123  1.61  0.237  3.65  0.129  1.56  0.300  0.11  0.795  2.98  0.334  
Superior Periventricular 5.49  0.036  7.89  0.015  19.86  0.001  8.38  0.013  6.78  0.026  25.98  0.004  3.99  0.140  0.11  0.795  2.98  0.334  
Periventricular 1.25  0.285  2.15  0.169  8.72  0.012  4.53  0.057  8.24  0.017  7.72  0.039  0.18  0.698  0.01  0.954  0.58  0.585  
PLIC 0.95  0.367  0.18  0.684  0.74  0.423  1.09  0.345  1.14  0.345          
PC
r/P
i 
Sagittal 0.19  0.670  0.24  0.631  1.09  0.316  1.26  0.284  4.00  0.073  13.14  0.015  1.25  0.346  0.03  0.883  0.67  0.563  
Parietal 0.35  0.566  0.30  0.593  1.44  0.253  1.63  0.227  5.18  0.049  4.20  0.096  0.18  0.698  0.27  0.697  0.00  0.983  
Temporal 1.68  0.219  3.03  0.107  6.41  0.026  4.36  0.061  3.26  0.104  1.28  0.322  1.25  0.346  0.03  0.883  0.67  0.563  
Superior Periventricular 7.51  0.017  10.60  0.006  18.40  0.001  12.66  0.004  10.40  0.009  11.18  0.020  0.59  0.500  0.03  0.883  0.67  0.563  
Periventricular 2.83  0.118  3.95  0.070  8.95  0.011  6.09  0.031  9.38  0.012  9.31  0.028  0.00  0.987  0.05  0.866  0.09  0.814  
PLIC 0.99  0.359  0.24  0.641  1.51  0.265  2.23  0.196  0.66  0.462          
P-values presented without correction for multiple comparisons. P-values for the periods after 24 hours are presented only for reference because of the 
limited number of surviving subjects. Abbreviation: PCIC, posterior limb of the internal capsule. 
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Supplemental Table 4.3-6: Regional ADC 1-48 h after resuscitation and histo-pathological injury in corresponding 
regions (adjusted for AED and survival time after resuscitation) 
A. ADC 1 to 48 hours after resuscitation and neuronal death assessed using H & E stains 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
 
Sagittal top 3.32  0.090  9.93  0.007 54.45  0.000
 
43.40  0.000
 
58.25  0.000
 
6.70  0.049  0.37  0.653  0.70  0.556  0.98  0.503  
Sagittal bottom 1.04  0.325  2.98  0.106  4.52  0.053  3.39  0.091  4.81  0.064  18.90  0.007  30.96  0.113  52.20  0.088  4.89  0.270  
Parietal top 0.84  0.375  4.29  0.057  6.01  0.029  7.83  0.016  10.18  0.015  3.39  0.125  0.16  0.759  0.49  0.611  0.17  0.754  
Parietal bottom 3.90  0.068  4.17  0.060  4.11  0.064  3.56  0.084  5.84  0.046  20.36  0.006  1.38  0.449  0.74  0.549  1.43  0.443  
Temporal  0.75  0.403  3.78  0.076  4.59  0.055  6.26  0.034  0.05  0.830  0.71  0.446  5.34  0.260  1.74  0.413  
  
Hippocampus 0.03  0.862  0.06  0.826  0.15  0.725  3.67  0.306  . . 
        
Caudate nucleus 0.90  0.366  2.49  0.146  4.60  0.061  5.80  0.053  1.18  0.357  3.12  0.175  0.38  0.649  0.17  0.750  . . 
Putamen 0.01  0.931  1.09  0.321  2.20  0.169  2.38  0.161  4.95  0.077  1.21  0.332  19.06  0.143  71.11  0.075  . . 
Anterior thalamus 4.60  0.058  5.41  0.042  4.82  0.053  6.76  0.035  0.51  0.517  10.59  0.031  5.35  0.260  11.76  0.181  . . 
Lateral thalamus 4.46  0.058  4.77  0.051  4.71  0.055  10.12  0.013  0.79  0.414  0.00  0.997  27.61  0.120  26.41  0.122  . . 
Medial thalamus 4.96  0.048  1.56  0.238  1.89  0.200  10.70  0.011  1.61  0.261  0.86  0.407  28.41  0.118  13.32  0.170      
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B. ADC 1-48 h after resuscitation and TUNEL positive apoptotic cell death 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
 
Sagittal top 0.31  0.587  0.79  0.388  1.98  0.183  4.89  0.047  3.94  0.088  4.00  0.102  0.07  0.841  0.01  0.938  0.00  0.992  
Sagittal bottom 0.04  0.839  0.23  0.639  4.22  0.061  4.16  0.064  2.33  0.170  4.86  0.079  4.72  0.275  73.42  0.074  1.54  0.432  
Parietal top 0.15  0.701  4.28  0.058  6.32  0.026  5.97  0.031  4.41  0.074  1.99  0.217  0.78  0.539  2.01  0.391  0.00  0.974  
Parietal bottom 0.04  0.853  0.06  0.813  2.60  0.131  2.33  0.153  1.86  0.215  6.75  0.048  2.53  0.357  0.40  0.640  2.64  0.351  
Temporal  2.21  0.163  0.03  0.858  0.01  0.931  0.01  0.928  0.30  0.607  0.37  0.575  3.76  0.303  1.32  0.456  
  
Hippocampus 0.36  0.582  0.01  0.914  1.16  0.360  0.74  0.547  
          
Caudate nucleus 3.20  0.104  3.61  0.087  1.11  0.319  0.16  0.708  0.66  0.477  1.00  0.391  0.01  0.925  0.08  0.824  . . 
Putamen 0.76  0.405  1.44  0.257  3.01  0.113  1.11  0.324  0.12  0.745  0.58  0.487  0.01  0.934  0.00  0.998  . . 
Anterior thalamus 1.21  0.296  0.60  0.456  0.11  0.745  0.21  0.658  0.08  0.792  0.52  0.510  0.01  0.936  0.05  0.857  . . 
Lateral thalamus 10.42  0.008  5.37  0.041  4.30  0.065  1.58  0.245  0.00  0.950  0.29  0.618  0.00  0.961  0.00  0.958  . . 
Medial thalamus 0.49  0.500  0.06  0.808  0.05  0.836  2.16  0.185  0.00  0.979  2.60  0.205              
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C-1. ADC 1-48 h after resuscitation and CD68 positive microglia in the grey matter 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
 
Sagittal top 1.46  0.246  3.27  0.092  6.24  0.027  2.92  0.113  4.82  0.064  15.48  0.011  0.63  0.574  0.32  0.671  0.21  0.724  
Sagittal bottom 3.60  0.079  7.49  0.016  9.10  0.010  4.11  0.065  3.71  0.095  2.23  0.196  340.2
  
0.034  14.00  0.166  10.36  0.192  
Parietal top 4.32  0.057  5.46  0.035  3.60  0.080  4.86  0.048  7.85  0.026  27.60  0.003  22.21  0.133  1888.
  
0.015  0.46  0.620  
Parietal bottom 0.41  0.531  0.83  0.379  1.59  0.230  1.20  0.295  2.10  0.191  15.96  0.010  0.01  0.931  77.74  0.072  0.01  0.936  
Temporal  4.35  0.059  1.40  0.260  0.23  0.645  0.01  0.932  0.11  0.759  0.69  0.452  0.42  0.633  1.14  0.480    
Hippocampus 7.78  0.049  155.3
  
0.000  0.25  0.651  0.08  0.829            
Caudate nucleus 5.68  0.036  5.47  0.039  5.93  0.035  9.87  0.016  0.38  0.569  0.86  0.407  1.38  0.449  2.70  0.348  . . 
Putamen 0.13  0.727  0.02  0.902  0.00  0.953  0.61  0.458  0.12  0.748  0.64  0.470  192.7
  
0.046  30.54  0.114  . . 
Anterior thalamus 3.67  0.082  3.95  0.072  3.45  0.093  2.73  0.142  1.67  0.266  0.16  0.707  0.33  0.666  0.18  0.746  . . 
Lateral thalamus 4.43  0.059  6.24  0.030  3.52  0.090  11.74  0.009  0.11  0.759  0.05  0.840  0.03  0.897  0.03  0.894  . . 
Medial thalamus 10.38  0.009  12.00  0.006  1.37  0.273  3.29  0.113  0.19  0.682  0.33  0.608        
 
C-2. ADC 1-48 h after resuscitation and CD68 positive microglia in the white matter 
  Time after resuscitation (h) 
  1 - < 3 3- < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
 
Sagittal 2.74  0.124  3.51  0.085  4.35  0.061  5.48  0.041  9.46  0.018  24.63  0.004  15.09  0.160  6.34  0.241  1.76  0.412  
Parietal 1.11  0.315  1.95  0.190  2.28  0.162  1.58  0.240  3.56  0.101  5.70  0.063  0.83  0.529  0.03  0.892  0.01  0.928  
Temporal 1.43  0.256  0.29  0.598  1.37  0.269  2.76  0.131  1.05  0.345  0.03  0.864  16.25  0.155  4.65  0.276  3.02  0.333  
Superior Periventricular 0.58  0.463  0.75  0.406  2.05  0.182  0.37  0.561  0.00  0.991  0.38  0.573  0.00  0.966  0.00  0.972  0.01  0.930  
Periventricular 0.40  0.541  1.49  0.250  0.56  0.473  0.07  0.799  0.00  0.994  1.76  0.255  0.36  0.656  0.41  0.637  1.90  0.400  
PLIC 5.14  0.064  3.36  0.117  2.42  0.181  3.35  0.141  0.17  0.723          
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D-1. ADC 1-48 h after resuscitation and CD68 positive vessels in the grey matter 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
 
Sagittal top 5.35  0.036  6.50  0.023  7.38  0.018  5.34  0.039  13.05  0.009  24.28  0.004  1.34  0.453  0.73  0.550  0.52  0.603  
Sagittal bottom 6.47  0.023  8.32  0.012  9.32  0.009  5.71  0.034  7.24  0.031  8.09  0.036  0.08  0.824  0.00  0.975  0.33  0.667  
Parietal top 11.15  0.005  14.19  0.002  10.46  0.007  17.06  0.001  9.26  0.019  32.33  0.002  22.21  0.133  1888.
  
0.015  0.46  0.620  
Parietal bottom 1.42  0.254  2.02  0.177  3.18  0.098  2.49  0.141  2.67  0.146  16.01  0.010  0.48  0.614  2.12  0.383  0.50  0.609  
Temporal  3.95  0.070  1.42  0.256  0.21  0.653  0.02  0.902  0.04  0.856  0.88  0.401  0.35  0.661  0.95  0.508    
Hippocampus 8.36  0.045  90.38  0.001  0.31  0.615  0.29  0.684            
Caudate nucleus 6.45  0.028  6.34  0.029  6.00  0.034  4.18  0.080            
Putamen 0.00  0.968  0.27  0.615  1.31  0.279  0.30  0.597  0.07  0.802  0.44  0.542  0.13  0.778  0.24  0.710  . . 
Anterior thalamus 4.91  0.049  7.53  0.019  5.17  0.046  23.96  0.002  1.67  0.266  0.16  0.707  0.33  0.666  0.18  0.746    
Lateral thalamus 4.66  0.054  2.30  0.160  2.30  0.160  13.99  0.006  0.11  0.759  0.05  0.840  0.03  0.897  0.03  0.894  . . 
Medial thalamus 0.02  0.895  0.10  0.758  1.80  0.213  11.79  0.011  0.17  0.699  0.33  0.608        
 
D-2. ADC 1-48 h after resuscitation and CD68 positive vessels in the white matter 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
 
Sagittal 2.43  0.145  4.19  0.063  4.58  0.056  6.25  0.031  6.42  0.039  7.88  0.038  7.52  0.223  12.07  0.178  2.68  0.349  
Parietal 7.11  0.022  6.67  0.025  12.74  0.005  10.26  0.011  6.59  0.037  6.27  0.054        
Temporal 0.05  0.835  0.03  0.873  0.07  0.790  1.84  0.208  1.46  0.273  0.00  0.950  0.34  0.664  0.12  0.786  0.06  0.842  
Superior Periventricular 1.48  0.250  7.31  0.021  0.97  0.348  0.04  0.850  0.04  0.854  1.21  0.333  0.79  0.537  1.17  0.475  1.53  0.432  
Periventricular 0.28  0.609  0.05  0.820  0.10  0.755  0.28  0.613  0.64  0.461  1.76  0.255  0.36  0.656  0.41  0.637  1.90  0.400  
PLIC 5.13  0.064  3.79  0.099  4.91  0.078  7.92  0.048  0.58  0.525          
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E. ADC 1-48 h after resuscitation and white matter injury assessed using H & E stains 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
 
Sagittal 5.38  0.039  15.13  0.002  25.07  0.000 51.68  0.000
 
21.80  0.002  18.24  0.008  0.18  0.743  0.05  0.856  0.29  0.685  
Parietal 2.89  0.117  9.92  0.009  13.82  0.004  11.45  0.008  17.47  0.004  22.97  0.005  9.01  0.205  15.61  0.158  10.17  0.193  
Temporal 3.29  0.097  1.68  0.221  5.49  0.041  7.42  0.023  3.86  0.097  1.36  0.309  0.47  0.619  1.02  0.497  1.45  0.441  
Superior Periventricular 0.01  0.906  0.73  0.411  4.89  0.051  10.18  0.015  4.66  0.083  3.06  0.155        
Periventricular 0.96  0.351  0.30  0.593  2.67  0.137  1.20  0.309  1.68  0.251  0.72  0.443  3.56  0.310  3.10  0.329  0.66  0.566  
PLIC 0.92  0.365  6.65  0.033  6.16  0.042  5.34  0.060  4.32  0.106  1.09  0.406        
  
F. ADC 1-48 h after resuscitation and white matter injury assessed using LFB/Nissl stains 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
 
Sagittal 0.29  0.603  0.28  0.604  0.32  0.581  0.12  0.737  0.54  0.486  0.02  0.882        
Parietal 0.09  0.767  0.10  0.758  0.02  0.903  0.00  0.962  0.43  0.535  0.29  0.614  0.08  0.829  0.10  0.808  0.14  0.772  
Temporal 2.34  0.154  12.24  0.005  5.86  0.036  1.09  0.325  1.07  0.342  3.40  0.139  126.2
  
0.057  95.31  0.065  26.92  0.121  
Superior Periventricular 0.75  0.405  8.73  0.013  3.93  0.075  0.14  0.719  0.30  0.609          
Periventricular 0.06  0.815  1.14  0.311  1.43  0.263  0.01  0.941  0.34  0.583          
PLIC 5.24  0.051  6.82  0.031  2.54  0.155  3.00  0.134  0.43  0.549  0.00  0.989        
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G. ADC 1-48 h after resuscitation and axonal injury assessed using β-APP immune-histochemical stain 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
AD
C
 
Sagittal 2.06  0.177  1.06  0.324  3.77  0.078  3.70  0.083  7.14  0.032  27.79  0.003  2.40  0.365  311.8
  
0.036  8.81  0.207  
Parietal 0.11  0.751  0.75  0.406  1.59  0.236  0.70  0.424  2.56  0.153  2.39  0.183  5.02  0.267  0.43  0.630  0.34  0.665  
Temporal 1.07  0.324  0.17  0.686  2.98  0.115  4.65  0.060  2.59  0.158  1.24  0.329  9.58  0.199  66.89  0.077  899.3
  
0.021  
Superior Periventricular 0.03  0.862  0.10  0.763  6.18  0.032  3.60  0.100  0.47  0.524  0.23  0.659  0.11  0.797  0.19  0.736  0.27  0.693  
Periventricular 4.72  0.055  1.90  0.198  5.74  0.040  1.31  0.290  0.92  0.381  0.54  0.505  0.01  0.951  0.00  0.970  0.11  0.792  
PLIC 2.33  0.178  1.52  0.264  2.61  0.167  2.92  0.163  0.01  0.945          
P-values presented without correction for multiple comparisons. 
P-values for the periods after 24 hours are presented only for reference because of the limited number of surviving subjects.  
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Supplemental Table 4.3-7: Regional T2 relaxation time 1-48 h after resuscitation and histo-pathological injury in 
corresponding regions (adjusted for AED and survival time after resuscitation) 
A. T2 1-48 h after resuscitation and neuronal death assessed using H & E stains 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
T2
 
Sagittal top 1.74  0.229  3.27  0.114  2.66  0.154  2.40  0.182  1.95  0.235  4.80  0.160  
 
     
Sagittal bottom 0.22  0.653  0.91  0.373  0.15  0.710  0.06  0.820  0.01  0.947  3.42  0.205  
      
Parietal top 2.95  0.129  3.09  0.122  2.82  0.144  3.70  0.112  4.47  0.102  7.64  0.110  
      
Parietal bottom 2.02  0.198  3.01  0.127  3.02  0.133  1.67  0.253  0.30  0.613  2.67  0.244  
      
Temporal  0.08  0.783  0.16  0.699  0.14  0.724  0.12  0.750  0.15  0.732  
        
Hippocampus 0.83  0.458  0.54  0.540  0.03  0.889  
            
Caudate nucleus 0.58  0.475  1.30  0.298  9.30  0.028  5.68  0.097  98.22  0.010  
        
Putamen 0.04  0.852  0.47  0.518  1.33  0.292  0.23  0.659  0.26  0.645  0.23  0.718  
      
Anterior thalamus 0.00  0.988  0.78  0.412  1.62  0.250  0.14  0.729  1.36  0.327  1.02  0.497  
      
Lateral thalamus 2.19  0.183  4.94  0.062  2.14  0.194  1.40  0.303  0.97  0.398  547.2
  
0.027  
      
Medial thalamus 2.40  0.165  26.18  0.001  6.04  0.049  15.58  0.011  25.36  0.007  19.72 0.141              
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B. T2 1-48 h after resuscitation and TUNEL positive apoptotic cell death 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
T2
 
Sagittal top 0.92  0.369  0.95  0.362  0.48  0.513  1.05  0.353  2.81  0.169  104.4
  
0.009  
      
Sagittal bottom 5.93  0.045  9.79  0.017  6.12  0.048  9.19  0.029  9.03  0.040  2.56  0.251  
      
Parietal top 2.75  0.141  1.05  0.340  2.82  0.144  3.65  0.114  10.43  0.032  3.69  0.195  
      
Parietal bottom 1.56  0.252  4.77  0.065  3.68  0.103  7.19  0.044  6.66  0.061  1.02  0.419  
      
Temporal  1.60  0.247  11.69  0.011  8.58  0.026  27.63  0.013  4.74  0.161  
        
Hippocampus 0.06  0.828  10.17  0.086  1.65  0.422  
            
Caudate nucleus 0.21  0.661  2.23  0.186  0.49  0.515  0.18  0.698  0.01  0.927  
        
Putamen 1.11  0.333  0.09  0.774  1.01  0.354  2.21  0.211  0.41  0.570  42.16  0.097  
      
Anterior thalamus 0.22  0.657  0.02  0.888  0.00  0.986  0.11  0.757  0.00  0.959  1.81  0.407  
      
Lateral thalamus 0.00  0.964  0.72  0.426  0.09  0.776  0.07  0.799  2.43  0.217  0.01  0.947  
      
Medial thalamus 2.44  0.162  1.26  0.299  0.17  0.693  7.00  0.046  2.30  0.204  7.79  0.219              
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C-1. T2 1-48 h after resuscitation and CD68 positive microglia in the grey matter 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
T2
 
Sagittal top 0.11  0.748  0.13  0.730  0.23  0.647  0.40  0.557  0.17  0.699  1.01  0.420        
Sagittal bottom 0.73  0.420  2.37  0.168  1.38  0.284  0.83  0.403  0.75  0.435  0.00  0.997        
Parietal top 0.67  0.441  1.47  0.265  0.83  0.397  0.98  0.368  0.31  0.607  0.11  0.770        
Parietal bottom 0.04  0.849  0.95  0.362  1.22  0.312  2.89  0.150  1.44  0.297  0.04  0.860        
Temporal  0.52  0.496  0.37  0.561  1.53  0.262  0.18  0.699  0.04  0.854          
Hippocampus 1.58  0.336  0.61  0.518  5.81  0.250              
Caudate nucleus 0.19  0.680  0.92  0.369  1.18  0.318  1.25  0.327  0.91  0.410  14.96  0.161        
Putamen 1.30  0.292  1.12  0.326  0.18  0.689  2.53  0.187  3.59  0.154  4.76  0.274        
Anterior thalamus 0.25  0.633  0.07  0.792  0.08  0.783  0.37  0.575            
Lateral thalamus 0.00  0.983  0.00  0.956  0.01  0.923  0.45  0.541            
Medial thalamus 0.00  0.970  0.01  0.937  0.00  0.992  0.16  0.703  1.12  0.349  0.27  0.693        
 
C-2. T2 1-48 h after resuscitation and CD68 positive microglia in the white matter 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
T2
 
Sagittal 0.08  0.787  0.96  0.373  3.71  0.127  0.04  0.863  0.14  0.733          
Parietal 0.39  0.554  10.68  0.017  10.96  0.021  1.91  0.239  3.02  0.157  1.04  0.493        
Temporal 2.38  0.167  0.25  0.634  1.52  0.264  0.23  0.657  0.00  0.994  0.18  0.744        
Superior Periventricular 4.89  0.063  0.38  0.557  0.11  0.751  0.13  0.736  0.04  0.859          
Periventricular                   
PLIC 4.18  0.096  0.00  0.998  0.32  0.602  0.17  0.709  0.32  0.631          
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D-1. T2 1-48 h after resuscitation and CD68 positive vessels in the grey matter 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
T2
 
Sagittal top 0.22  0.653  0.28  0.612  0.62  0.460  1.02  0.359  0.47  0.533  0.59  0.522        
Sagittal bottom 0.84  0.391  2.26  0.176  1.25  0.307  0.71  0.439  0.85  0.410  0.18  0.711        
Parietal top 0.78  0.407  1.81  0.221  0.96  0.365  1.39  0.292  0.38  0.570  0.11  0.770        
Parietal bottom 0.35  0.575  1.16  0.317  1.11  0.332  0.91  0.384  0.11  0.761  0.04  0.860        
Temporal  0.76  0.413  0.42  0.536  1.36  0.288              
Hippocampus 1.53  0.342  0.90  0.444                
Caudate nucleus 0.63  0.452  0.52  0.495  2.37  0.175              
Putamen 0.68  0.437  0.47  0.513  0.01  0.919  0.28  0.628  3.11  0.176  4.76  0.274        
Anterior thalamus 0.28  0.611  0.08  0.779  0.16  0.701  0.37  0.575            
Lateral thalamus 0.02  0.891  0.03  0.861  0.01  0.909  0.45  0.541            
Medial thalamus 0.08  0.785  0.00  0.969  0.01  0.944  1.11  0.341  1.06  0.361  0.27  0.693        
 
D-2. T2 1-48 h after resuscitation and CD68 positive vessels in the white matter 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
T2
 
Sagittal 0.03  0.871  0.32  0.598  1.93  0.237  0.03  0.883  0.00  0.954          
Parietal 1.46  0.273  10.26  0.019  5.61  0.064  1.43  0.297  3.19  0.149          
Temporal 0.05  0.838  0.11  0.751  3.13  0.127  1.81  0.249  0.44  0.553  0.58  0.585        
Superior Periventricular 0.22  0.657  0.03  0.869  2.06  0.201  0.14  0.727  0.11  0.758          
Periventricular                   
PLIC 0.05  0.825  0.70  0.442  3.22  0.147  0.71  0.460  0.01  0.921          
  
 193 
E. T2 1-48 h after resuscitation and white matter injury assessed using H & E stains 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
T2
 
Sagittal 1.90  0.227  0.69  0.445  8.58  0.043  1.72  0.281  3.77  0.147          
Parietal 3.46  0.112  4.23  0.085  7.19  0.044  3.33  0.142  10.46  0.032  8.47  0.211        
Temporal 2.42  0.164  0.08  0.782  1.39  0.284  0.36  0.583  2.30  0.226  0.04  0.868        
Superior Periventricular 2.47  0.160  0.73  0.421  0.12  0.737  1.41  0.300  0.07  0.809          
Periventricular                   
PLIC 0.13  0.734  4.83  0.070  11.22  0.020  3.66  0.128  1.48  0.311          
 
F. T2 1-48 h after resuscitation and white matter injury assessed using LFB/Nissl stains 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
T2
 
Sagittal 0.22  0.659  1.01  0.362  1.03  0.368  0.00  0.968  0.00  0.969          
Parietal 0.39  0.557  9.90  0.020  16.86  0.009  7.97  0.048  3.62  0.130  1.04  0.493        
Temporal 0.04  0.845  1.49  0.261  1.92  0.215  0.22  0.665  0.03  0.883  0.58  0.585        
Superior Periventricular 0.06  0.809  0.30  0.602  1.96  0.211  1.06  0.361  1.06  0.378          
Periventricular                   
PLIC 0.85  0.393  0.42  0.539  4.51  0.087  0.84  0.412  0.40  0.573          
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G. T2 1-48 h after resuscitation and axonal injury assessed using β-APP immune-histochemical stain 
  Time after resuscitation (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  F p F p F p F p F p F p F p F p F p 
T2
 
Sagittal 2.15  0.202  0.00  0.995  2.18  0.214  0.31  0.617  1.24  0.347          
Parietal 0.10  0.765  1.55  0.260  2.99  0.145  1.32  0.315  2.04  0.226  1.06  0.491        
Temporal 2.45  0.162  0.64  0.448  0.20  0.672  0.45  0.541  1.01  0.389  0.78  0.540        
Superior Periventricular 15.07  0.006  3.54  0.102  1.17  0.321  0.13  0.736  3.08  0.178          
Periventricular                   
PLIC 0.01  0.925  1.69  0.250  1.58  0.277  0.33  0.606  0.02  0.893          
P-values presented without correction for multiple comparisons. 
P-values for the periods after 24 hours are presented only for reference because of the limited number of surviving subjects.  
Abbreviation: PLIC, posterior limb of the internal capsule. 
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Supplemental Table 4.3-8: Serial 31P MRS biomarkers 1-48 h before termination and histo-pathological injury 
 
A. 31P MRS biomarkers 1-48 h before termination and neuronal death in the grey matter assessed using H & E stains 
        Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
N
TP
/E
P
P
 
Sagittal top -0.59  0.011  -0.55  0.019  -0.57  0.013  -0.48  0.054  -0.35  0.219  -0.49  0.184  -0.38  0.403  0.11  0.856  -0.23  0.768  
Sagittal bottom -0.37  0.134  -0.24  0.330  -0.38  0.123  -0.25  0.335  -0.21  0.475  -0.26  0.495  0.38  0.408  0.42  0.484  -0.50  0.501  
Parietal top -0.38  0.121  -0.33  0.175  -0.45  0.062  -0.33  0.192  -0.38  0.175  -0.42  0.256  -0.27  0.560  0.45  0.444  -0.07  0.929  
Parietal bottom -0.40  0.097  -0.29  0.251  -0.42  0.081  -0.26  0.323  -0.38  0.180  -0.42  0.257  -0.23  0.622  0.50  0.388  0.43  0.568  
Temporal  -0.57  0.021  -0.46  0.071  -0.56  0.024  -0.41  0.129  -0.28  0.350  -0.57  0.144  -0.44  0.319  -0.85  0.072  0.01  0.987  
Hippocampus -0.59  0.093  -0.84  0.005  -0.74  0.024  -0.56  0.146  -0.24  0.607          
Caudate nucleus -0.62  0.019  -0.55  0.041  -0.66  0.011  -0.55  0.052  -0.34  0.277  -0.50  0.259  -0.42  0.411  -0.20  0.743  -0.02  0.978  
Putamen -0.43  0.122  -0.39  0.172  -0.49  0.076  -0.45  0.109  -0.55  0.053  -0.56  0.146  -0.47  0.290  -0.68  0.209  -0.08  0.924  
Anterior thalamus -0.66  0.011  -0.54  0.045  -0.61  0.021  -0.68  0.008  -0.56  0.045  -0.81  0.016  -0.85  0.015  0.01  0.983  -0.80  0.202  
Lateral thalamus -0.20  0.475  -0.24  0.398  -0.44  0.102  -0.50  0.068  -0.32  0.294  -0.43  0.293  -0.35  0.436  0.31  0.607  -0.50  0.505  
Medial thalamus -0.47  0.079  -0.58  0.023  -0.71  0.003  -0.55  0.044  -0.19  0.530  -0.52  0.189  -0.57  0.187  -0.34  0.580  -0.45  0.552  
PC
r/E
PP
 
Sagittal top -0.71  0.001  -0.78  <0.00
 
-0.63  0.005  -0.50  0.041  -0.74  0.002  -0.57  0.106  -0.31  0.493  0.76  0.140  -0.29  0.708  
Sagittal bottom -0.65  0.003  -0.62  0.006  -0.55  0.017  -0.44  0.075  -0.44  0.115  -0.54  0.133  0.15  0.752  0.62  0.265  0.04  0.965  
Parietal top -0.62  0.006  -0.68  0.002  -0.58  0.012  -0.44  0.078  -0.60  0.024  -0.58  0.103  -0.27  0.557  0.59  0.298  -0.36  0.643  
Parietal bottom -0.66  0.003  -0.67  0.002  -0.59  0.010  -0.44  0.075  -0.62  0.018  -0.56  0.115  -0.23  0.620  0.52  0.367  -0.02  0.984  
Temporal  -0.48  0.059  -0.49  0.057  -0.41  0.115  -0.28  0.320  -0.40  0.175  -0.41  0.318  -0.38  0.398  0.55  0.338  -0.54  0.463  
Hippocampus -0.58  0.100  -0.86  0.003  -0.73  0.026  -0.60  0.120  -0.90  0.006          
Caudate nucleus -0.56  0.036  -0.71  0.005  -0.53  0.049  -0.43  0.139  -0.69  0.012  -0.43  0.330  -0.31  0.554  0.85  0.072  -0.51  0.491  
Putamen -0.32  0.269  -0.35  0.223  -0.26  0.373  -0.16  0.598  -0.36  0.233  -0.41  0.314  -0.35  0.445  0.70  0.191  -0.46  0.541  
Anterior thalamus -0.80  0.001  -0.68  0.008  -0.67  0.009  -0.56  0.036  -0.72  0.005  -0.79  0.019  -0.82  0.024  0.46  0.435  0.43  0.566  
Lateral thalamus -0.19  0.489  -0.46  0.082  -0.33  0.237  -0.27  0.344  -0.47  0.109  -0.45  0.268  -0.34  0.452  0.69  0.194  -0.01  0.987  
Medial thalamus -0.36  0.187  -0.66  0.008  -0.56  0.031  -0.52  0.056  -0.54  0.057  -0.45  0.269  -0.39  0.393  0.69  0.196  -0.07  0.935  
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  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
Pi
/E
P
P
 
Sagittal top 0.68  0.002  0.72  0.001  0.63  0.005  0.58  0.015  0.63  0.015  0.64  0.062  0.43  0.330  -0.49  0.404  0.68  0.319  
Sagittal bottom 0.53  0.022  0.51  0.031  0.45  0.060  0.43  0.084  0.38  0.187  0.52  0.156  -0.43  0.330  -0.65  0.240  0.58  0.421  
Parietal top 0.55  0.019  0.60  0.009  0.53  0.024  0.48  0.052  0.56  0.036  0.63  0.068  0.29  0.536  -0.64  0.247  0.41  0.592  
Parietal bottom 0.57  0.014  0.56  0.016  0.51  0.033  0.44  0.081  0.60  0.024  0.63  0.070  0.25  0.593  -0.67  0.218  -0.95  0.047  
Temporal  0.53  0.035  0.52  0.037  0.49  0.056  0.42  0.119  0.37  0.211  0.56  0.150  0.56  0.192  0.43  0.469  0.70  0.297  
Hippocampus 0.57  0.110  0.80  0.010  0.68  0.044  0.58  0.130  0.79  0.035          
Caudate nucleus 0.62  0.017  0.69  0.006  0.62  0.019  0.53  0.060  0.65  0.022  0.56  0.188  0.63  0.182  -0.20  0.746  0.72  0.277  
Putamen 0.41  0.149  0.42  0.131  0.37  0.196  0.33  0.249  0.51  0.078  0.58  0.134  0.59  0.165  0.21  0.733  0.72  0.276  
Anterior thalamus 0.77  0.001  0.65  0.013  0.67  0.009  0.61  0.021  0.69  0.009  0.74  0.035  0.74  0.055  -0.50  0.391  0.50  0.500  
Lateral thalamus 0.26  0.343  0.43  0.114  0.42  0.117  0.40  0.162  0.37  0.218  0.50  0.203  0.36  0.427  -0.60  0.283  0.70  0.299  
Medial thalamus 0.42  0.119  0.63  0.012  0.61  0.015  0.57  0.032  0.35  0.239  0.52  0.191  0.62  0.137  -0.19  0.758  0.70  0.301  
PC
r/P
i 
Sagittal top -0.81  0.000 -0.84  0.000
 
-0.70  0.001  -0.58  0.015  -0.73  0.003  -0.67  0.050  -0.42  0.346  0.77  0.132  -0.77  0.231  
Sagittal bottom -0.87  0.000
 
-0.77  0.000 -0.67  0.002  -0.56  0.020  -0.49  0.075  -0.70  0.035  0.23  0.618  0.85  0.069  -0.59  0.415  
Parietal top -0.82  0.000
 
-0.78  0.000
 
-0.66  0.003  -0.57  0.018  -0.65  0.012  -0.73  0.026  -0.26  0.568  0.83  0.085  -0.55  0.446  
Parietal bottom -0.85  0.000
 
-0.81  0.000
 
-0.69  0.002  -0.58  0.014  -0.70  0.005  -0.72  0.029  -0.21  0.655  0.83  0.084  0.84  0.161  
Temporal  -0.64  0.007  -0.59  0.017  -0.47  0.069  -0.29  0.288  -0.39  0.188  -0.51  0.197  -0.63  0.127  -0.17  0.789  -0.85  0.149  
Hippocampus -0.64  0.065  -0.92  0.000  -0.73  0.025  -0.69  0.056  -0.93  0.002          
Caudate nucleus -0.61  0.020  -0.76  0.002  -0.56  0.038  -0.56  0.045  -0.74  0.006  -0.47  0.291  -0.53  0.284  0.53  0.358  -0.86  0.139  
Putamen -0.11  0.717  -0.26  0.376  -0.23  0.428  -0.28  0.361  -0.19  0.553  0.08  0.871  0.18  0.740  0.23  0.707  0.44  0.557  
Anterior thalamus -0.71  0.004  -0.61  0.021  -0.64  0.015  -0.64  0.015  -0.67  0.013  -0.76  0.027  -0.82  0.025  0.69  0.197  -0.38  0.618  
Lateral thalamus -0.44  0.104  -0.46  0.086  -0.35  0.199  -0.32  0.267  -0.33  0.279  -0.43  0.291  -0.38  0.406  0.84  0.073  -0.70  0.298  
Medial thalamus -0.55  0.036  -0.69  0.005  -0.56  0.031  -0.52  0.056  -0.44  0.137  -0.45  0.263  -0.60  0.152  0.48  0.409  -0.72  0.283  
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B. 31P MRS biomarkers 1-48 h before termination and TUNEL positive apoptotic cell death in the grey matter 
        Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
N
TP
/E
P
P
 
Sagittal top -0.19  0.460  -0.20  0.430  -0.26  0.291  -0.10  0.705  0.40  0.152  0.47  0.200  0.41  0.367  0.71  0.176  0.15  0.850  
Sagittal bottom -0.22  0.389  -0.44  0.071  -0.54  0.022  -0.53  0.028  0.05  0.861  -0.01  0.982  -0.23  0.615  0.64  0.241  0.62  0.376  
Parietal top -0.21  0.393  -0.42  0.083  -0.40  0.104  -0.46  0.061  0.10  0.740  0.24  0.540  -0.10  0.825  0.89  0.044  -0.26  0.742  
Parietal bottom -0.17  0.496  -0.45  0.065  -0.44  0.067  -0.53  0.030  0.05  0.861  0.02  0.961  -0.22  0.640  0.55  0.337  0.58  0.424  
Temporal  -0.03  0.917  -0.25  0.356  -0.16  0.568  -0.17  0.544  0.49  0.086  0.55  0.157  0.44  0.321  0.86  0.065  0.20  0.796  
Hippocampus -0.56  0.119  -0.71  0.031  -0.27  0.475  0.14  0.749  0.57  0.184          
Caudate nucleus -0.10  0.723  -0.14  0.644  -0.14  0.624  -0.10  0.753  0.32  0.319  0.22  0.629  -0.04  0.942  0.89  0.043  -0.02  0.982  
Putamen -0.34  0.238  -0.42  0.131  -0.56  0.036  -0.63  0.016  0.01  0.982  0.02  0.965  -0.45  0.316  0.46  0.439  -0.75  0.252  
Anterior thalamus -0.05  0.860  -0.07  0.807  0.02  0.942  0.17  0.568  0.35  0.244  0.66  0.078  0.38  0.399  0.75  0.148  -0.34  0.658  
Lateral thalamus -0.37  0.170  -0.29  0.303  -0.22  0.432  0.05  0.866  0.18  0.551  0.58  0.128  0.22  0.640  0.29  0.642  -0.26  0.742  
Medial thalamus -0.34  0.241  -0.42  0.133  -0.32  0.265  -0.28  0.348  0.22  0.502  0.18  0.700  -0.02  0.970  0.92  0.078  -0.82  0.392  
PC
r/E
PP
 
Sagittal top -0.21  0.404  -0.37  0.135  -0.29  0.250  -0.31  0.231  0.03  0.927  0.19  0.617  0.51  0.246  0.01  0.993  0.17  0.828  
Sagittal bottom -0.33  0.181  -0.58  0.011  -0.57  0.013  -0.66  0.004  -0.32  0.268  -0.16  0.684  -0.36  0.427  0.25  0.689  -0.16  0.836  
Parietal top -0.31  0.219  -0.50  0.033  -0.41  0.090  -0.53  0.031  -0.24  0.402  0.03  0.946  0.13  0.777  0.27  0.662  0.50  0.496  
Parietal bottom -0.30  0.222  -0.50  0.033  -0.45  0.063  -0.56  0.020  -0.22  0.447  -0.15  0.711  -0.41  0.358  0.10  0.873  -0.08  0.919  
Temporal  -0.12  0.647  -0.35  0.182  -0.31  0.238  -0.44  0.098  -0.02  0.943  0.38  0.350  0.35  0.439  -0.28  0.649  0.32  0.680  
Hippocampus -0.47  0.205  -0.44  0.239  -0.36  0.346  -0.16  0.697  -0.10  0.835          
Caudate nucleus -0.06  0.831  -0.27  0.360  -0.24  0.415  -0.29  0.340  -0.25  0.438  0.07  0.876  -0.06  0.916  0.04  0.947  0.39  0.611  
Putamen -0.37  0.189  -0.57  0.032  -0.52  0.060  -0.73  0.003  -0.38  0.197  -0.22  0.596  -0.32  0.487  0.71  0.183  0.49  0.511  
Anterior thalamus -0.04  0.901  -0.17  0.554  -0.11  0.700  -0.15  0.615  -0.05  0.870  0.47  0.237  0.65  0.118  -0.02  0.970  0.56  0.442  
Lateral thalamus -0.21  0.464  -0.31  0.257  -0.21  0.447  -0.01  0.963  -0.14  0.648  0.54  0.172  0.62  0.135  0.21  0.740  0.23  0.766  
Medial thalamus -0.28  0.341  -0.52  0.059  -0.32  0.261  -0.38  0.197  -0.50  0.098  -0.15  0.755  0.05  0.930  0.27  0.728  1.00  0.027  
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  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
Pi
/E
P
P
 
Sagittal top 0.21  0.415  0.32  0.200  0.23  0.368  0.26  0.319  -0.21  0.482  -0.24  0.537  -0.42  0.344  0.03  0.962  -0.18  0.817  
Sagittal bottom 0.29  0.236  0.56  0.016  0.58  0.013  0.70  0.002  0.13  0.671  0.11  0.769  0.21  0.644  -0.48  0.413  -0.63  0.374  
Parietal top 0.27  0.280  0.46  0.055  0.41  0.089  0.57  0.018  0.07  0.816  -0.09  0.811  0.06  0.906  -0.34  0.578  -0.02  0.984  
Parietal bottom 0.24  0.331  0.51  0.033  0.45  0.063  0.62  0.008  0.05  0.872  0.07  0.866  0.20  0.676  -0.71  0.180  -.976
 
0.024  
Temporal  0.06  0.816  0.29  0.273  0.24  0.367  0.36  0.188  -0.28  0.361  -0.52  0.183  -0.51  0.242  -0.43  0.472  -0.68  0.319  
Hippocampus 0.48  0.189  0.67  0.048  0.31  0.415  0.04  0.932  -0.17  0.718          
Caudate nucleus 0.11  0.705  0.20  0.496  0.21  0.470  0.22  0.467  0.02  0.951  -0.13  0.779  -0.16  0.757  -0.29  0.642  -0.27  0.728  
Putamen 0.39  0.169  0.50  0.070  0.54  0.049  0.73  0.003  0.15  0.623  0.07  0.876  0.30  0.514  -0.17  0.783  0.75  0.253  
Anterior thalamus 0.03  0.930  0.05  0.863  0.05  0.860  -0.01  0.970  -0.13  0.666  -0.52  0.184  -0.44  0.327  0.00  0.995  0.04  0.963  
Lateral thalamus 0.31  0.262  0.30  0.271  0.18  0.516  -0.02  0.945  0.08  0.804  -0.45  0.262  -0.17  0.709  0.49  0.400  0.46  0.538  
Medial thalamus 0.31  0.276  0.42  0.140  0.30  0.304  0.30  0.315  0.14  0.659  -0.07  0.890  -0.12  0.822  -0.93  0.069  -0.15  0.902  
PC
r/P
i 
Sagittal top -0.37  0.130  -0.42  0.085  -0.33  0.179  -0.34  0.188  0.01  0.963  0.04  0.917  0.57  0.184  -0.09  0.887  0.30  0.697  
Sagittal bottom -0.39  0.109  -0.50  0.036  -0.52  0.026  -0.62  0.008  -0.28  0.330  -0.28  0.464  -0.20  0.669  0.52  0.371  0.58  0.418  
Parietal top -0.36  0.140  -0.45  0.063  -0.38  0.121  -0.50  0.042  -0.21  0.478  -0.07  0.850  0.16  0.735  0.37  0.535  0.24  0.757  
Parietal bottom -0.38  0.122  -0.44  0.070  -0.40  0.100  -0.54  0.025  -0.19  0.506  -0.25  0.523  -0.22  0.636  0.70  0.185  0.87  0.132  
Temporal  -0.17  0.523  -0.29  0.272  -0.31  0.244  -0.39  0.154  0.07  0.813  0.43  0.286  0.58  0.177  0.26  0.675  0.78  0.223  
Hippocampus -0.35  0.363  -0.40  0.286  -0.35  0.350  -0.19  0.645  -0.06  0.894          
Caudate nucleus -0.11  0.717  -0.26  0.376  -0.23  0.428  -0.28  0.361  -0.19  0.553  0.08  0.871  0.18  0.740  0.23  0.707  0.44  0.557  
Putamen -0.38  0.179  -0.49  0.078  -0.48  0.084  -0.62  0.018  -0.27  0.368  -0.15  0.720  -0.34  0.457  0.41  0.493  -0.50  0.498  
Anterior thalamus -0.15  0.609  -0.25  0.392  -0.20  0.495  -0.10  0.742  0.03  0.924  0.57  0.139  0.63  0.130  -0.06  0.927  0.21  0.792  
Lateral thalamus -0.38  0.167  -0.45  0.093  -0.32  0.245  -0.08  0.798  -0.13  0.669  0.53  0.175  0.43  0.340  -0.44  0.458  -0.28  0.723  
Medial thalamus -0.37  0.198  -0.55  0.041  -0.36  0.212  -0.34  0.259  -0.34  0.276  0.05  0.913  0.16  0.756  0.98  0.018  0.46  0.699  
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C-1. 31P MRS biomarkers 1-48 h before termination and CD68 positive microglia in the grey matter 
        Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
N
TP
/E
P
P
 
Sagittal top 0.23  0.367  0.30  0.222  0.43  0.076  0.25  0.342  0.21  0.462  0.19  0.616  -0.67  0.097  -0.36  0.548  0.01  0.986  
Sagittal bottom 0.20  0.430  0.37  0.127  0.34  0.168  0.21  0.418  0.00  0.993  -0.11  0.780  -0.36  0.433  -0.05  0.938  -0.73  0.272  
Parietal top 0.36  0.141  0.33  0.179  0.55  0.017  0.43  0.089  0.20  0.497  0.18  0.637  -0.17  0.717  -0.21  0.741  -0.19  0.813  
Parietal bottom 0.24  0.340  0.28  0.260  0.39  0.115  0.19  0.466  0.30  0.301  0.27  0.487  0.20  0.667  -0.08  0.893  -0.65  0.348  
Temporal  0.09  0.736  0.12  0.672  0.26  0.337  0.26  0.343  -0.07  0.817  -0.44  0.276  -0.55  0.202  0.14  0.822  -0.77  0.234  
Hippocampus -0.12  0.754  0.19  0.618  -0.31  0.410  0.34  0.406  0.51  0.242          
Caudate nucleus -0.13  0.647  0.12  0.671  0.18  0.533  0.07  0.801  0.03  0.927  -0.52  0.185  -0.08  0.870  -0.31  0.611  -0.38  0.618  
Putamen -0.14  0.629  0.16  0.580  -0.13  0.645  -0.07  0.813  -0.09  0.767  -0.61  0.108  -0.35  0.445  -0.03  0.968  -0.77  0.234  
Anterior thalamus 0.00  0.997  0.08  0.788  0.15  0.589  0.00  0.997  -0.05  0.865  -0.50  0.206  -0.03  0.951  -0.21  0.741  -0.19  0.813  
Lateral thalamus -0.24  0.397  0.07  0.807  0.10  0.724  0.05  0.863  0.07  0.823  -0.50  0.206  -0.03  0.951  -0.21  0.741  -0.19  0.813  
Medial thalamus -0.09  0.770  0.19  0.521  -0.15  0.599  0.02  0.949  0.00  0.989  -0.43  0.333  -0.43  0.394  0.13  0.871  -0.82  0.388  
PC
r/E
PP
 
Sagittal top 0.39  0.113  0.40  0.098  0.44  0.068  0.29  0.262  0.42  0.138  0.46  0.214  -0.62  0.141  -0.08  0.893  -0.12  0.876  
Sagittal bottom 0.26  0.304  0.51  0.032  0.48  0.046  0.42  0.095  0.31  0.288  0.08  0.835  -0.18  0.706  0.48  0.418  0.35  0.653  
Parietal top 0.49  0.038  0.56  0.016  0.65  0.003  0.59  0.013  0.46  0.096  0.41  0.273  -0.46  0.304  -0.10  0.873  0.10  0.904  
Parietal bottom 0.53  0.025  0.51  0.030  0.51  0.031  0.37  0.141  0.38  0.180  0.49  0.180  0.32  0.479  0.38  0.528  0.31  0.688  
Temporal  0.16  0.559  0.21  0.431  0.34  0.192  0.41  0.134  -0.16  0.603  -0.60  0.114  -0.36  0.425  0.76  0.140  0.36  0.642  
Hippocampus 0.01  0.973  -0.06  0.880  -0.16  0.679  -0.07  0.864  0.16  0.725          
Caudate nucleus -0.24  0.398  0.11  0.688  0.13  0.645  0.02  0.953  -0.02  0.954  -0.68  0.065  -0.38  0.405  -0.06  0.925  0.19  0.813  
Putamen -0.08  0.772  0.02  0.958  -0.01  0.974  -0.14  0.632  -0.22  0.466  -0.85  0.007  -0.48  0.281  0.53  0.357  0.36  0.636  
Anterior thalamus -0.12  0.660  0.10  0.731  0.12  0.660  -0.04  0.886  -0.16  0.609  -0.60  0.116  -0.36  0.431  -0.10  0.873  0.10  0.904  
Lateral thalamus -0.29  0.300  0.04  0.894  0.10  0.712  0.07  0.811  -0.04  0.902  -0.60  0.116  -0.36  0.431  -0.10  0.873  0.10  0.904  
Medial thalamus -0.01  0.967  0.01  0.977  -0.03  0.925  0.00  0.995  -0.11  0.744  -0.76  0.048  -0.34  0.505  0.75  0.247  0.38  0.752  
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  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
Pi
/E
P
P
 
Sagittal top -0.35  0.159  -0.42  0.084  -0.39  0.113  -0.39  0.123  -0.41  0.146  -0.44  0.234  0.73  0.063  -0.48  0.417  -0.23  0.773  
Sagittal bottom -0.22  0.380  -0.46  0.056  -0.42  0.080  -0.34  0.187  -0.17  0.562  -0.07  0.850  0.35  0.445  -0.49  0.397  0.49  0.511  
Parietal top -0.45  0.058  -0.53  0.025  -0.57  0.013  -0.55  0.021  -0.40  0.153  -0.43  0.252  0.10  0.832  -0.62  0.269  -0.23  0.772  
Parietal bottom -0.41  0.088  -0.47  0.050  -0.41  0.092  -0.41  0.100  -0.43  0.124  -0.49  0.179  -0.17  0.715  -0.55  0.341  0.36  0.640  
Temporal  -0.12  0.659  -0.20  0.452  -0.25  0.344  -0.30  0.286  0.17  0.570  0.56  0.146  0.44  0.323  -0.05  0.931  0.88  0.121  
Hippocampus 0.10  0.796  0.00  0.992  0.16  0.676  -0.04  0.920  -0.22  0.643          
Caudate nucleus 0.14  0.615  -0.19  0.509  -0.19  0.510  -0.06  0.829  0.02  0.942  0.46  0.249  -0.04  0.929  -0.48  0.414  -0.01  0.992  
Putamen 0.13  0.641  -0.10  0.727  -0.01  0.968  0.05  0.857  0.17  0.581  0.67  0.070  0.20  0.676  -0.45  0.442  0.57  0.434  
Anterior thalamus 0.00  0.995  -0.20  0.486  -0.19  0.495  -0.03  0.921  0.10  0.739  0.42  0.297  -0.05  0.911  -0.62  0.269  -0.23  0.772  
Lateral thalamus 0.24  0.400  -0.11  0.705  -0.14  0.614  -0.07  0.818  0.04  0.903  0.42  0.297  -0.05  0.911  -0.62  0.269  -0.23  0.772  
Medial thalamus 0.09  0.770  -0.08  0.781  0.02  0.956  -0.04  0.899  0.10  0.769  0.57  0.179  0.30  0.564  -0.12  0.876  0.88  0.319  
PC
r/P
i 
Sagittal top 0.57  0.013  0.51  0.032  0.50  0.034  0.46  0.065  0.60  0.024  0.66  0.054  -0.65  0.117  0.48  0.412  0.09  0.914  
Sagittal bottom 0.39  0.112  0.52  0.027  0.49  0.040  0.39  0.123  0.18  0.534  0.33  0.388  -0.33  0.475  0.69  0.194  -0.40  0.596  
Parietal top 0.57  0.013  0.54  0.020  0.67  0.003  0.71  0.001  0.51  0.062  0.64  0.063  -0.33  0.474  0.61  0.278  0.15  0.847  
Parietal bottom 0.72  0.001  0.66  0.003  0.57  0.013  0.54  0.027  0.61  0.022  0.70  0.036  0.18  0.700  0.71  0.177  -0.31  0.695  
Temporal  0.13  0.636  0.11  0.682  0.30  0.261  0.53  0.043  -0.23  0.442  -0.52  0.184  -0.48  0.275  0.34  0.580  -0.69  0.310  
Hippocampus -0.07  0.850  -0.12  0.761  -0.22  0.570  -0.07  0.863  -0.01  0.983          
Caudate nucleus -0.05  0.855  0.08  0.791  0.09  0.742  -0.01  0.979  -0.10  0.747  -0.50  0.210  -0.26  0.576  0.50  0.395  -0.02  0.980  
Putamen -0.02  0.956  -0.03  0.930  -0.05  0.852  -0.08  0.774  -0.27  0.377  -0.67  0.070  -0.45  0.317  0.67  0.214  -0.46  0.538  
Anterior thalamus 0.06  0.840  0.07  0.809  0.12  0.669  -0.03  0.917  -0.20  0.507  -0.45  0.269  -0.22  0.643  0.61  0.278  0.15  0.847  
Lateral thalamus -0.21  0.444  -0.06  0.847  0.03  0.923  -0.01  0.979  -0.12  0.692  -0.45  0.269  -0.22  0.643  0.61  0.278  0.15  0.847  
Medial thalamus -0.07  0.818  -0.06  0.848  -0.10  0.747  0.00  1.000  -0.19  0.550  -0.56  0.194  -0.41  0.419  0.48  0.522  -0.68  0.522  
 
  
 201 
C-2. 31P MRS biomarkers 1-48 h before termination and CD68 positive microglia in the white matter 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
N
TP
/E
P
P
 
Sagittal  0.27  0.296  0.39  0.123  0.46  0.064  0.18  0.501  0.21  0.479  0.20  0.599  -0.43  0.337  0.11  0.862  -0.81  0.194  
Parietal  0.19  0.475  0.38  0.153  0.43  0.100  0.20  0.484  0.20  0.507  0.20  0.613  -0.23  0.621  -0.12  0.850  -0.56  0.440  
Temporal  0.35  0.188  0.40  0.127  0.29  0.284  -0.01  0.985  -0.24  0.439  -0.50  0.208  -0.34  0.463  -0.13  0.832  -0.82  0.178  
Superior Periventricular  0.08  0.765  0.35  0.170  0.15  0.555  -0.07  0.799  -0.19  0.508  -0.64  0.064  -0.26  0.572  -0.10  0.876  -0.62  0.382  
Periventricular -0.48  0.061  -0.04  0.883  -0.24  0.379  -0.03  0.922  0.08  0.782  -0.32  0.403  -0.42  0.349  0.17  0.780  -0.70  0.303  
PLIC 0.37  0.298  0.51  0.136  0.29  0.413  0.07  0.856  -0.11  0.794  -0.46  0.543  -0.34  0.658  -0.02  0.987    
PC
r/E
PP
 
Sagittal  0.49  0.047  0.55  0.024  0.57  0.016  0.40  0.125  0.41  0.141  0.40  0.282  -0.38  0.406  0.74  0.154  0.38  0.622  
Parietal  0.33  0.213  0.41  0.115  0.44  0.088  0.26  0.355  0.38  0.197  0.41  0.278  -0.47  0.291  0.28  0.654  0.27  0.730  
Temporal  0.54  0.029  0.64  0.008  0.69  0.003  0.58  0.024  0.26  0.388  -0.76  0.030  -0.39  0.387  0.51  0.381  0.39  0.611  
Superior Periventricular  -0.02  0.927  0.26  0.319  0.28  0.269  0.24  0.365  0.12  0.688  -0.80  0.009  -0.48  0.281  0.34  0.575  0.30  0.703  
Periventricular -0.37  0.158  -0.17  0.533  -0.15  0.572  -0.12  0.670  -0.17  0.552  -0.51  0.164  -0.26  0.579  0.75  0.144  0.33  0.675  
PLIC 0.42  0.232  0.52  0.122  0.48  0.158  0.19  0.632  0.38  0.356  -0.92  0.082  -0.34  0.663  1.00  0.048    
Pi
/E
P
P
 
Sagittal  -0.40  0.110  -0.53  0.030  -0.46  0.063  -0.42  0.102  -0.43  0.128  -0.42  0.263  0.29  0.533  -0.15  0.809  0.85  0.146  
Parietal  -0.30  0.265  -0.46  0.074  -0.41  0.119  -0.37  0.180  -0.38  0.196  -0.43  0.252  0.10  0.839  -0.59  0.299  0.22  0.778  
Temporal  -0.43  0.101  -0.55  0.028  -0.51  0.046  -0.38  0.157  -0.18  0.563  0.57  0.141  0.17  0.713  -0.14  0.821  0.73  0.271  
Superior Periventricular  0.00  0.991  -0.26  0.316  -0.23  0.374  -0.12  0.654  -0.06  0.829  0.64  0.066  0.12  0.797  -0.56  0.323  0.31  0.693  
Periventricular 0.46  0.072  0.15  0.582  0.13  0.641  0.08  0.779  0.13  0.667  0.45  0.221  0.30  0.507  0.06  0.925  0.88  0.119  
PLIC -0.35  0.328  -0.46  0.177  -0.34  0.331  -0.13  0.734  -0.25  0.546  0.69  0.309  0.23  0.768  0.00  0.998    
PC
r/P
i 
Sagittal  0.68  0.003  0.67  0.003  0.62  0.007  0.60  0.014  0.63  0.015  0.64  0.066  -0.43  0.334  0.43  0.469  -0.68  0.325  
Parietal  0.55  0.029  0.51  0.046  0.48  0.060  0.44  0.104  0.56  0.048  0.64  0.063  -0.38  0.402  0.72  0.175  -0.20  0.801  
Temporal  0.56  0.026  0.69  0.003  0.72  0.002  0.66  0.007  0.39  0.193  -0.58  0.129  -0.40  0.373  0.36  0.554  -0.59  0.415  
Superior Periventricular  -0.05  0.859  0.23  0.379  0.23  0.365  0.20  0.464  0.13  0.664  -0.58  0.101  -0.40  0.374  0.72  0.174  -0.26  0.736  
Periventricular -0.30  0.268  -0.23  0.385  -0.23  0.383  -0.17  0.539  -0.24  0.402  -0.39  0.296  -0.36  0.429  0.22  0.727  -0.69  0.313  
PLIC 0.62  0.058  0.67  0.033  0.57  0.086  0.36  0.339  0.37  0.366  -0.71  0.290  -0.40  0.600  0.45  0.702    
 
 202 
D-1. 31P MRS biomarkers 1-48 h before termination and CD68 positive vessels in the grey matter 
        Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
N
TP
/E
P
P
 
Sagittal top 0.38  0.120  0.42  0.082  0.46  0.054  0.31  0.222  0.12  0.696  0.16  0.690  -0.78  0.041  -0.21  0.741  -0.19  0.813  
Sagittal bottom 0.25  0.315  0.42  0.079  0.32  0.197  0.27  0.294  0.05  0.869  0.14  0.728  -0.76  0.050  0.17  0.780  -0.70  0.303  
Parietal top 0.51  0.032  0.39  0.107  0.56  0.017  0.40  0.108  0.08  0.782  -0.02  0.970  -0.28  0.540  -0.21  0.741  -0.19  0.813  
Parietal bottom 0.32  0.199  0.35  0.158  0.45  0.063  0.25  0.336  0.29  0.311  0.28  0.462  0.24  0.608  0.17  0.780  -0.70  0.303  
Temporal  0.05  0.841  0.10  0.708  0.28  0.291  0.26  0.357  -0.03  0.935  -0.30  0.472  -0.42  0.349  0.17  0.780  -0.70  0.303  
Hippocampus -0.16  0.684  0.18  0.639  -0.25  0.510  0.13  0.766  0.27  0.564          
Caudate nucleus -0.24  0.396  0.09  0.764  0.17  0.550  0.06  0.835  0.07  0.827          
Putamen -0.12  0.676  0.03  0.908  -0.36  0.184  -0.48  0.081  -0.35  0.240  -0.63  0.097  -0.28  0.544  -0.08  0.893  -0.65  0.348  
Anterior thalamus -0.17  0.552  0.03  0.922  0.17  0.552  0.03  0.927  0.02  0.942  -0.50  0.206  -0.03  0.951  -0.21  0.741  -0.19  0.813  
Lateral thalamus -0.19  0.505  0.06  0.826  0.13  0.649  0.04  0.882  0.05  0.872  -0.50  0.206  -0.03  0.951  -0.21  0.741  -0.19  0.813  
Medial thalamus -0.28  0.338  0.09  0.754  -0.05  0.871  -0.06  0.839  -0.02  0.964  -0.43  0.333  -0.43  0.394  0.13  0.871  -0.82  0.388  
PC
r/E
PP
 
Sagittal top 0.49  0.038  0.49  0.039  0.54  0.020  0.46  0.061  0.59  0.027  0.45  0.221  -0.58  0.170  -0.10  0.873  0.10  0.904  
Sagittal bottom 0.27  0.279  0.41  0.091  0.39  0.110  0.27  0.292  0.47  0.089  0.41  0.279  -0.30  0.512  0.75  0.144  0.33  0.675  
Parietal top 0.64  0.004  0.68  0.002  0.73  0.001  0.67  0.003  0.51  0.063  0.23  0.560  -0.53  0.226  -0.10  0.873  0.10  0.904  
Parietal bottom 0.59  0.010  0.57  0.014  0.57  0.014  0.40  0.112  0.46  0.097  0.50  0.166  0.61  0.147  0.75  0.144  0.33  0.675  
Temporal  0.09  0.736  0.20  0.462  0.34  0.201  0.39  0.151  -0.13  0.673  -0.52  0.192  -0.26  0.579  0.75  0.144  0.33  0.675  
Hippocampus -0.11  0.772  -0.11  0.786  -0.18  0.642  -0.08  0.847  0.01  0.981          
Caudate nucleus -0.37  0.177  0.04  0.876  0.09  0.758  0.04  0.888  0.03  0.922          
Putamen -0.13  0.640  -0.23  0.415  -0.28  0.317  -0.56  0.037  -0.63  0.021  -0.84  0.009  -0.48  0.278  0.38  0.528  0.31  0.688  
Anterior thalamus -0.29  0.304  0.05  0.856  0.12  0.678  0.01  0.965  -0.09  0.761  -0.60  0.116  -0.36  0.431  -0.10  0.873  0.10  0.904  
Lateral thalamus -0.22  0.441  0.08  0.770  0.18  0.528  0.12  0.684  -0.06  0.850  -0.60  0.116  -0.36  0.431  -0.10  0.873  0.10  0.904  
Medial thalamus -0.36  0.205  -0.08  0.788  -0.07  0.808  -0.13  0.662  -0.17  0.591  -0.76  0.048  -0.34  0.505  0.75  0.247  0.38  0.752  
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  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
Pi
/E
P
P
 
Sagittal top -0.44  0.067  -0.46  0.054  -0.43  0.072  -0.47  0.056  -0.50  0.071  -0.41  0.268  0.83  0.021  -0.62  0.269  -0.23  0.772  
Sagittal bottom -0.26  0.293  -0.42  0.085  -0.40  0.104  -0.32  0.208  -0.31  0.283  -0.35  0.355  0.78  0.039  0.06  0.925  0.88  0.119  
Parietal top -0.59  0.010  -0.59  0.009  -0.62  0.006  -0.59  0.013  -0.41  0.144  -0.26  0.500  0.22  0.630  -0.62  0.269  -0.23  0.772  
Parietal bottom -0.49  0.039  -0.54  0.022  -0.48  0.044  -0.46  0.062  -0.47  0.087  -0.50  0.169  -0.15  0.755  0.06  0.925  0.88  0.119  
Temporal  -0.07  0.784  -0.20  0.469  -0.26  0.331  -0.29  0.304  0.14  0.640  0.45  0.260  0.30  0.507  0.06  0.925  0.88  0.119  
Hippocampus 0.17  0.663  0.02  0.964  0.16  0.678  0.05  0.914  -0.04  0.930          
Caudate nucleus 0.28  0.321  -0.10  0.734  -0.13  0.655  -0.04  0.880  -0.01  0.972          
Putamen 0.16  0.578  0.10  0.715  0.25  0.371  0.45  0.109  0.43  0.146  0.65  0.083  0.14  0.772  -0.55  0.341  0.36  0.640  
Anterior thalamus 0.17  0.544  -0.13  0.648  -0.17  0.537  -0.04  0.886  0.07  0.822  0.42  0.297  -0.05  0.911  -0.62  0.269  -0.23  0.772  
Lateral thalamus 0.16  0.563  -0.15  0.594  -0.21  0.463  -0.11  0.720  0.05  0.874  0.42  0.297  -0.05  0.911  -0.62  0.269  -0.23  0.772  
Medial thalamus 0.32  0.271  -0.03  0.911  0.02  0.946  0.10  0.758  0.14  0.672  0.57  0.179  0.30  0.564  -0.12  0.876  0.88  0.319  
PC
r/P
i 
Sagittal top 0.55  0.019  0.55  0.017  0.59  0.010  0.61  0.009  0.74  0.002  0.63  0.068  -0.64  0.120  0.61  0.278  0.15  0.847  
Sagittal bottom 0.37  0.126  0.42  0.085  0.43  0.076  0.28  0.277  0.36  0.203  0.59  0.094  -0.54  0.212  0.22  0.727  -0.69  0.313  
Parietal top 0.70  0.001  0.69  0.001  0.78  0.000 0.78  0.000
 
0.54  0.048  0.48  0.194  -0.41  0.358  0.61  0.278  0.15  0.847  
Parietal bottom 0.79  0.000 0.71  0.001  0.65  0.004  0.57  0.017  0.65  0.012  0.71  0.032  0.35  0.442  0.22  0.727  -0.69  0.313  
Temporal  0.08  0.779  0.09  0.735  0.28  0.287  0.49  0.062  -0.20  0.504  -0.43  0.287  -0.36  0.429  0.22  0.727  -0.69  0.313  
Hippocampus -0.23  0.551  -0.19  0.627  -0.27  0.486  -0.19  0.661  -0.10  0.837          
Caudate nucleus -0.25  0.377  -0.01  0.986  0.02  0.952  -0.04  0.905  -0.04  0.895          
Putamen -0.23  0.419  -0.26  0.350  -0.33  0.232  -0.47  0.089  -0.48  0.099  -0.65  0.079  -0.41  0.359  0.71  0.177  -0.31  0.695  
Anterior thalamus -0.13  0.646  -0.01  0.977  0.08  0.787  -0.04  0.903  -0.16  0.592  -0.45  0.269  -0.22  0.643  0.61  0.278  0.15  0.847  
Lateral thalamus -0.14  0.613  -0.02  0.955  0.12  0.683  0.05  0.858  -0.14  0.652  -0.45  0.269  -0.22  0.643  0.61  0.278  0.15  0.847  
Medial thalamus -0.31  0.274  -0.16  0.595  -0.16  0.575  -0.20  0.519  -0.22  0.488  -0.56  0.194  -0.41  0.419  0.48  0.522  -0.68  0.522  
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D-2. 31P MRS biomarkers 1-48 h before termination and CD68 positive vessels in the white matter 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
N
TP
/E
P
P
 
Sagittal 0.10  0.705  0.45  0.072  0.31  0.220  0.05  0.844  0.05  0.864  0.10  0.793  -0.42  0.349  0.17  0.780  -0.70  0.303  
Parietal 0.13  0.619  0.35  0.185  0.48  0.062  0.25  0.361  0.18  0.567  0.27  0.486        
Temporal 0.12  0.658  0.19  0.478  0.25  0.344  -0.05  0.854  -0.20  0.520  -0.61  0.108  -0.35  0.445  -0.03  0.968  -0.77  0.234  
Superior Periventricular -0.37  0.140  -0.02  0.938  -0.20  0.450  -0.35  0.189  -0.23  0.438  -0.49  0.185  -0.42  0.352  0.07  0.909  -0.83  0.174  
Periventricular -0.14  0.602  0.22  0.407  -0.13  0.631  -0.18  0.522  -0.16  0.580  -0.17  0.653  -0.42  0.349  0.17  0.780  -0.70  0.303  
PLIC 0.38  0.278  0.60  0.070  0.36  0.309  0.07  0.855  -0.09  0.833  -0.46  0.543  -0.34  0.658  -0.02  0.987    
PC
r/E
PP
 
Sagittal  0.24  0.358  0.43  0.083  0.45  0.068  0.32  0.227  0.32  0.259  0.23  0.558  -0.26  0.579  0.75  0.144  0.33  0.675  
Parietal  0.32  0.233  0.64  0.008  0.68  0.004  0.64  0.010  0.44  0.137  0.49  0.177        
Temporal  0.17  0.530  0.31  0.237  0.48  0.057  0.38  0.160  0.19  0.544  -0.85  0.007  -0.48  0.281  0.53  0.357  0.36  0.636  
Superior Periventricular  -0.26  0.321  -0.06  0.827  0.02  0.955  -0.07  0.797  -0.39  0.164  -0.64  0.062  -0.42  0.350  0.70  0.187  0.39  0.611  
Periventricular 0.00  0.995  0.06  0.818  0.04  0.875  -0.16  0.576  -0.13  0.660  -0.25  0.526  -0.26  0.579  0.75  0.144  0.33  0.675  
PLIC 0.32  0.365  0.54  0.110  0.52  0.128  0.39  0.294  0.55  0.154  -0.92  0.082  -0.34  0.663  1.00  0.048    
Pi
/E
P
P
 
Sagittal  -0.15  0.565  -0.44  0.076  -0.34  0.184  -0.28  0.291  -0.29  0.312  -0.25  0.514  0.30  0.507  0.06  0.925  0.88  0.119  
Parietal  -0.23  0.400  -0.52  0.040  -0.56  0.023  -0.50  0.059  -0.35  0.237  -0.49  0.177        
Temporal  -0.17  0.535  -0.32  0.229  -0.41  0.115  -0.26  0.350  -0.12  0.705  0.67  0.070  0.20  0.676  -0.45  0.442  0.57  0.434  
Superior Periventricular  0.34  0.184  0.02  0.951  0.05  0.865  0.15  0.585  0.29  0.323  0.52  0.152  0.27  0.563  -0.25  0.687  0.80  0.199  
Periventricular 0.12  0.672  -0.15  0.578  0.01  0.965  0.10  0.715  0.13  0.661  0.19  0.616  0.30  0.507  0.06  0.925  0.88  0.119  
PLIC -0.30  0.408  -0.44  0.203  -0.34  0.330  -0.23  0.554  -0.40  0.324  0.69  0.309  0.23  0.768  0.00  0.998    
PC
r/P
i 
Sagittal  0.38  0.135  0.51  0.035  0.45  0.070  0.45  0.081  0.48  0.079  0.47  0.197  -0.36  0.429  0.22  0.727  -0.69  0.313  
Parietal  0.48  0.062  0.67  0.005  0.68  0.004  0.64  0.010  0.42  0.154  0.70  0.036        
Temporal  0.10  0.717  0.25  0.343  0.47  0.068  0.35  0.198  0.28  0.360  -0.67  0.070  -0.45  0.317  0.67  0.214  -0.46  0.538  
Superior Periventricular  -0.17  0.519  -0.07  0.804  -0.03  0.914  -0.04  0.899  -0.27  0.345  -0.40  0.285  -0.45  0.313  0.52  0.369  -0.64  0.362  
Periventricular 0.12  0.655  0.10  0.712  0.04  0.878  0.02  0.953  -0.04  0.882  -0.04  0.918  -0.36  0.429  0.22  0.727  -0.69  0.313  
PLIC 0.32  0.376  0.67  0.035  0.54  0.110  0.46  0.208  0.64  0.091  -0.71  0.290  -0.40  0.600  0.45  0.702    
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E. 31P MRS biomarkers 1-48 h before termination and white matter injury assessed using H & E stains 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
N
TP
/E
P
P
 
Sagittal  -0.67  0.003  -0.71  0.002  -0.66  0.004  -0.43  0.101  -0.12  0.693  -0.15  0.703  -0.18  0.702  0.89  0.041  -0.78  0.225  
Parietal  -0.57  0.021  -0.73  0.001  -0.53  0.035  -0.38  0.166  -0.14  0.653  -0.15  0.703  -0.18  0.702  0.89  0.041  -0.78  0.225  
Temporal  -0.61  0.012  -0.44  0.090  -0.52  0.040  -0.34  0.210  -0.01  0.969  0.32  0.446  -0.06  0.899  0.95  0.014  -0.45  0.553  
Superior Periventricular  -0.62  0.008  -0.43  0.082  -0.59  0.013  -0.24  0.362  -0.01  0.972  0.12  0.759  0.27  0.562  0.71  0.182    
Periventricular -0.65  0.007  -0.65  0.007  -0.72  0.002  -0.40  0.143  0.08  0.784  -0.20  0.602  -0.43  0.331  0.89  0.041  -0.78  0.225  
PLIC -0.87  0.000
 
-0.76  0.004  -0.68  0.015  -0.51  0.111  0.11  0.753  0.12  0.816  -0.63  0.252  0.74  0.262  -0.50  0.667  
PC
r/E
PP
 
Sagittal  -0.77  0.000
 
-0.80  0.000
 
-0.70  0.002  -0.66  0.005  -0.71  0.004  -0.39  0.305  -0.18  0.702  0.45  0.450  0.78  0.225  
Parietal  -0.75  0.001  -0.78  0.000
 
-0.65  0.006  -0.64  0.010  -0.64  0.019  -0.39  0.305  -0.18  0.702  0.45  0.450  0.78  0.225  
Temporal  -0.67  0.004  -0.72  0.002  -0.65  0.007  -0.74  0.002  -0.54  0.056  0.28  0.510  0.06  0.899  0.53  0.361  0.89  0.106  
Superior Periventricular  -0.65  0.005  -0.72  0.001  -0.66  0.004  -0.73  0.001  -0.61  0.020  -0.19  0.626  0.27  0.562  0.71  0.182    
Periventricular -0.57  0.020  -0.74  0.001  -0.68  0.004  -0.72  0.002  -0.50  0.068  -0.32  0.407  -0.43  0.331  0.45  0.450  0.78  0.225  
PLIC -0.68  0.015  -0.74  0.006  -0.53  0.078  -0.50  0.116  -0.44  0.205  -0.09  0.862  -0.32  0.604  0.63  0.368  0.50  0.667  
Pi
/E
P
P
 
Sagittal  0.76  0.000
 
0.81  0.000
 
0.72  0.001  0.72  0.002  0.62  0.019  0.39  0.305  0.05  0.924  -0.89  0.041  -0.26  0.742  
Parietal  0.67  0.004  0.77  0.001  0.61  0.012  0.67  0.007  0.65  0.016  0.39  0.305  0.05  0.924  -0.89  0.041  -0.26  0.742  
Temporal  0.66  0.006  0.68  0.004  0.66  0.005  0.72  0.003  0.42  0.155  -0.18  0.672  0.06  0.899  -0.53  0.361  0.00  1.000  
Superior Periventricular  0.69  0.002  0.72  0.001  0.72  0.001  0.75  0.001  0.48  0.080  0.19  0.626  -0.13  0.775  -0.71  0.182    
Periventricular 0.65  0.007  0.76  0.001  0.78  0.000
 
0.72  0.002  0.32  0.260  0.32  0.407  0.34  0.463  -0.89  0.041  -0.26  0.742  
PLIC 0.75  0.005  0.77  0.004  0.63  0.029  0.63  0.037  0.38  0.277  0.31  0.552  0.63  0.252  0.11  0.895  0.50  0.667  
PC
r/P
i 
Sagittal  -0.76  0.000
 
-0.81  0.000
 
-0.72  0.001  -0.71  0.002  -0.69  0.007  -0.39  0.305  -0.18  0.702  0.89  0.041  0.26  0.742  
Parietal  -0.73  0.001  -0.79  0.000
 
-0.65  0.006  -0.67  0.007  -0.65  0.016  -0.39  0.305  -0.18  0.702  0.89  0.041  0.26  0.742  
Temporal  -0.66  0.005  -0.68  0.004  -0.64  0.007  -0.70  0.004  -0.46  0.113  0.28  0.510  -0.06  0.899  0.53  0.361  0.00  1.000  
Superior Periventricular  -0.67  0.003  -0.70  0.002  -0.69  0.002  -0.73  0.001  -0.55  0.041  -0.19  0.626  0.27  0.562  0.71  0.182    
Periventricular -0.55  0.028  -0.73  0.001  -0.73  0.001  -0.72  0.002  -0.45  0.105  -0.32  0.407  -0.43  0.331  0.89  0.041  0.26  0.742  
PLIC -0.70  0.011  -0.77  0.004  -0.63  0.027  -0.58  0.059  -0.53  0.117  -0.09  0.862  -0.63  0.252  -0.11  0.895  -0.50  0.667  
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F. 31P MRS biomarkers 1-48 h before termination and white matter injury assessed using LFB/Nissl stains 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
N
TP
/E
P
P
 
Sagittal  0.58  0.015  0.33  0.201  0.33  0.192  0.09  0.749  -0.22  0.458  0.41  0.272  0.61  0.144      
Parietal  0.70  0.002  0.34  0.205  0.47  0.067  0.26  0.358  -0.02  0.951  0.52  0.154  0.79  0.034  -0.35  0.559  0.78  0.225  
Temporal  0.60  0.014  0.16  0.552  0.34  0.203  0.21  0.454  -0.10  0.751  0.25  0.555  0.41  0.363  -0.35  0.559  0.78  0.225  
Superior Periventricular  0.41  0.104  0.31  0.232  0.15  0.557  -0.14  0.605  -0.38  0.182          
Periventricular 0.42  0.105  0.31  0.246  0.14  0.605  -0.12  0.660  -0.38  0.182          
PLIC 0.70  0.012  0.42  0.176  0.42  0.176  0.19  0.568  -0.11  0.754  -0.66  0.158  0.00  1.000  -0.26  0.742  0.00  1.000  
PC
r/E
PP
 
Sagittal  0.34  0.184  0.20  0.432  0.12  0.656  0.02  0.952  -0.01  0.970  0.14  0.725  0.61  0.144      
Parietal  0.45  0.079  0.31  0.243  0.24  0.365  0.17  0.537  0.15  0.618  0.41  0.268  0.63  0.127  -0.71  0.182  -0.26  0.742  
Temporal  0.42  0.102  0.19  0.481  0.10  0.706  0.07  0.805  0.20  0.523  0.41  0.310  0.20  0.661  -0.71  0.182  -0.26  0.742  
Superior Periventricular  0.36  0.159  0.26  0.323  0.15  0.557  -0.08  0.757  -0.10  0.726          
Periventricular 0.36  0.166  0.25  0.346  0.14  0.605  -0.12  0.660  -0.10  0.726          
PLIC 0.47  0.120  0.47  0.120  0.36  0.247  0.32  0.333  0.19  0.599  -0.66  0.158  -0.35  0.559  0.26  0.742  -0.87  0.333  
Pi
/E
P
P
 
Sagittal  -0.46  0.066  -0.25  0.331  -0.20  0.445  -0.05  0.842  -0.04  0.903  -0.14  0.725  -0.61  0.144      
Parietal  -0.58  0.019  -0.34  0.205  -0.30  0.257  -0.19  0.498  -0.21  0.490  -0.52  0.154  -0.79  0.034  0.00  1.000  -0.78  0.225  
Temporal  -0.51  0.043  -0.22  0.414  -0.16  0.552  -0.11  0.710  -0.29  0.332  -0.58  0.134  -0.41  0.363  0.00  1.000  -0.78  0.225  
Superior Periventricular  -0.41  0.104  -0.31  0.232  -0.15  0.557  -0.03  0.918  -0.03  0.907          
Periventricular -0.42  0.105  -0.31  0.246  -0.14  0.605  0.00  1.000  -0.03  0.907          
PLIC -0.53  0.077  -0.47  0.120  -0.42  0.176  -0.45  0.163  -0.27  0.458  0.39  0.441  0.00  1.000  -0.78  0.225  0.00  1.000  
PC
r/P
i 
Sagittal  0.34  0.176  0.25  0.331  0.16  0.546  0.08  0.780  0.06  0.836  0.14  0.725  0.61  0.144      
Parietal  0.46  0.073  0.34  0.205  0.26  0.332  0.21  0.452  0.27  0.376  0.41  0.268  0.79  0.034  0.00  1.000  0.78  0.225  
Temporal  0.45  0.078  0.22  0.414  0.13  0.627  0.14  0.620  0.34  0.253  0.41  0.310  0.41  0.363  0.00  1.000  0.78  0.225  
Superior Periventricular  0.41  0.104  0.31  0.232  0.20  0.432  0.03  0.918  0.03  0.907          
Periventricular 0.42  0.105  0.31  0.246  0.20  0.467  0.00  1.000  0.03  0.907          
PLIC 0.53  0.077  0.47  0.120  0.42  0.176  0.39  0.239  0.27  0.458  -0.66  0.158  0.00  1.000  0.78  0.225  0.00  1.000  
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G. 31P MRS biomarkers 1-48 h before termination and white matter injury assessed using β-APP immune-histochemical stain 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
N
TP
/E
P
P
 
Sagittal -0.38  0.129  -0.44  0.078  -0.39  0.121  -0.40  0.121  -0.04  0.887  0.13  0.742  0.00  1.000  0.58  0.308  0.26  0.742  
Parietal -0.37  0.156  -0.54  0.033  -0.39  0.133  -0.47  0.080  -0.05  0.879  -0.12  0.768  -0.43  0.332  0.87  0.058  -0.45  0.553  
Temporal -0.42  0.104  -0.35  0.187  -0.43  0.099  -0.41  0.129  -0.03  0.930  0.41  0.310  0.00  1.000  0.58  0.308  0.26  0.742  
Superior Periventricular -0.64  0.005  -0.52  0.032  -0.62  0.008  -0.51  0.042  -0.22  0.453  -0.02  0.964  -0.30  0.515  0.58  0.308  0.26  0.742  
Periventricular -0.63  0.008  -0.63  0.009  -0.46  0.076  -0.32  0.240  0.11  0.721  0.22  0.572  0.06  0.899  0.63  0.252  -0.21  0.789  
PLIC -0.33  0.353  -0.54  0.107  -0.40  0.259  -0.44  0.240  -0.13  0.762  -0.89  0.106  -0.89  0.106  0.00  1.000    
PC
r/E
PP
 
Sagittal  -0.27  0.289  -0.38  0.136  -0.31  0.229  -0.50  0.047  -0.51  0.066  -0.17  0.654  0.16  0.735  0.58  0.308  0.26  0.742  
Parietal  -0.28  0.294  -0.32  0.222  -0.26  0.338  -0.36  0.183  -0.49  0.086  -0.30  0.430  -0.29  0.530  0.29  0.638  0.89  0.106  
Temporal  -0.50  0.050  -0.61  0.012  -0.59  0.016  -0.78  0.001  -0.48  0.098  0.23  0.578  0.16  0.735  0.58  0.308  0.26  0.742  
Superior Periventricular  -0.66  0.004  -0.72  0.001  -0.69  0.002  -0.72  0.002  -0.61  0.021  -0.20  0.604  -0.18  0.701  0.58  0.308  0.26  0.742  
Periventricular -0.56  0.024  -0.60  0.014  -0.46  0.075  -0.58  0.025  -0.42  0.139  -0.02  0.964  0.24  0.606  0.21  0.734  0.74  0.262  
PLIC -0.28  0.440  -0.45  0.195  -0.40  0.259  -0.62  0.073  -0.49  0.219  -0.89  0.106  -0.89  0.106  0.87  0.333    
Pi
/E
P
P
 
Sagittal  0.28  0.280  0.36  0.155  0.34  0.189  0.52  0.041  0.31  0.285  0.24  0.537  0.16  0.735  0.00  1.000  0.26  0.742  
Parietal  0.28  0.288  0.33  0.212  0.24  0.376  0.37  0.180  0.45  0.123  0.36  0.336  0.29  0.530  -0.29  0.638  0.00  1.000  
Temporal  0.44  0.089  0.55  0.028  0.57  0.022  0.75  0.001  0.30  0.317  -0.14  0.745  0.16  0.735  0.00  1.000  0.26  0.742  
Superior Periventricular  0.68  0.003  0.70  0.002  0.68  0.003  0.77  0.001  0.53  0.049  0.25  0.510  0.42  0.350  0.00  1.000  0.26  0.742  
Periventricular 0.54  0.031  0.57  0.022  0.49  0.054  0.58  0.023  0.28  0.335  0.10  0.806  0.00  1.000  0.11  0.866  0.11  0.895  
PLIC 0.22  0.534  0.36  0.304  0.45  0.195  0.56  0.116  0.21  0.625  0.89  0.106  0.89  0.106  0.00  1.000    
PC
r/P
i 
Sagittal  -0.30  0.235  -0.35  0.168  -0.32  0.204  -0.49  0.056  -0.40  0.159  -0.17  0.654  0.00  1.000  0.00  1.000  -0.26  0.742  
Parietal  -0.29  0.283  -0.32  0.234  -0.24  0.376  -0.35  0.200  -0.45  0.123  -0.30  0.430  -0.43  0.332  0.29  0.638  0.00  1.000  
Temporal  -0.50  0.047  -0.57  0.023  -0.57  0.020  -0.73  0.002  -0.36  0.234  0.23  0.578  0.00  1.000  0.00  1.000  -0.26  0.742  
Superior Periventricular  -0.68  0.002  -0.71  0.001  -0.68  0.003  -0.74  0.001  -0.54  0.047  -0.20  0.604  -0.30  0.515  0.00  1.000  -0.26  0.742  
Periventricular -0.56  0.024  -0.58  0.018  -0.49  0.054  -0.57  0.026  -0.35  0.217  -0.02  0.964  0.06  0.899  -0.11  0.866  -0.11  0.895  
PLIC -0.28  0.440  -0.36  0.304  -0.45  0.195  -0.56  0.116  -0.41  0.311  -0.89  0.106  -0.89  0.106  0.00  1.000    
P-values presented without correction for multiple comparisons. R and p values for the periods after 24 hours are presented only for reference because of 
the limited number of surviving subjects. Abbreviation: PLIC, posterior limb of the internal capsule.  
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Supplemental Table 4.3-9: Serial ADC 1-48 h before termination and histo-pathological injury in corresponding 
regions 
 
A. ADC 1 to 48 hours before termination and neuronal death in the grey matter assessed using H & E stains 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
 
Sagittal top -0.75  0.000
 
-0.80  0.000
 
-0.82  0.000
 
-0.85  0.000
 
-0.57  0.052  -0.35  0.362  -0.20  0.669  -0.74  0.156  -0.58  0.423  
Sagittal bottom -0.82  0.000
 
-0.73  0.001  -0.70  0.002  -0.62  0.011  -0.38  0.224  -0.46  0.210  -0.64  0.125  -0.64  0.245  -0.85  0.146  
Parietal top -0.72  0.001  -0.60  0.008  -0.50  0.043  -0.60  0.015  -0.38  0.221  -0.32  0.399  0.05  0.908  0.25  0.681  0.43  0.575  
Parietal bottom -0.74  0.000
 
-0.74  0.000
 
-0.63  0.007  -0.63  0.008  -0.46  0.135  -0.43  0.248  -0.12  0.792  -0.35  0.564  -0.15  0.848  
Temporal  -0.64  0.007  -0.51  0.042  -0.58  0.024  -0.51  0.078  -0.82  0.004  -0.50  0.209  -0.66  0.104  0.53  0.363  -0.34  0.781  
Hippocampus -0.46  0.252  -0.53  0.175  -0.48  0.276  -0.66  0.222            
Caudate nucleus -0.49  0.074  -0.54  0.048  -0.56  0.047  -0.46  0.151  -0.29  0.449  -0.49  0.266  -0.48  0.333  -0.78  0.121  0.50  0.668  
Putamen -0.33  0.249  -0.40  0.161  -0.29  0.322  -0.47  0.121  -0.34  0.334  -0.25  0.554  -0.15  0.746  -0.75  0.145  -0.84  0.371  
Anterior thalamus -0.63  0.017  -0.53  0.050  -0.58  0.031  -0.69  0.013  -0.67  0.035  -0.77  0.025  -0.65  0.112  -0.80  0.102  -0.36  0.763  
Lateral thalamus -0.37  0.169  -0.35  0.197  -0.39  0.165  -0.53  0.077  -0.45  0.198  -0.54  0.165  -0.44  0.328  -0.65  0.237  -0.94  0.222  
Medial thalamus -0.61  0.015  -0.60  0.019  -0.56  0.038  -0.54  0.071  -0.47  0.176  -0.47  0.236  -0.46  0.294  -0.60  0.281  -0.97  0.148  
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B. ADC 1-48 h before termination and TUNEL positive apoptotic cell death in the grey matter 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
 
Sagittal top -0.50  0.035  -0.47  0.052  -0.45  0.069  -0.35  0.184  -0.10  0.761  -0.06  0.884  0.27  0.556  0.23  0.714  0.10  0.901  
Sagittal bottom -0.45  0.060  -0.47  0.048  -0.48  0.050  -0.49  0.056  -0.34  0.275  -0.03  0.946  -0.14  0.771  -0.09  0.889  0.93  0.075  
Parietal top -0.55  0.019  -0.45  0.064  -0.41  0.099  -0.62  0.011  -0.57  0.051  -0.29  0.446  -0.20  0.669  -0.29  0.638  -0.40  0.603  
Parietal bottom -0.35  0.153  -0.33  0.183  -0.42  0.095  -0.48  0.061  -0.15  0.641  -0.02  0.958  -0.03  0.944  -0.02  0.969  0.11  0.892  
Temporal  -0.04  0.871  -0.03  0.917  -0.02  0.956  -0.06  0.855  0.24  0.512  -0.18  0.670  0.55  0.198  -0.50  0.397  0.85  0.348  
Hippocampus -0.25  0.543  -0.45  0.267  -0.73  0.064  0.30  0.627  0.91  0.277          
Caudate nucleus -0.29  0.309  -0.37  0.192  -0.39  0.194  -0.35  0.289  -0.21  0.588  -0.10  0.838  -0.19  0.725  -0.21  0.740  -0.87  0.334  
Putamen -0.33  0.256  -0.29  0.317  -0.34  0.232  -0.37  0.241  -0.32  0.362  -0.17  0.689  -0.50  0.257  -0.61  0.271  -0.90  0.289  
Anterior thalamus -0.15  0.602  -0.13  0.655  -0.20  0.496  0.06  0.859  0.02  0.962  0.16  0.707  -0.17  0.713  -0.20  0.750  -0.97  0.170  
Lateral thalamus -0.24  0.386  -0.28  0.308  -0.23  0.427  -0.10  0.765  0.23  0.517  0.30  0.467  0.31  0.503  0.19  0.758  -0.29  0.811  
Medial thalamus -0.15  0.607  -0.15  0.599  -0.10  0.751  -0.10  0.776  -0.02  0.951  -0.22  0.640  -0.01  0.987  0.92  0.083    
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C-1. ADC 1-48 h before termination and CD68 positive microglia in the grey matter 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
 
Sagittal top 0.55  0.018  0.53  0.024  0.53  0.028  0.56  0.024  0.38  0.226  0.42  0.259  0.30  0.520  -0.08  0.905  0.30  0.701  
Sagittal bottom 0.46  0.053  0.46  0.055  0.45  0.068  0.28  0.294  0.33  0.292  0.05  0.897  -0.23  0.615  -0.79  0.112  -0.95  0.047  
Parietal top 0.64  0.005  0.50  0.034  0.59  0.013  0.59  0.017  0.52  0.085  0.32  0.397  0.48  0.282  0.92  0.029  0.86  0.140  
Parietal bottom 0.55  0.018  0.51  0.031  0.46  0.066  0.45  0.084  0.30  0.348  0.25  0.518  -0.32  0.483  -0.91  0.034  -0.78  0.218  
Temporal  -0.07  0.797  -0.09  0.751  -0.15  0.606  0.02  0.957  -0.47  0.176  -0.54  0.167  -0.54  0.209  0.47  0.429  -0.82  0.390  
Hippocampus -0.52  0.188  -0.17  0.693  -0.27  0.559  0.19  0.760  -0.31  0.802          
Caudate nucleus 0.43  0.106  0.45  0.094  0.34  0.241  0.37  0.241  -0.45  0.193  -0.53  0.179  -0.59  0.160  -0.01  0.994  1.00  0.043  
Putamen -0.18  0.522  0.08  0.782  -0.15  0.613  -0.16  0.616  -0.63  0.052  -0.67  0.072  -0.78  0.041  -0.89  0.045  -0.84  0.371  
Anterior thalamus 0.10  0.715  0.17  0.543  0.28  0.337  0.13  0.683  0.01  0.977  -0.55  0.154  -0.22  0.644  -0.07  0.916  0.59  0.598  
Lateral thalamus -0.15  0.600  -0.16  0.566  0.13  0.652  0.11  0.730  -0.35  0.324  -0.51  0.192  -0.59  0.160  -0.54  0.347  -0.18  0.888  
Medial thalamus -0.32  0.270  0.02  0.947  0.15  0.616  -0.01  0.981  -0.65  0.058  -0.92  0.003  -0.82  0.044  0.15  0.855    
 
C-2. ADC 1-48 h before termination and CD68 positive microglia in the white matter 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
 
Sagittal  0.69  0.003  0.75  0.001  0.73  0.002  0.64  0.013  0.45  0.141  0.35  0.357  -0.76  0.046  -0.84  0.079  -0.72  0.276  
Parietal  0.67  0.007  0.58  0.022  0.53  0.053  0.51  0.075  0.34  0.274  0.27  0.483  -0.86  0.012  -0.98  0.003  -0.95  0.055  
Temporal  0.53  0.042  0.48  0.068  0.45  0.105  0.34  0.262  -0.07  0.831  -0.54  0.168  -0.44  0.327  -0.48  0.416  0.02  0.979  
Superior Periventricular  0.14  0.627  0.32  0.239  0.32  0.261  -0.20  0.543  -0.50  0.137  -0.59  0.166  -0.71  0.073  -0.41  0.491  0.49  0.506  
Periventricular -0.27  0.349  0.01  0.963  -0.39  0.193  -0.38  0.247  -0.19  0.607  -0.40  0.328  -0.50  0.256  -0.22  0.728  -0.25  0.752  
PLIC 0.74  0.014  0.72  0.019  0.72  0.028  0.61  0.106  -0.10  0.836  -0.94  0.059  -0.98  0.025  -1.00  0.006    
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D-1. ADC 1-48 h before termination and CD68 positive vessels in the grey matter 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
 
Sagittal top 0.56  0.016  0.65  0.004  0.69  0.002  0.70  0.003  0.44  0.157  0.40  0.289  0.46  0.304  -0.05  0.943  0.24  0.756  
Sagittal bottom 0.51  0.032  0.54  0.020  0.54  0.026  0.41  0.112  0.39  0.210  0.33  0.392  0.12  0.797  -0.87  0.056  -0.71  0.294  
Parietal top 0.81  0.000
 
0.72  0.001  0.80  0.000
 
0.64  0.007  0.53  0.076  0.41  0.269  0.52  0.237  0.92  0.029  0.86  0.140  
Parietal bottom 0.67  0.002  0.62  0.006  0.57  0.017  0.55  0.028  0.33  0.292  0.26  0.493  0.15  0.753  -0.63  0.257  -0.15  0.848  
Temporal  -0.05  0.851  -0.08  0.758  -0.14  0.613  0.06  0.848  -0.22  0.541  -0.55  0.157  -0.55  0.200  0.30  0.624  -0.71  0.499  
Hippocampus -0.51  0.198  -0.17  0.680  -0.17  0.718  -0.31  0.606            
Caudate nucleus 0.43  0.114  0.42  0.119  0.32  0.262  0.28  0.377            
Putamen -0.32  0.239  -0.03  0.927  -0.37  0.192  -0.46  0.136  -0.59  0.072  -0.64  0.085  -0.75  0.052  -0.83  0.079  -0.61  0.583  
Anterior thalamus 0.15  0.597  0.18  0.511  0.27  0.358  0.16  0.614  0.01  0.977  -0.55  0.154  -0.22  0.644  -0.07  0.916  0.59  0.598  
Lateral thalamus -0.16  0.564  -0.19  0.493  0.13  0.657  0.10  0.754  -0.35  0.324  -0.51  0.192  -0.59  0.160  -0.54  0.347  -0.18  0.888  
Medial thalamus -0.14  0.625  0.05  0.856  0.07  0.829  -0.02  0.958  -0.73  0.025  -0.92  0.003  -0.82  0.044  0.15  0.855    
 
D-2. ADC 1-48 h before termination and CD68 positive vessels in the white matter 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
 
Sagittal  0.45  0.079  0.63  0.009  0.66  0.007  0.55  0.044  0.36  0.254  0.20  0.613  -0.59  0.162  -0.65  0.234  -0.88  0.121  
Parietal  0.76  0.001  0.74  0.002  0.71  0.004  0.58  0.038  0.41  0.186  0.34  0.375        
Temporal  0.10  0.735  0.10  0.718  0.15  0.622  0.27  0.376  0.04  0.919  -0.55  0.160  -0.15  0.753  -0.14  0.823  0.24  0.757  
Superior Periventricular  -0.34  0.216  -0.19  0.505  -0.21  0.470  -0.43  0.168  -0.52  0.128  -0.59  0.166  -0.80  0.032  -0.91  0.033  -0.21  0.792  
Periventricular -0.23  0.436  0.02  0.939  -0.17  0.589  -0.23  0.494  -0.56  0.092  -0.40  0.328  -0.50  0.256  -0.22  0.728  -0.25  0.752  
PLIC 0.35  0.329  0.62  0.055  0.62  0.076  0.50  0.209  0.23  0.623  -0.94  0.059  -0.98  0.025  -1.00  0.006    
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E. ADC 1-48 h before termination and white matter injury assessed using H & E stains 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
 
Sagittal -0.65  0.006  -0.84  0.000
 
-0.77  0.001  -0.76  0.002  -0.48  0.118  -0.55  0.130  -0.22  0.631  -0.67  0.215  0.26  0.742  
Parietal -0.76  0.001  -0.72  0.002  -0.73  0.003  -0.72  0.005  -0.40  0.197  -0.48  0.196  0.27  0.562  -0.45  0.450  -0.78  0.225  
Temporal -0.80  0.000
 
-0.76  0.001  -0.61  0.020  -0.40  0.171  -0.14  0.681  0.28  0.510  0.24  0.606  -0.05  0.933  -0.89  0.106  
Superior Periventricular -0.81  0.000
 
-0.68  0.005  -0.76  0.002  -0.26  0.413  0.08  0.831  0.13  0.775  0.13  0.775  0.00  1.000    
Periventricular -0.58  0.029  -0.36  0.204  -0.68  0.010  -0.47  0.146  -0.05  0.886  0.32  0.441  0.02  0.967  0.11  0.858  0.78  0.225  
PLIC -0.56  0.060  -0.71  0.009  -0.94  0.000
 
-0.86  0.001  -0.50  0.174  0.15  0.770  0.32  0.604  -0.32  0.684  -0.50  0.667  
 
F. ADC 1-48 h before termination and white matter injury assessed using LFB/Nissl stains 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
 
Sagittal 0.33  0.219  0.52  0.041  0.61  0.016  0.34  0.239  0.31  0.329  0.14  0.725  -0.20  0.661      
Parietal 0.06  0.838  0.17  0.537  0.09  0.750  0.21  0.492  0.51  0.091  0.31  0.416  0.00  1.000  0.35  0.559  0.26  0.742  
Temporal 0.31  0.254  0.42  0.120  0.54  0.046  0.57  0.042  0.52  0.100  0.41  0.310  0.61  0.144  0.71  0.182  0.26  0.742  
Superior Periventricular 0.12  0.660  0.00  1.000  0.24  0.407  0.31  0.334  -0.06  0.873          
Periventricular -0.10  0.726  0.03  0.907  0.31  0.305  0.30  0.370  -0.06  0.873          
PLIC 0.64  0.025  0.70  0.012  0.71  0.014  0.65  0.044  0.00  1.000  -0.66  0.158  -0.71  0.182  -0.26  0.742  0.00  1.000  
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G. ADC 1-48 h before termination and white matter injury assessed using β-APP immune-histochemical stain 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
 
Sagittal -0.52  0.041  -0.69  0.003  -0.54  0.040  -0.63  0.016  -0.53  0.076  -0.22  0.569  0.00  1.000  -0.29  0.638  -0.78  0.225  
Parietal -0.44  0.104  -0.38  0.166  -0.19  0.515  -0.45  0.126  -0.41  0.184  -0.20  0.615  0.29  0.530  0.00  1.000  0.00  1.000  
Temporal -0.69  0.004  
 
-0.73  0.002  -0.53  0.050  -0.41  0.169  -0.19  0.567  0.04  0.923  0.00  1.000  -0.29  0.638  -0.78  0.225  
Superior Periventricular -0.56  0.031  -0.65  0.009  0.60  0.024  -0.17  0.607  0.34  0.341  0.43  0.335  0.10  0.832  0.29  0.638  -0.78  0.225  
Periventricular -0.65  0.012  -0.62  0.018  -0.46  0.114  -0.27  0.419  0.19  0.604  0.66  0.073  0.30  0.515  -0.53  0.361  -0.32  0.684  
PLIC -0.24  0.510  -0.36  0.314  -0.60  0.090  -0.41  0.311  -0.78  0.041  -0.89  0.106  -0.45  0.553  -0.87  0.333    
P-values presented without correction for multiple comparisons.. 
R and p values for the periods after 24 hours are presented only for reference because of the limited number of surviving subjects.  
Abbreviation: PLIC, posterior limb of the internal capsule. 
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Supplemental Table 4.3-10: Serial T2 maps 1-48 h before termination and histo-pathological injury in 
corresponding regions 
 
A. T2 1-48 h before termination and neuronal death in the grey matter assessed using H & E stains 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
 
Sagittal top 0.43  0.187  0.43  0.191  0.41  0.210  0.68  0.044  0.58  0.102  0.66  0.110  0.42  0.404  0.13  0.918  -0.14  0.912  
Sagittal bottom 0.36  0.283  0.28  0.400  0.27  0.420  0.39  0.294  0.42  0.259  0.06  0.899  0.63  0.184  0.68  0.521  0.66  0.546  
Parietal top 0.54  0.087  0.43  0.183  0.51  0.113  0.69  0.042  0.66  0.054  0.78  0.041  0.80  0.054  0.99  0.102  0.84  0.371  
Parietal bottom 0.30  0.376  0.36  0.278  0.37  0.262  0.67  0.049  0.60  0.090  0.67  0.101  0.59  0.222  0.90  0.292  0.77  0.444  
Temporal  0.01  0.972  -0.04  0.903  -0.01  0.988  0.23  0.589  0.00  0.995  -0.38  0.533  -0.69  0.309      
Hippocampus 0.25  0.633  0.46  0.363  0.58  0.229  0.77  0.227  0.85  0.356          
Caudate nucleus 0.25  0.481  0.33  0.348  0.38  0.274  0.77  0.025  0.38  0.406  0.70  0.186  -0.10  0.899  -0.10  0.937    
Putamen -0.02  0.965  0.34  0.337  0.30  0.406  0.10  0.795  0.32  0.441  0.45  0.369  -0.04  0.946  -0.51  0.658    
Anterior thalamus 0.00  0.993  0.24  0.505  0.53  0.116  0.52  0.156  0.38  0.354  0.45  0.374  0.62  0.260  0.64  0.559    
Lateral thalamus 0.09  0.803  0.10  0.769  0.13  0.710  0.41  0.278  0.65  0.080  0.95  0.004  0.92  0.028  0.78  0.427    
Medial thalamus 0.74  0.009  0.68  0.021  0.38  0.256  0.56  0.118  0.59  0.094  0.50  0.257  0.62  0.264  0.99  0.084  0.93  0.234  
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B. T2 1-48 h before termination and TUNEL positive apoptotic cell death in the grey matter 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
 
Sagittal top 0.57  0.067  0.52  0.103  0.33  0.321  0.42  0.265  0.59  0.097  0.43  0.335  0.36  0.484  0.97  0.162  0.87  0.332  
Sagittal bottom 0.87  0.000
 
0.84  0.001  0.72  0.013  0.68  0.042  0.74  0.024  0.60  0.154  0.55  0.259  0.98  0.130  0.97  0.155  
Parietal top 0.79  0.004  0.76  0.007  0.54  0.085  0.65  0.058  0.56  0.117  0.55  0.201  0.52  0.293  1.00  0.059  0.95  0.209  
Parietal bottom 0.67  0.024  0.68  0.023  0.50  0.115  0.55  0.128  0.65  0.058  0.37  0.414  0.52  0.291  1.00  0.059  0.99  0.092  
Temporal  0.81  0.002  0.85  0.001  0.80  0.003  0.66  0.073  0.83  0.020  0.08  0.894  0.70  0.296      
Hippocampus 0.16  0.761  0.32  0.531  0.10  0.851  0.20  0.805  -0.04  0.977          
Caudate nucleus 0.24  0.509  0.31  0.379  0.36  0.301  0.18  0.669  0.25  0.589  0.45  0.445  0.99  0.012  0.97  0.150    
Putamen 0.68  0.030  0.55  0.096  0.70  0.025  0.58  0.102  0.50  0.212  0.61  0.202  0.54  0.344  0.41  0.732    
Anterior thalamus 0.29  0.411  0.43  0.219  0.26  0.465  0.32  0.409  0.12  0.783  0.04  0.934  0.26  0.674  0.87  0.329    
Lateral thalamus 0.16  0.643  0.05  0.891  0.13  0.715  0.44  0.234  0.19  0.647  -0.05  0.924  -0.13  0.836  -0.03  0.984    
Medial thalamus 0.56  0.072  0.56  0.075  0.39  0.236  0.50  0.176  0.62  0.076  0.37  0.417  0.04  0.953  0.29  0.811  0.51  0.661  
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C-1. T2 1-48 h before termination and CD68 positive microglia in the grey matter 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
 
Sagittal top -0.43  0.189  -0.33  0.315  -0.29  0.383  -0.36  0.336  -0.35  0.362  -0.31  0.495  0.23  0.656  -0.58  0.606  -0.35  0.775  
Sagittal bottom -0.56  0.072  -0.53  0.091  -0.55  0.079  -0.54  0.138  -0.50  0.171  -0.65  0.117  0.12  0.819  -0.17  0.889  -0.21  0.864  
Parietal top -0.62  0.044  -0.57  0.068  -0.50  0.117  -0.53  0.140  -0.43  0.246  -0.38  0.404  0.04  0.947      
Parietal bottom -0.48  0.132  -0.49  0.126  -0.52  0.101  -0.60  0.088  -0.58  0.103  -0.36  0.425  0.24  0.647  0.01  0.996  -0.23  0.852  
Temporal  -0.37  0.267  -0.35  0.289  -0.44  0.174  -0.10  0.809  -0.48  0.276  0.59  0.297  0.03  0.966      
Hippocampus -0.08  0.874  -0.07  0.903  -0.58  0.225  -0.19  0.806  -0.85  0.356          
Caudate nucleus -0.50  0.117  -0.53  0.092  -0.33  0.328  -0.26  0.493  -0.46  0.249  -0.64  0.169  -0.70  0.184  -0.97  0.167    
Putamen -0.43  0.185  -0.43  0.185  -0.50  0.114  -0.08  0.844  -0.30  0.474  0.35  0.494  0.32  0.594  0.07  0.955    
Anterior thalamus -0.37  0.265  -0.42  0.203  -0.56  0.072  -0.32  0.407  -0.41  0.317          
Lateral thalamus -0.51  0.111  -0.45  0.170  -0.51  0.106  -0.32  0.408  -0.52  0.182          
Medial thalamus 0.24  0.480  -0.12  0.737  -0.34  0.306  0.22  0.573  0.20  0.599  0.90  0.005  0.91  0.031  1.00  0.066  0.99  0.084  
 
C-2. T2 1-48 h before termination and CD68 positive microglia in the white matter 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
 
Sagittal  -0.17  0.668  0.00  0.999  0.14  0.720  0.13  0.781  0.17  0.723  -0.11  0.831  0.31  0.694  1.00  0.023  0.98  0.116  
Parietal  -0.10  0.789  -0.21  0.570  -0.23  0.524  -0.08  0.855  -0.03  0.936  -0.09  0.854  0.94  0.017  0.81  0.396  0.56  0.620  
Temporal  -0.28  0.397  -0.32  0.337  -0.36  0.273  0.09  0.815  0.92  0.001  0.90  0.015  0.76  0.134  1.00  0.020  0.20  0.874  
Superior Periventricular 0.01  0.988  0.05  0.887  0.24  0.484  0.84  0.005  0.66  0.074  0.89  0.019  0.98  0.023  -0.02  0.989  -0.28  0.819  
Periventricular 0.94  0.219  0.94  0.221  0.88  0.321  0.99  0.088  1.00  0.043  0.95  0.212        
PLIC -0.09  0.816  -0.13  0.732  0.18  0.649  0.16  0.726  0.45  0.312  0.41  0.490  0.96  0.180  0.94  0.220  0.99  0.109  
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D-1. T2 1-48 h before termination and CD68 positive vessels in the grey matter 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
 
Sagittal top -0.43  0.189  -0.33  0.315  -0.29  0.383  -0.36  0.336  -0.35  0.362  -0.31  0.495  0.23  0.656  -0.58  0.606  -0.35  0.775  
Sagittal bottom -0.56  0.072  -0.53  0.091  -0.55  0.079  -0.54  0.138  -0.50  0.171  -0.65  0.117  0.12  0.819  -0.17  0.889  -0.21  0.864  
Parietal top -0.62  0.044  -0.57  0.068  -0.50  0.117  -0.53  0.140  -0.43  0.246  -0.38  0.404  0.04  0.947      
Parietal bottom -0.48  0.132  -0.49  0.126  -0.52  0.101  -0.60  0.088  -0.58  0.103  -0.36  0.425  0.24  0.647  0.01  0.996  -0.23  0.852  
Temporal  -0.37  0.267  -0.35  0.289  -0.44  0.174  -0.10  0.809  -0.48  0.276  0.59  0.297  0.03  0.966      
Hippocampus -0.08  0.874  -0.07  0.903  -0.58  0.225  -0.19  0.806  -0.85  0.356          
Caudate nucleus -0.50  0.117  -0.53  0.092  -0.33  0.328  -0.26  0.493  -0.46  0.249  -0.64  0.169  -0.70  0.184  -0.97  0.167    
Putamen -0.43  0.185  -0.43  0.185  -0.50  0.114  -0.08  0.844  -0.30  0.474  0.35  0.494  0.32  0.594  0.07  0.955    
Anterior thalamus -0.37  0.265  -0.42  0.203  -0.56  0.072  -0.32  0.407  -0.41  0.317          
Lateral thalamus -0.51  0.111  -0.45  0.170  -0.51  0.106  -0.32  0.408  -0.52  0.182          
Medial thalamus 0.24  0.480  -0.12  0.737  -0.34  0.306  0.22  0.573  0.20  0.599  0.90  0.005  0.91  0.031  1.00  0.066  0.99  0.084  
 
D-2. T2 1-48 h before termination and CD68 positive vessels in the white matter 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
 
Sagittal  0.03  0.934  0.15  0.709  0.21  0.595  0.32  0.485  0.35  0.446  0.07  0.901  0.31  0.694  1.00  0.023  0.98  0.116  
Parietal  -0.41  0.237  -0.45  0.192  -0.35  0.319  -0.29  0.494  -0.26  0.542  -0.27  0.555        
Temporal  -0.13  0.694  -0.10  0.782  -0.32  0.344  -0.09  0.820  0.72  0.043  0.97  0.001  0.83  0.081  0.93  0.232  -0.14  0.914  
Superior Periventricular -0.03  0.933  -0.10  0.773  0.12  0.728  0.22  0.574  0.53  0.179  0.89  0.019  0.98  0.023  -0.02  0.989  -0.28  0.819  
Periventricular  0.94  0.219  0.94  0.221  0.88  0.321  0.99  0.088  1.00  0.043  0.95  0.212        
PLIC -0.21  0.592  -0.31  0.421  -0.08  0.834  -0.14  0.760  0.11  0.813  -0.08  0.902  0.96  0.180  0.94  0.220  0.99  0.109  
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E. T2 1-48 h before termination and white matter injury assessed using H & E stains 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
 
Sagittal  0.73  0.027  0.73  0.027  0.52  0.154  0.79  0.034  0.79  0.034  0.62  0.188  0.78  0.225  0.00  1.000  0.00  1.000  
Parietal 0.49  0.153  0.51  0.133  0.76  0.010  0.76  0.030  0.76  0.030  0.32  0.490  0.00  1.000  0.87  0.333  0.87  0.333  
Temporal 0.40  0.218  0.29  0.380  0.33  0.316  0.28  0.458  -0.38  0.351  0.13  0.805  0.00  1.000  0.00  1.000  -0.87  0.333  
Superior Periventricular -0.03  0.921  -0.22  0.512  -0.24  0.475  -0.56  0.118  -0.43  0.292  -0.17  0.749  0.26  0.742  -0.87  0.333  -0.87  0.333  
Periventricular -0.87  0.333  -0.87  0.333  -0.87  0.333  -0.87  0.333  -0.87  0.333  -0.87  0.333        
PLIC 0.59  0.075  0.76  0.012  0.72  0.018  0.79  0.019  0.03  0.952  0.09  0.864  0.95  0.051      
 
F. T2 1-48 h before termination and white matter injury assessed using LFB/Nissl stains 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
 
Sagittal  -0.09  0.825  0.17  0.656  0.00  1.000  0.00  1.000  0.00  1.000  -0.13  0.805        
Parietal  -0.38  0.275  -0.59  0.071  -0.31  0.378  -0.62  0.101  -0.39  0.334  0.00  1.000  -0.71  0.182  -0.87  0.333  -0.87  0.333  
Temporal  -0.30  0.372  -0.12  0.726  -0.12  0.726  -0.62  0.074  -0.25  0.547  -0.66  0.158  -0.71  0.182  -0.87  0.333  0.00  1.000  
Superior Periventricular 0.10  0.770  0.10  0.770  -0.50  0.117  -0.27  0.476  -0.08  0.846          
Periventricular                    
PLIC -0.35  0.324  -0.52  0.122  -0.35  0.324  -0.38  0.356  0.25  0.547  -0.39  0.441        
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G. T2 1-48 h before termination and white matter injury assessed using β-APP immune-histochemical stain 
  Time before termination (h) 
  1 - < 3 3 - < 6 6 - < 12 12 - < 18 18 - < 24 24 - < 30 30 - < 36 36 - < 42 42 - < 48 
  r p r p r p r p r p r p r p r p r p 
 
Sagittal  0.63  0.068  0.74  0.023  0.28  0.464  0.36  0.434  0.36  0.434  0.70  0.123  0.95  0.051  0.00  1.000  0.00  1.000  
Parietal 0.61  0.061  0.45  0.198  0.55  0.102  0.50  0.206  0.35  0.395  0.04  0.937  0.26  0.668  0.87  0.333  0.87  0.333  
Temporal  0.40  0.219  0.41  0.213  0.29  0.380  0.10  0.803  -0.36  0.385  0.17  0.749  -0.22  0.718  0.00  1.000  -0.87  0.333  
Superior Periventricular 0.00  1.000  -0.05  0.889  -0.43  0.191  -0.70  0.035  -0.72  0.042  -0.58  0.231  0.32  0.684  -0.87  0.333  -0.87  0.333  
Periventricular 0.00  1.000  -0.87  0.333  0.00  1.000  -0.87  0.333  -0.87  0.333  0.00  1.000        
PLIC 0.17  0.663  0.60  0.090  0.39  0.297  0.30  0.510  0.15  0.746  0.53  0.361  0.87  0.333  0.87  0.333  0.87  0.333  
P-values are presented without correction for multiple comparisons. 
R and p values for the periods after 24 hours are presented only for reference because of the limited number of surviving subjects.  
Abbreviation: PLIC, posterior limb of the internal capsule. 
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Appendix 2. 
 
"Therapeutic time window" duration decreases with increasing severity of cerebral 
hypoxia-ischaemia under normothermia and delayed hypothermia in newborn piglets. 
 
Iwata O, Iwata S, Thornton JS, De Vita E, Bainbridge A, Herbert L, Scaravilli F, Peebles D, Wyatt 
JS, Cady EB, Robertson NJ. 
 
Brain Res. 2007 Jun 18;1154:173-80. 
 
  
